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ABSTRACT 
Redox maintenance is critical for all biological species. Prolonged electrophilic or 
oxidative events shorten life and induce tissue pathogenesis. Amplification of 
mechanisms that reduces oxidative/electrophilic stress promotes health and extends life. 
Nuclear factor, erythroid derived 2, like 2 (Nrf2) is a master regulator of 
biochemical mechanisms that respond to oxidative/electrophilic stress. Under basal 
conditions, Nrf2 is held in an inactive state in the cytoplasm by binding to the 
cytoskeletal anchoring protein Kelch-like ECH-associated protein 1 (Keap1).  Upon 
generation of oxidative/electrophilic stress, Nrf2 is released from Keap1 and 
translocates to the nucleus, where it promotes transcription of a battery of cytoprotective 
genes.  
The antioxidative role of Nrf2 has been extensively studied for more than ten 
years, but the global Nrf2 target genes in liver still remain unknown. The present 
dissertation utilizes a Nrf2 “gene dose-response” model to genetically modulate the 
levels of Nrf2 in mouse liver, where the transcription profiles in livers of mice with 
graded Nrf2 activation is correlated with activation of Nrf2-target genes. Thus, the Nrf2-
target genes in mouse liver were investigated systematically. Pathway analyses indicate 
that genes induced by Nrf2 are involved in glutathione synthesis, oxidation/reduction 
using NADPH as the co-factor, and xenobiotic metabolism. Moreover, mRNA of genes 
involved in the pentose phosphate pathway and malic enzyme levels had a clear dose-
dependent correlation to active levels of Nrf2, indicating that Nrf2 promotes NADPH 
generation. The use of these genetic mice with graded Nrf2 activation identified 115 
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genes that are induced and 80 genes that are suppressed with increasing levels of Nrf2. 
Among genes suppressed by Nrf2, the majority are involved in lipid synthesis and fatty-
acid desaturation. Thus, Nrf2 promotes generation of NADPH, and reduces fatty acid 
synthesis and desaturation, contributing factors towards protecting liver against 
environmental oxidative/electrophilic stress. 
In addition to oxidative stress scavenging and reduction, Nrf2 also plays a role in 
xenobiotic detoxification. The mRNA abundance of 124 drug processing genes in the 
Nrf2 “gene dose-response” model was determined in this dissertation. Nrf2 has a 
minimal effect on the mRNA of uptake transporters and cytochrome P450 phase-I 
enzymes. However, Nrf2 does increase mRNA of many non P-450 phase-I enzymes, 
such as aldo-keto reductases, carbonyl reductases, and aldehyde dehydrogenase 1.  
Many genes involved in phase-II drug metabolism are induced by Nrf2, including most 
isoforms of the Gst gene family. In contrast to uptake transporters, a number of efflux 
transporters, such as Mrps, Bcrp (Abcg2), as well as Abcg5 and Abcg8 were induced by 
Nrf2. Nrf2 also facilitates electrophile detoxification through inducing non P-450 phase-I 
enzymes that reduce electrophiles, Gsts that conjugate electrophiles, and efflux 
transporters that excretes electrophile-GSH conjugates out of cells.  
In addition to the assessment of the effect of Nrf2 on the global gene 
transcription profiles in mouse liver, the function of Nrf2 in vivo was examined by testing 
whether Nrf2 activation protects against chemical-induced oxidative stress and 
subsequent liver injury in mice. Diquat is a contact herbicide that undergoes 
oxidation/reduction cycling, resulting in the generation of superoxide. Nrf2 activation 
prevents diquat-induced lethality, alveolar collapse in lungs, and necrosis in livers of 
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mice. Nrf2 activation also prevents glutathione depletion in mouse lung and liver tissues, 
and increased ROS staining in primary hepatocytes. Oxidative stress and lipid 
accumulation play important roles in ethanol-induced liver injury. Ethanol increased 
serum ALT and LDH activities in Nrf2-null mice and wild-type mice, but not in Nrf2-
enhanced mice, indicating that Nrf2-enhanced mice are more resistant to ethanol 
toxicity. After ethanol exposure, ROS were increased in livers and primary hepatoctyes 
in Nrf2-null mice but not in Nrf2-enhanced mice.  Ethanol increased free fatty acids in 
livers of Nrf2-null mice, and this increase was blunted in Nrf2-enhanced mice. 
Mechanistic studies show that Nrf2 prevents ethanol-induced oxidative stress through 
inducing cytoprotective genes including Nqo1 and Gclc, and prevents accumulation of 
free fatty acids in liver by suppressing the Srebp1 pathway. Oxidative stress also plays 
an important role in cadmium-induced liver injury. Nrf2-null mice are more susceptible, 
whereas Nrf2-enhanced mice are more resistant to cadmium-induced acute livery injury. 
Gclc, Gpx2, and Srxn-1, genes that involved in GSH synthesis and reducing oxidative 
stress, were only induced in Nrf2-enhanced mice, but not in Nrf2-null mice, indicating 
that Nrf2 protects against cadmium induced oxidative stress and acute liver injury, at 
least partially, through the induction of these cytoprotective genes. Surprisingly, 
metallothioneins (Mt-1 and Mt-2), cysteine-rich proteins that scavenge cadmium to 
prevent toxicity, were induced markedly in both Nrf2-null and Nrf2-enhanced mice. Thus, 
there are at least two distinct pathways to protect cadmium-induced toxicity: Nrf2-
dependent induction of antioxidative genes and Nrf2-independent induction of 
metallothioneins. 
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These findings suggest potential therapeutic applications of the Keap1-Nrf2 
pathway, and thus Nrf2 activators are promising drug candidates for the treatment of 
oxidative/electrophilic stress-induced diseases. To develop effective and potent Nrf2 
activators, a library of synthetic and natural existing compounds was screened to test 
their efficacy and potency to activate Nrf2. After screening 47,000 compounds, 238 
compounds (0.5%) had comparable or better efficacy to activate Nrf2 than tertiary 
butylhydroquinone (tBHQ), the prototypical Nrf2 activator. Among these 238 compounds, 
19 produce more induction of Nrf2 than 2-cyano-3,12-dioxooleana-1,9-dien-28-
imidazolide (CDDO-Im), the most effective and potent Nrf2 activator known. However, 
none of the tested compounds were more potent in activating Nrf2 than CDDO-Im. In 
addition, chemical structural relationship analysis of these 238 compounds showed 
enrichment of four chemical scaffolds (diaryl amides and diaryl ureas, oxazoles and 
thiazoles, pyranones and thiapyranones, and pyridinones and pyridazinones). The top 
30 compounds were screened in Hepa1c1c7 cells to increase Nqo1 mRNA, the 
prototypical Nrf2 target gene. The results indicate that 17 of the 30 most active hits also 
increased Nqo1 mRNA in the cell line in a concentration-dependent manner.  
In addition to synthetic compounds, a number of natural compounds are known 
to be antioxidants, and some of these natural compounds have been shown to exhibit 
antioxidant effects through activating the Nrf2 pathway. Utilizing the same screening 
system (AREc32 cells), 54 natural existing compounds were tested. Andrographolide 
had the highest efficacy, followed by trans-chalcone, sulforaphane, curcumin, flavone, 
kahweol, and carnosol, which were all more potent and effective than tBHQ. None of 
the natural compounds were more potent than CDDO-Im. 
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In conclusion, Nrf2-target genes are involved in NADPH generation, NADPH-
facilitated oxidative stress reduction, and detoxification and excretion of electrophiles. 
Nrf2 activation protects against ethanol-, cadmium-, and diquat-induced liver oxidative 
stress and liver injury in mice. Lastly, a few synthetic and natural existing compounds 
were shown to be effective in activating the Keap1-Nrf2-ARE pathway. 
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Free radicals and oxidative stress 
One of the major challenges in a biological system is to maintain cellular redox 
homeostasis through balancing the rate and magnitude of oxidant generation and 
oxidant detoxification. An imbalanced ratio between reactive oxygen species (ROS) 
production and adaptive antioxidant capacity will result in oxidative stress, a pathogenic 
stage that serves as both cause and consequence of numerous acute toxicities and 
chronic diseases.  
ROS refers to oxygen-containing free radicals with one or more unpaired 
electrons, which make them highly reactive. Most common cellular oxidative stress is 
generated from oxygen metabolism, resulting in generation of superoxide radical (O•-).  
In the presence of superoxide dismutase (SOD), superoxide radical is catalyzed into 
hydrogen peroxide (H2O2). In fact, the cellular concentration of SOD is so high (10 µM 
versus 1-10 pM of superoxide radical), that the majority of superoxide radicals are 
rapidly catalyzed into hydrogen peroxide. In the presence of transient metal ions, such 
as Fe2+, Cu+, and Mn2+, hydrogen peroxide undergoes a Fenton-like reaction and 
generates hydroxyl free radicals (HO•). Hydroxyl free radicals react with almost every 
type of molecule found in living cells, including sugars, amino acids, phospholipids, and 
nucleotides, with extremely high rate-constants (105-1010 M-1S-1) (Anbar and Neta, 
1967). Thus, the hydroxyl free radical is especially difficult to detoxify. Hydrogen 
peroxide can also be used to oxidize chloride to produce hypochlorous acid through 
myeloperoxidase (Winterbourn and Kettle, 2004). In addition, superoxide radical can 
bind to nitric oxide (NO) to generate peroxynitrite radical (ONOO•), and subsequently 
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nitrogen dioxide (NO2
•) as well as carbonate radical (CO2
.). Examples of ROS and 
reactive nitrogen species (RNS) are illustrated in figure 1.1.  
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Superoxide radicals are generated during normal physiological processes, 
xenobiotic metabolism, as well as pathological responses. Among numerous sources of 
superoxide radical generation, the electron transport chain in mitochondria is the 
primary and the most important source. Under ideal conditions, one oxygen molecule 
should receive two hydrogen molecules to generate water, but even under physiological 
conditions, 2% of the oxygen receive one electron to become superoxide radical. Thus, 
the hydrogen peroxide concentration in mitochondria is always 5-fold higher than the 
cytosol (Mari et al., 2009).  
Cellular oxidases serve as another important source to generate ROS, and 
oxidases are widely distributed in tissues and various cell types that generate 
superoxide radical as a product. For example, NADPH oxidases (Nox) represent a class 
of enzymes whose primary function is the generation of ROS. Seven isoforms of Nox 
have been identified, each with a distinct cell and tissue distribution (Manea, 2010). 
Nox1 is predominantly found in the colon, Nox2 is the NADPH oxidase in phagocytes, 
Nox3 is almost exclusively expressed in the inner ear, and Nox4 is the most abundant 
Nox and widely expressed in kidney, vascular cells, osteoclasts, etc. Nox5 is 
predominantly expressed in lymphoid tissues and testis. Duox1(dual oxidase 1) is 
expressed in the thyroid and in respiratory epithelia, whereas Duox2 is expressed in the 
thyroid and in gastrointestinal glandular epithelia (Krause, 2004). In addition to the Nox 
enzyme family, superoxide radical is also the product of other oxidase catalyzed 
reactions, such as xanthine oxidase, glucose oxidase, and amino acid oxidases.  
In addition to cellular oxidases, the cytochrome P-450 (Cyps) enzyme family 
generates superoxide radicals. Cyp2e1 oxidizes a variety of small, hydrophobic 
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substrates and drugs using oxygen. When Cyp2e1 uses oxygen to metabolize its 
substrates, reactive oxygen species (ROS) can be generated by a chain of uncoupled 
reactions (Comporti et al., 2010). Various toxicants, including ethanol, carbon 
tetrachloride, acetaminophen, benzene, halothane, and many other halogenated 
substrates, have been reported to generate oxidative stress, at least partially through 
this mechanism (Lu and Cederbaum, 2008).  Certain xenobiotics, including paraquat, 
diquat, doxorubicin, and nitrofurantoin can receive one electron from NADPH through 
cytochrome P450 reductase, and donate this electron to molecular oxygen to generate 
superoxide radical. Through this cytochrome P450 reductase-mediated redox cycling, 
small amounts of these xenobiotics are able to produce excessive amounts of 
superoxide radicals.   
The immediate outcome of oxidative stress includes lipid peroxidation, protein 
oxidation, and DNA damage. Some of the products of oxidative stress are detectable 
and can serve as biomarkers. For example, lipid peroxidation is initiated by an attack of 
hydroxyl radicals on polyunsaturated fatty acids that begins a chain reaction to generate 
lipid hydroperoxides. A single initiating event can trigger the peroxidation of a large 
number of target molecules. Biological membranes contain large amounts of 
polyunsaturated fatty acids, which make them highly vulnerable to oxidative stress. Lipid 
peroxidation of membranes results in a decrease of fluidity, increase in permeability, 
and abnormal activity of membrane bound enzymes.  ROS can also attack thiol groups 
on cysteine residues of proteins to form disulfide bonds, leading to structural changes of 
the proteins. Carbon-carbon double bonds in amino acid residues, such as tryptophan, 
can react with ROS, resulting in the formation of protein carbonyl. RNS (peroxynitrite) 
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can react with tyrosine residues and generate nitrotyrosine as protein adducts. Finally, 
DNA is also an important cellular target for attack by oxidative stress. The attack of 
hydroxyl radicals on DNA produces a wide range of chemical changes. These include 
conversion of thymine residues into thymine glycol and 5-hydroxy-methyluracil. These 
damaged thymine residues undergo base excision repair and are secreted into urine. It 
has been reported that normal humans excrete 10 nanomoles of thymidine glycol and 
hydroxymethyluracil every day (Loft and Poulsen, 1998).  
ROS also have important roles in diverse physiological and pathological 
processes, and the hypothetical model showing the role of ROS in different biological 
process is illustrated in Fig. 1.2. Low levels of ROS play important roles in regulating 
vascular tone (Gutterman et al., 2005), cell adhesion (Chiarugi et al., 2003; Huo et al., 
2009), immune responses (Grisham, 2004), and growth factor actions (Hensley et al., 
2000). Intermediate levels of oxidative stress induce an adaptive protective signal 
pathway (i.e. Keap1-Nrf2 signal pathway) to induce the antioxidant response. The ROS-
induced Keap1-Nrf2 pathway will be discussed later. Higher amounts of ROS can 
trigger an inflammatory response through activation of NFκB and Ap-1. In T cells, ROS 
induces the phosphorylation of Tyr42 on IκBα through activating spleen tyrosine kinase 
(Syk), or phosphorylation of Ser32 and 36 on IκBα through inhibition of kappaB kinase 
(IKK). In epithelial cells, ROS triggers IKK complex activation through the Src-PKD 
pathway (Gloire et al., 2006). High levels of oxidative stress can trigger apoptosis-
mediated cell death through activating apoptosis signal-regulating kinase 1 (Ask1). Ask1 
is one of MAP3Ks identified in the JNK and p38 pathways (Ichijo et al., 1997), and 
activation of Ask1 induces death of various cells through mitochondria-dependent  
 
 
 
 
Figure 
stress m
adhesio
adaptiv
trigger 
of oxida
from (G
 
1.2. Hypot
ediates p
n, and pro
e antioxida
an inflamm
tive stress
loire et al.
hetical mo
hysiologic
liferation. 
nt respon
atory resp
 can induc
, 2006). 
 
del of hier
al function
An interme
se through
onse throu
e activatio
achical role
s including
diate amo
 Nrf2. A hi
gh activat
n of Ask1 
 of oxidat
 vasocons
unt of oxid
gher amou
ion of NFκ
and subse
ive stress. 
triction, ch
ative stres
nt of oxida
B and Ap-
quent apo
Low oxida
emotaxis, 
s induces
tive stress
1. A high a
ptosis. Mo
8
tive 
cell 
 
 can 
mount 
dified 
9 
 
caspase activation. Under basal conditions, Ask1 is inactivated by thioredoxin (Trx) by 
direct binding to the N-terminal region of Ask1. Under oxidative stress conditions, Trx is 
oxidized, dissociates from Ask1, and thereby activates Ask1-mediated apoptosis 
(Takeda et al., 2008).  
Given the toxic effects of high levels of ROS, it is not surprising that oxidative 
stress has been implicated in ageing-related diseases (Lee and Wei, 2007), 
atherosclerosis (Stocker and Keaney, 2004), neurodegenerative diseases (Knight, 
1997), tumor progression (Storz, 2005), obesity, and diabetes (Martinez, 2006). Thus, 
cellular antioxidant defense systems are crucial for cell survival and prevention of 
oxidative stress-induced diseases. 
In general, there are three cellular antioxidant defense systems to fight against 
oxidative stress: low-molecular-weight antioxidants, enzymatic-antioxidant pathways, 
and free-ion sequestration. The major endogenous low-molecular-weight antioxidants 
are ascorbic acid (vitamin C), tocopherol (vitamin E), glutathione (GSH), and bilirubin. 
Ascorbic acid is a water soluble compound which reacts rapidly with the superoxide 
radical and even more rapidly with the hydroxyl free radical. It also scavenges singlet 
oxygen and hypochlorous acid. Oxidation of ascorbic acid gives the 
semidehydroascorbate radical, which is further oxidized to dehydroascorbate. 
Dehydroascrobate is unstable and breaks down rapidly to produce oxalic and L-threonic 
acids. Given the reducing properties of ascorbic acid, several studies have shown the 
beneficial effects of ascorbic acid in prevention and treatment of cancer (Mamede et al., 
2011). Plants and most animals can synthesize ascorbic acid from glucose, but humans 
rely on ascorbic acid (vitamin C) from the diet (Puertollano et al., 2011). In contrast to 
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vitamin C, vitamin E is a lipid soluble antioxidant. Dietary vitamin E is absorbed with 
lipids, bound to α-tocopherol transfer protein in the liver, and distributed throughout the 
body (Brigelius-Flohe and Traber, 1999). Vitamin E is localized in the membranes of the 
cell, where it primarily serves as a chain-breaking antioxidant to prevent lipid 
peroxidation. GSH serves as the most abundant cellular thiol resource, and provides a 
buffer system to maintain cellular redox status. GSH reduces hydrogen peroxide 
through glutathione peroxidase (Gpx), and is also oxidized to its disulfide form (GSSG). 
GSSG is returned to GSH through glutathione reductase using NADPH as the co-factor. 
Multiple studies have shown that the Gpx-GSH pathway is also a major intracellular 
antioxidative mechanism that repairs lipid peroxidation (Imai and Nakagawa, 2003), 
DNA fragmentation (Higuchi, 2004), and protein adduction (Filippin et al., 2008). 
Bilirubin, which is formed by biliverdin reductase, is the major degradation product of 
heme catabolism. Bilirubin reduces oxidative stress and becomes oxidized to biliverdin 
once again. Biliverdin reductase, together with biliverdin and bilirubin, are important 
players in cellular signal transduction pathways, gene expression, and oxidative 
responses (Florczyk et al., 2008).  
The enzymatic antioxidant pathways include catalase, peroxiredoxin pathway, 
and glutathione peroxidase pathway. Catalase reduces two molecules of hydrogen 
peroxide into water, producing one molecule of singlet oxygen. Catalase is localized in 
peroxisomes, and is found in every organ, with particularly high concentrations in liver. 
Glutathione peroxidase (GPX) reduces hydrogen peroxide to water and spontaneously 
oxidizes GSH into GSSG. GSH can be either synthesized from glutamate-cysteine 
ligase (Gcl) and GSH synthase (Gss), or recovered from GSSG via GSH reductase 
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(Gsr). However, the enzyme activity of GPX is about one-tenth of catalase in multiple 
organs (i.e., liver, kidney, spleen, and lung) (Marklund et al., 1982), indicating a minor 
role of GPX in detoxifying ROS. In addition, hydrogen peroxide can be reduced by 
peroxiredoxin (Prdx), resulting in oxidation of Prdx from the reduced form (Prdx-SH) to 
the oxidized form (Prdx-S-S-Prdx). Prdx-S-S-Prdx can be reduced to Prdx-SH through 
thioredoxin (Txn) and thioredoxin reductase (Txnrd). If Prdx is further oxidized into the 
sulfinic acid form (Prdx-SOOH), it can be reduced by sulfiredoxin. The gene names, 
tissue distribution, and cellular localization of the genes involved in enzymatic 
antioxidant pathways are summarized in table 1.1. 
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Table 1.1.  Genes involved in enzymatic antioxidant pathways. Gene names, tissue 
distribution, and cellular localization of genes involved in enzymatic antioxidant 
pathways. 
Gene Tissue distribution Subcellular 
localization 
Reference 
Txnrd1 Lung, liver, kidney, heart, 
muscle, and brain 
Cytosol (Deroo et al., 2004) 
(Kiermayer et al., 
2007) 
Txnrd2 Lung, liver, kidney, heart, 
muscle, and brain 
Mitochondria (Deroo et al., 2004) 
Txnrd3 Testis Endoplasmic
reticulum 
(Deroo et al., 2004) 
(Soerensen et al., 
2008) 
Txn1 Ubiquitous Cytosol and 
nucleus 
(Deroo et al., 2004) 
(Hoshino et al., 2007) 
Txn2 Metabolically active 
tissues such as heart, 
brain, and liver 
Mitochondria (Perez et al., 2008) 
Prdx1 Ubiquitous, especially 
abundant in liver 
Cytosol (Ishii et al., 1993) 
Prdx2 Brain, testis, and spleen Cytosol (Chiba et al., 2008) 
Prdx3 Ubiquitous Mitochondria 
 
(Deroo et al., 2004) 
(Chae et al., 1999) 
Prdx4 Pancreas and testis Extracellular 
space 
(Okado-Matsumoto 
et al., 2000) 
Prdx5 Ubiquitous Mitochondria 
 
(Kropotov et al., 
2007) 
Prdx6 Ubiquitous, especially 
abundant in liver and lung
Cytosol (Eismann et al., 
2009) 
Grx1 Ubiquitous Cytosol (Jurado et al., 2003) 
Grx2 Testis Mitochondria (Jurado et al., 2003) 
Srx1 NA NA  
Gpx1  Ubiquitous Cytosol and 
mitochondria 
(Takebe et al., 2002) 
Gpx2  Gastrointestinal tract Cytosol (Takebe et al., 2002) 
Gpx3 Mainly expressed by the 
kidneys from where it is 
released into the blood 
Extracellular 
space 
(Takebe et al., 2002) 
Gpx4 Ubiquitous Cell membrane (Takebe et al., 2002) 
Catalase Ubiquitous Peroxisome (Lenzen et al., 1996) 
SOD1 Ubiquitous Cytosol (Lenzen et al., 1996) 
SOD2 Ubiquitous Mitochondria (Lenzen et al., 1996) 
SOD3 Ubiquitous Extracellular (Lenzen et al., 1996) 
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As discussed above, transient metal ions (especially Fe2+ and Cu+), facilitate 
generation of hydroxyl free radicals from hydrogen peroxide through the Fenton-like 
reaction. Thus, free ion binding proteins are important in preventing oxidative stress. 
Ferritin is a high-molecular-weight protein (450 KDa) consisting of 24 subunits. In 
vertebrates, these subunits consist of light (L) and heavy (H) chains with molecular 
weights of 19 kDa and 21 kDa, respectively. Ferritin serves to store, deposit, and 
transfer iron in a non-toxic form (Arosio and Levi, 2010). Some heavy metals, including 
cadmium and mercury, readily bind to thiol groups of proteins, leading to disruption of 
redox homeostasis and protein damage. Metallothioneins are a family of low-molecular-
weight (6 kDa), cysteine-rich (22%-33%) proteins that bind endogenous and 
exdogenous heavy metals. Metallothioneins are highly inducible upon heavy ion 
overload, and metallothionein-bound metals are generally considered as non-toixic 
(Klaassen et al., 1999). Collectively, the functions of low-molecular-weight antioxidants, 
enzymatic antioxidant pathways, and free-ion sequestration are illustrated in Fig. 1.3. 
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Nrf2 and Keap1 Signaling Pathway 
Nrf2 was first cloned as one of the proteins that activates transcription by binding 
to the NF-E2/AP-1 motif of the hypersensitive site-2 in the β-globin locus control region, 
and belongs to a subset of basic leucine-zipper (bZip) genes highly homologous to that 
of NF-E2 (Moi et al., 1994). Early studies on Nrf2 showed that it is not essential for 
murine erythropoiesis and development (Chan et al., 1996), however, evidence from the 
past 10 years points to Nrf2 as a key regulator of the cellular response to oxidative 
stress in multiple tissues and cell types. Under basal conditions, Nrf2 is sequestered by 
the cytoskeletal anchoring protein Kelch-like ECH-associated protein 1 (Keap1) through 
extensive hydrogen bonds in the cytoplasm (Fig. 1.4).  Upon stimuli of oxidative stress 
or antioxidants, Nrf2 is released from Keap1 and translocates into the nucleus (Itoh et 
al., 1999).  Once in the nucleus, Nrf2 heterodimerizes with a variety of transcriptional 
regulatory proteins, including members of the activator protein-1 family (such as Jun 
and Fos) or the small Maf family of transcription factors (Itoh et al., 1997; Jeyapaul and 
Jaiswal, 2000; Zhu and Fahl, 2001).  These protein complexes then bind to antioxidant 
response elements (ARE) located in the upstream promoter regions of a battery of 
genes to drive transcription of these genes (Rushmore et al., 1991).   
Nrf2 target genes 
Genomic analyses indicate that a number of gene families are affected by Nrf2: 
(a) provide direct antioxidants or encode enzymes that inactivate oxidants, (b) increase 
levels of glutathione synthesis and regeneration, (c) conjugate xenobiotics with 
glutathione or glucuronic acid to make them more water soluble, (d ) increase multidrug  
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Table 1.2. Typical Nrf2 target genes reported in the literature. 
Gene Function Reference 
Anti-oxidative enzymes and proteins 
Heme oxygenase-1(Ho-1) Catalyzes pro-oxidant heme 
into bilirubin 
(Primiano et al., 1996) 
NAD(P)H quinone 
oxidoreductase 1 (Nqo1) 
Reduces highly reactive 
quinones 
(Dhakshinamoorthy and 
Jaiswal, 2000) 
Glutathione peroxidase 
(Gpx) 
Reduces hydrogen peroxide (Thimmulappa et al., 
2002) 
Ferritin (Ftn) Ion sequester (Primiano et al., 1996) 
Thioredoxin-1 (Txn1) Reduces oxidized protein to 
restore enzyme activity 
(Kim et al., 2003) 
Thioredoxin reductase-1 
(Txnrd1) 
Reduces oxidized thioredoxin (Kim et al., 2003) 
Glutathione homeostasis   
Glutamate-cysteine ligase 
(Gcl, Gclc and Gclm)  
Catalyzes rate-limiting step in 
GSH synthesis 
(Moinova and Mulcahy, 
1999) 
Glutathione reductase (Gr) Reduces GSSG into GSH to 
restore GSH concentration 
(Moinova and Mulcahy, 
1999) 
 
Conjugation   
Glutathione-S-transferases 
(GSTs) 
Conjugates GSH to 
electrophiles for 
detoxification 
(Thimmulappa et al., 
2002) 
Glucuronosyltransferases 
(UGTs) 
Conjugates glucuronic acid to 
xenobiotics to increase 
excretion 
(Thimmulappa et al., 
2002) 
Transporters   
Multidrug resistance-
associated proteins 
(Mrps) 
Effluxes conjugates from liver 
to bile or blood for excretion 
(Maher et al., 2007) 
NADPH regenerating 
system 
  
Glucose 6-phosphate 
dehydrogenase, 6-
phosphogluconate 
dehydrogenase 
Regenerate NADPH from 
NADP 
(Thimmulappa et al., 
2002) 
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response transporters and enhance chemical export, and (e) stimulate NADPH 
synthesis (Table 1.2). 
Recently, our laboratory characterized the gene expression profile in liver of Nrf2-
null mice and mice with decreased Keap1 protein throughout the body, and identified a 
pattern of genes with low expression in Nrf2-null mice, and high expression in Keap1-
knock down mice (Table 1.3). In this way, biological effects of increased Nrf2 function 
were studied in vivo, and Nrf2 target genes were investigated systematically (Reisman 
et al., 2009e).  
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Table 1.3. Characterization of gene expression profile in liver of wild-type, Nrf2-null, and 
Keap1-KD mice. Percent change from wild-type mice in Nrf2-null and Keap1-KD mice 
are presented. 
Gene Function Nrf2-null % change Keap1-KD % change
Gstp2 Conjugation enzyme -40 586 
Gsta1 Conjugation enzyme -84 448 
Gstm3 Conjugation enzyme -81 336 
Nqo1 Phase-I metabolizing enzyme -88 222 
Gstm1 Conjugation enzyme -74 140 
Mrp3 Efflux transporter -85 111 
Gstm4 Conjugation enzyme -67 102 
Ugdh Co-substrate synthesis -50 75 
Gstm2 Conjugation enzyme -57 65 
Gclc Glutathione synthesis -37 63 
Ces1e1 Phase I metabolizing enzyme -94 59 
Mrp4 Efflux transporter -3 55 
Gsta4 Conjugation enzyme -53 45 
Abcg5 Transporter -29 45 
Abcg8 Transporter -20 40 
Ces2a6 Phase-I metabolizing enzyme -85 28 
Ugt2b35 Conjugation enzyme -79 32 
Mrp2 Efflux transporter -17 24 
Ugt1a6 Conjugation enzyme -46 23 
Txnrd1 Anti-oxidative enzyme -41 23 
Gclm Glutathione synthesis -16 22 
Gsr Glutathione homeostasis -23 17 
Bcrp Transporter -27 16 
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Mechanism of induction of Keap-Nrf2 signal pathway and Nrf2 activators 
Studies using functional ARE reporter assays together with Keap1 and Nrf2 
expression vectors revealed that coexpression of Keap1 with Nrf2 in cells repressed the 
transcription of Nrf2 target genes compared with expressing Nrf2 alone (Kobayashi et 
al., 2002). Inducer treatment of cells with dual expression of Keap1 and Nrf2 abrogated 
the repressing activity of Keap1. Exaggerated Nrf2 activation in Keap1-disrupted mice 
provided additional evidence that Keap1 is a negative regulator of Nrf2, and the key 
process of Nrf2 activation is releasing Nrf2 from Keap1 binding. 
The interaction between Keap1 and Nrf2 is through the C-terminal Kelch domain, 
which contains six copies of the evolutionarily conserved Kelch repeat sequence motif 
(Kobayashi et al., 2004). The structure of the Kelch domain from human Keap1 has 
been determined by x-ray crystallography (Li et al., 2004). The Kelch domain forms a 6-
bladed β-propeller structure, with residues at the C terminus forming the first strand in 
the first blade. Key structural roles have been identified for the highly conserved glycine, 
tyrosine, and tryptophan residues that define the Kelch repeat sequence motif. The 
crystal structure of the C-terminal Kelch domain of Keap1 provides structure basis to 
design Nrf2 activators.  
The high cysteine content of Keap1 suggested that cysteine residues would be 
an excellent candidate as the sensor for inducers. Keap1 has 27 highly-reactive 
cysteine residues that have the potential to sense electrophilic Nrf2 activators by forming 
covalent adducts with them. Yamamoto and coworkers have therefore proposed the 
model that Nrf2-activating compounds directly modify the sulfhydryl groups of Keap1 
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cysteines by oxidation, reduction, or alkylation, which alters the conformation of Keap1 
and ceases the ubiquitination of Nrf2 (Kobayashi and Yamamoto, 2006).  Consistent 
with this hypothesis, a number of Nrf2 activators have been reported to react with 
different cysteine residues in Keap1 (Table 1.4).  
A variety of synthetic and natural compounds have been identified as Nrf2 
activators with various potency and selectivity. The doses used in animal studies and 
concentrations used in cell studies that were able to either induce transcription of Nrf2 
target genes or protect against injury models were shown in table 1.5. Only a few 
compounds are potent enough to activate Nrf2 at low concentrations (Table 1.5) 
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Table 1.4. Nrf2 activators with chemical structure and response Keap1 cysteine 
residues. 
 
Nrf2 activator Structure Keap1 cysteine 
residues 
Reference 
Dexamethasone 21-
mesylate 
 
257, 273, 288,
297, and 613 
(human) 
(Dinkova-
Kostova et 
al., 2002) 
Iodoacetyl-N-
biotinylhexylenediamine 
 
 
196, 226, 241, 
257, 288, and 
319 (mouse) 
(Hong et al., 
2005a) 
Sulforaphane 77, 226, 249, 
257, 489, 513, 
518 (human) 
(Hong et al., 
2005a) 
Xanthohumol 151, 319, and 
613 (human) 
(Luo et al., 
2007) 
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Table 1.5. Known Nrf2 activators. 
Chemical Dose/Conc. Animal/cell line Reference 
Oltipraz 50 mg/kg i.p. 
once daily for 
2 days 
Mice (Tanaka et al., 2009) 
50 µM Human hepatocytes (Jigorel et al., 2006) 
tBHQ 
tert-
Butylhydroquinone 
10 μM ARE-reporter cell line 
(AREc32) 
(Wang et al., 2007) 
20 μM Mouse cortical 
neuronal cells 
(Shah et al., 2007) 
40 mg/kg i.p. 
single  dose 
Mice (Yueh and Tukey, 2007) 
BHA 
Butylated 
hydroxyanisole 
350 mg/kg i.p. 
single dose 
Mice (Buckley and Klaassen, 
2009) 
100 and 250 
μM 
Human hepatocellular 
carcinoma cells 
(Yuan et al., 2006) 
CDDO-Im 
1[2-Cyano-3,12-
dioxooleana-
1,9(11)-dien-28-
oyl]imidazole 
1 mg/kg, i.p. Mice (Reisman et al., 2009b) 
20 nM Human peripheral 
blood mononuclear 
cells and neutrophils 
(Thimmulappa et al., 
2007) 
CDDO 
 
300 nM Human leukemia cells (Liby et al., 2005) 
 
Curcumin 
50 mg/kg or 
100 mg/kg, ip 
Rats (Yang et al., 2009) 
15 µM Porcine renal 
epithelial proximal 
tubule cells 
(Balogun et al., 2003) 
Genistein 25 and 50 μM EA.hy926 cells 
(endothelial cell line) 
(Hernandez-Montes et 
al., 2006) 
2 g/kg in diet 
for 3 weeks 
Rats (Wiegand et al., 2009) 
Resveratrol 5 μM Human bronchial 
epithelial cell line 
(HBE1 cell) 
(Zhang et al., 2009) 
Caffeic acid 
phenethyl ester 
15 µM Porcine renal 
epithelial proximal 
tubule cells 
(Balogun et al., 2003) 
Oleanolic acid 90 mg/kg, i.p. 
once daily for 
3 days 
Mice (Reisman et al., 2009a) 
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Oxidative stress plays key roles in the pathogenesis of liver diseases. Nrf2 is a 
transcription factor that promotes transcription of a battery of genes involved in reducing 
reactive oxygen species (ROS) and oxidized protein, glutathione synthesis, as well as 
conjugation and excretion of electrophiles. The antioxidative properties of Nrf2 target 
genes make Nrf2 a promising target in therapies of liver diseases. However, there still is 
limited knowledge in alterations about gene expression after Nrf2 activation in liver. The 
critical role of Nrf2 in protection against oxidative stress-induced liver injury is unclear. 
Therefore, the present dissertation is poised to fill this critical knowledge gap. The 
central hypothesis of the present dissertation is that Nrf2 is essential in liver protection 
through its multifaceted roles in antioxidative defense and xenobiotic metabolism in the 
liver. The goal of this dissertation is to determine the gene regulation by Nrf2 activation, 
and determine the protective role of Nrf2 against oxidative stress-involved liver diseases 
using various research models, and develop activators of the Keap1-Nrf2 signaling 
pathway through high-throughput screening. 
Specific aim 1 was designed to investigate the role of Nrf2 on global gene 
expression in liver. Nrf2 is a transcription factor that has great therapeutic potential. It is 
important to study the role of Nrf2 for genomic gene expression if one wants to develop 
Nrf2 activators as drug candidates. Gene transcription profiles of Nrf2 target genes have 
been studied in mouse macrophages, lung tissue, and embryonic fibroblasts, but there 
is a significant gap in our understanding of the role Nrf2 plays on genomic gene 
expression in liver. Liver is the primary organ in regard to multiple vital functions, 
including protein synthesis (e.g., albumin and clotting factors), glucose homeostasis, 
and lipid metabolism. Liver also plays the major role in detoxication of environmental 
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chemicals, drugs, and endogenous toxicants. Thus, studying the function of Nrf2 in liver 
is of great importance. In the present study, I have utilized a ‘‘gene dose-response’’  
approach including Nrf2-null mice lacking any functional Nrf2, wild-type mice having 
normal Nrf2 activation, Keap1-KD mice having enhanced Nrf2 activation, and Keap1-
HKO mice having the highest Nrf2 activation in liver. Global gene expression profiles 
were performed by microarray analysis in this gene dose-response approach.  
Specific aim 2 was designed to investigate the protective role of Nrf2 against 
chemical-induced liver injury. Information has been obtained on the consequence of 
Nrf2 deficiency by studying Nrf2-null mice, indicating the importance of Nrf2 in 
preventing the development of liver injury. For example, compared with wild-type mice, 
Nrf2-null mice are more susceptible to liver injury by acetaminophen, ethanol, 
pentachlorophenol, and a high-fat diet. However, it is more important to know whether 
Nrf2 activation protects against chemical-induced liver injury. Diquat, ethanol, and 
cadmium produce oxidative stress and liver injury through diverse mechanisms. For 
example, diquat generates superoxide free radicals through redox cycling, ethanol 
generates reactive oxygen species through its metabolism, and cadmium generates 
oxidative stress through binding to the sulfhydryls of glutathione and proteins.  Specific 
aim 2 utilized the gene dose-response model with Nrf2-null, wild-type, Keap1-KD, and 
Keap1-HKO mice to investigate whether Nrf2 deficiency will aggravate, whereas Nrf2 
enhancement will protect against diquat, ethanol, and cadmium induced oxidative stress 
and subsequent liver injury.  
Specific aim 3 was designed to develop novel Nrf2 activators by high-throughput 
screening. A library of 47,000 synthetic and natural existing compounds was screened 
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in AREc32 cells, a stably transfected MCF7 cell line that contains a luciferase gene 
construct under the control of ARE. Pharmacological activation of Nrf2 was monitored 
by quantifying luminescent intensity as an indicator of activation of ARE. The active 
compounds identified from the primary screening were validated with a range of eleven 
concentrations using the same screening system.  The validated hits were further 
confirmed and prioritized by secondary screening in Hepa1c1c7 cells by monitoring 
induction of Nrf2 target genes. The lead compounds provide a starting point for 
chemical optimization and further development. Chemical structures of lead compounds 
also provide important information on structure-activity-relationship to activate the 
Keap1-Nrf2 signal pathway. 
In summary, utilizing a gene dose-response model and high-throughput 
techniques, the present dissertation has investigated the role of Nrf2 on genomic gene 
expression in liver, the protective effect of Nrf2 against chemical-induced oxidative 
stress and subsequent liver injury, and found multiple compounds that are highly 
effective in activating the Keap1-Nrf2 pathway. The data generated from these studies 
will provide fundamental knowledge to further understand the Keap1-Nrf2 pathway, and 
identify the Keap1-Nrf2 pathway as an important target in therapy of liver diseases. 
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Chapter 3 : EXPERIMENTAL MATERIALS AND METHODS 
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Reagents 
Nrf2 antibody was purchased from Santa Cruz Biotechnology (sc-30915, Santa Cruz, 
CA). TATA-box binding protein (TBP) antibody was purchased from Abcam (ab51841, 
Cambrdige, MA). Nqo1 and β-actin antibodies were purchased from Abcam (Ab2346, 
Ab8227, respectively, Cambridge, MA), Srebp1 antibody was purchased from Santa 
Cruz Biotechnology (sc-367, Santa Cruz, CA), and histone 3 antibody was purchased 
from Millipore (DAM170816, Billerica, MA). Gclc antibody was a gift from Dr. Terry 
Kavanagh (University of Washington, Seattle, WA). 2-Cyano-3,12-dioxooleana-1,9-
diene-28-imidazolide (CDDO-Im) was a generous gift from Dr. Michael Sporn 
(Dartmouth College, Hanover, New Hampshire). All other chemicals, unless otherwise 
specified, were purchased from Sigma-Aldrich (St Louis, MO). 
Animals and husbandry 
Eight-week-old male mice were used for this study. C57BL/6 mice were 
purchased from Charles River Laboratories, Inc. (Wilmington, MA). Nrf2-null mice were 
obtained from Dr Jefferson Chan (University of California, Irvine, CA) (Chan et al., 1996). 
Keap1-KD mice were supplied by Dr Masayuki Yamamoto (Tohoku University, Sendai, 
Japan). In an attempt to make a hepatocyte-specific Keap1-null mouse, utilizing a loxP, 
Alb-Cre system, a Keap1-Flox mouse, in which Keap1 was decreased throughout the 
body (Keap1-kncokdown, Keap1-KD mice), was engineered (Okada et al., 2008). Nrf2-
null and Keap1-KD mice were backcrossed into the C57BL/6 background, and > 99% 
congenicity was confirmed by Jackson Laboratories (Bar Harbor, ME). Keap1-HKO 
mice were generated by crossing Keap1-KD mice and AlbCre+ mice, which express Cre 
only in hepatocytes. All the mice used in the study were bred at University of Kansas 
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Medical Center and housed in a temperature-, light-, and humidity-controlled 
environment and had access to Teklad Rodent Diet #8604 (Harlan Laboratories, 
Madison, WI) and water ad libitum. The housing facility at the University of Kansas 
Medical Center is accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care. All the mice were euthanized in the morning (8:00-10:00am) 
under the fed state. All procedures were pre-approved in accordance with Institutional 
Animal Care and Use Committee guidelines.  
A modified “binge drinking” model was used to study ethanol-induced hepatic 
alterations (Bergheim et al., 2006). Nrf2-null mice, wild-type mice, Keap1-KD mice, and 
Keap1-HKO mice were treated with either ethanol (5 g/kg, oral gavage) or an isocaloric 
glucose solution. Six h after ethanol administration, blood and liver samples were 
collected and stored at -80°C for further analysis. Food and tap water were allowed ad 
libitum during the experimentation. 
To investigate whether Nrf2 protects against cadmium-induced toxicity, Nrf2-null 
mice, wild-type mice, Keap1-KD mice, and Keap1-HKO mice were treated with either 
cadmium chloride (3.5 mg Cd/kg, i.p.) or saline (10 mL/kg, i.p.). Eight h after 
administration of CdCl2, blood and liver samples were collected. Portions of liver were 
fixed in 10% zinc formalin for histological analysis, and other portions were frozen in 
liquid nitrogen and stored at -80℃. 
To investigate whether Nrf2 protects against diquat-induced toxicity, Nrf2-null, 
wild-type, and Keap1-KD mice were dosed with either saline (5 mL/kg, i.p.) or diquat dibromide 
(125 mg/kg, i.p.). Blood, livers, and lungs were collected at 1, 2, 4, and 6 h after diquat 
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treatment or 3 h after saline treatment. Upon removal, livers and lungs were weighed 
immediately. Portions of livers and lungs were fixed in 10% zinc formalin for histological analysis, 
and the remainder was frozen in liquid nitrogen and stored at -80℃. 
Nrf2 protein expression in hepatic nuclear extracts 
Nuclear extracts were prepared with the NE-PER nuclear extraction kit according 
to the manufacturer’s protocol (Pierce Biotechnology, Rockford, IL). Protein 
concentrations were determined with a BCA Assay Kit from Pierce Biotechnology. 
Nuclear proteins (40 μg protein per lane) were electrophoretically resolved using 
polyacrylamide gels (4% stacking and 10% resolving). Gels were transblotted overnight 
at 4°C onto polyvinylidene fluoride membranes. Membranes were then washed with 
PBS-buffered saline containing 0.05% Tween-20 (PBS-T). Membranes were blocked for 
1 h at room temperature with 5% nonfat milk in PBS-T. Blots were then incubated with 
primary antibody (1:1000 dilution in 2% nonfat milk in PBS-T) for 3 h at room 
temperature. Blots were washed in PBS-T and incubated with species-appropriate 
secondary antibody conjugated with horseradish peroxidase (1:2000 dilution) in 2% 
nonfat milk in PBS-T buffer for 1 h at room temperature. Blots were then washed with 
PBS-T. Protein-antibody complexes were detected using an ECL chemiluminescent kit 
(Pierce Biotechnology, Rockford, IL) and exposed to X-ray film (Denville Scientific, 
Metuchen, NJ). Equal protein loading was confirmed by TATA-box binding protein 
(TBP). Nrf2 and TBP proteins migrated the same distance as proteins of approximately 
110 and 37 kDa, respectively. Intensity of protein bands was quantified by Discovery 
Series Quantity One 1-D Analysis Software (Bio-Rad Laboratories, Hercules, CA). 
Individual blot densities were normalized to that of wild-type mice. 
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Gclc, Nqo1, and Srebp1 protein expression in hepatic cytosolic fraction 
Livers were homogenized in sucrose-Tris buffer (0.25 mol/L sucrose, 10 mmol/L 
Tris–HCl, pH 7.4) and centrifuged at 100,000 x g for 60 min at 4°C. The resulting 
supernatant, that is the cytosolic fraction, was used to assay Gclc and Nqo1 protein. 
Nuclear extracts were prepared with the NE-PER nuclear extraction kit, according to the 
manufacturer’s directions (Pierce Biotechnology, Rockford, IL). Nuclear extracts were 
used for Srebp1 immunoblotting.  
Cytosolic and nuclear proteins (40 μg protein/lane) were electrophoretically 
resolved using polyacrylamide gels. Gels were transblotted overnight at 4°C onto a 
nitrocellulose membrane. Membranes were then washed with PBS-buffered saline 
containing 0.05% Tween-20 (PBS-T). Membranes were blocked for 1 h at room 
temperature with 5% non-fat milk in PBS-T. Blots were then incubated with primary 
antibody (1:2000 dilution for Gclc, Nqo1, and histone 3, and 1:200 for Srebp1, in 1% 
non-fat milk in PBS-T) for 1 h at room temperature. Blots were then washed in PBS-T 
and incubated with secondary antibody conjugated with horseradish peroxidase (1:2000) 
in 2% non-fat milk in PBS-T buffer for 1 h at room temperature. Blots were then washed 
with PBS-T. Protein-antibody complexes were detected using an enhanced 
chemiluminescent kit (Pierce Biotechnology, Rockford, IL) and exposed to X-ray film 
(Denville Scientific, Metuchen, NJ). Intensity of protein bands was quantified using the 
Discovery Series Quantity One 1-D Analysis software (Bio-Rad Laboratories, Hercules, 
CA). Intensity values were normalized to β-actin or histone 3 and expressed as relative 
protein concentrations. 
GSH quantification 
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GSH concentrations were quantified by UPLC-MS/MS according to a previous 
method with small modifications (Guan et al., 2003; New and Chan, 2008).  Briefly, 
frozen liver tissue (50 mg) was diced, added to 200 µl of ice-cold KCl (1.15%) and 
homogenized over ice for 2 min.  Tissue homogenates (50 µL) were transferred to a 1.5 
ml snapcap conical-bottom centrifuge vial with glutathione ethyl ester (0.01 mg/ml, 20 
µL) added as the internal standard (IS).  Ellman’s reagent (10 mM, 100 µl) was added to 
the homogenate and vortexed, followed by addition of 30 µl of 5-sulfosalicylic acid 
(20%). After centrifuging at 11,600 g for 15 min, the supernatant was collected for 
LC/MS analysis. A Waters Acquity ultra performance LC system (Waters, Milford, MA) 
was used and all chromatographic separations were performed using an Acquity UPLC 
BEH C18 column (1.7 µm, 100 x 2.1 mm I.D.). The mass spectrometer was a Waters 
Quattro Premier XE triple quadrupole instrument with an ESI source (Waters, Milford, 
MA). The multiple reaction monitoring (MRM) transitions under ESI positive mode are 
as follows:  m/z 504.8>272.9 for GSH-Ellman, 532.88>204.9 for IS-Ellman.   
Total RNA isolation 
Total RNA was isolated using RNAzol B reagent (Tel Test, Inc., Friendswood, TX) 
according to the manufacturer's protocol. The concentration of total RNA in each sample 
was quantified spectrophotometrically at 260 nm. The integrity of each RNA sample was 
evaluated by formaldehyde-agarose gel electrophoresis before analysis.  
Quantification of mRNA expression by RT-PCR assay 
34 
 
Total RNA in mouse livers was reverse-transcribed into cDNA by High Capacity 
cDNA Archive Kit (Applied Biosystems, Foster City, CA), and the resulting cDNA was 
used for real-time PCR analysis using SYBR® Green PCR Master Mix in 7900HT Fast 
Real-Time PCR System (Applied Biosystems, Foster City, CA). Oligonucleotide primers 
specific to mouse β-actin, Gclc, Nqo1, Me1, G6pdx, Pgd, Scd1, Srebp1, MT-1, MT-2, 
Gpx2, Prdx1, Txnrd1, Srxn1, and Txn1  are described in table 3.1. 
Microarray and data analysis 
Gene expression in livers of Nrf2-null, WT, Keap1-KD, and Keap1-HKO mice 
was determined by the Affymetrix Mouse 430.20 arrays at the KUMC Microarray Core 
Facility. Biological replicates (n = 3) of each genotype were hybridized to individual 
arrays. Raw data CEL files were pre-processed using R in the Bioconducter by “affy” 
and Robust Multichip Averaging (gcRMA) packages (Irizarry et al., 2003). The mean 
probe intensities higher than log2100 in at least one group were selected for further 
analysis. Gene annotations were obtained using the mouse 4302 and “annaffy” 
packages.  Differential gene expression analysis was performed across all genotypes 
(P-value < 0.05) by the Linear Models for Microarray Data (Limma) package. Probes 
that were shown to be differentially expressed were included in a Venn diagram which 
identifies the common and exclusively expressed genes of each genotype (Nrf2-null, 
WT, Keap1-KD, and Keap1-HKO). Two-way hierarchical clustering of pathway specific 
gene expression was conducted using JMP 8.0 software (SAS Institute, Cary, NC) 
using agglomerative clustering for hierarchical clustering. The method starts with each 
point (gene) as its own cluster. At each step, the two clusters that are closest together 
are combined into a single cluster. This process continues until there is only one cluster 
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containing all the points (genes). This kind of clustering is good for smaller data sets (a 
few hundred observations). The distance between two genes was calculated by the 
Ward method.  
Pathway analysis 
Functional and pathway analysis of differentially expressed probe sets was 
performed using the Ingenuity Pathway Analysis (IPA, Ingenuity Systems, 
www.ingenuity.com), and Database for Annotation, Visualization and Integrated 
Discovery (DAVID) (http://david.abcc.ncifcrf.gov) database. Pathway enrichment was 
determined by P value ≤ 0.05 and a minimum of 4 probes in the pathway. False-
discovery rates (FDRs) are also reported. 
Motif analyses and transcription factor-binding site over-representation 
The core sequence of Antioxidant Response Element (ARE, TGACnnnGC) was 
searched for in the 5’ region (up to 10kb upstream of transcription start site) of each 
gene using Genamics Expression DNA Sequence Analyses Software (GENAMICS, 
Hamilton, New Zealand). Over-represented conserved transcription factor binding sites 
in genes induced by Nrf2 activation were searched for by the oPOSSUM system 
(http://opossum.cisreg.ca/oPOSSUM3). The over-representation was calculated on a 
conserved region (from 5kb upstream to 2kb downstream) around the transcription start 
site (TSS) of the drug processing genes that were induced by Nrf2, and the over-
representation was calculated by comparing with the same region in a battery of drug 
processing genes that were not altered by Nrf2 as a background. 
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Serum lactate dehydrogenase (LDH) and alanine aminotransferase (ALT) 
activities 
Serum LDH activities were determined as a biochemical indicator of hepacellular 
necrosis using a LDH-L Reagent Set (Thermo Fisher Scientific Inc., Fair Lawn, NJ). 
Serum ALT concentrations were determined using a Pointe Scientific Liquid ALT 
Reagent Set (Canton, MI) according to the manufacturer’s protocol. 
Lipid peroxidation in serum 
Lipid peroxidation in serum was monitored by quantifying thiobarbituric acid 
reactive substances (TBARS) using a TBARS assay kit (Thermo Fisher Scientific Inc., 
Fair Lawn, NJ). 
Isolation and purification of mitochondria 
Mitochondria were isolated as previously described with minor modifications 
(Chavan et al., 2011). Liver samples (50 mg) were homogenized in 400 µL of isolation 
buffer (250 mM sucrose, 1 mM EDTA , 10 mM Tris-HCl [pH 7.4]) containing 1× protease 
inhibitor cocktail (Roche Applied Science, Indianapolis, IN) on ice. The liver 
homogenates were centrifuged at 960 x g for 15 min at 4°C to remove large debris and 
nuclei. The resultant supernatants were centrifuged at 8,600 x g for 15 min at 4°C. The 
pellets (crude mitochondria) were stored in mitochondria stock buffer (210 mM mannitol, 
70 mM sucrose, 5 mM Tris-HCl, [pH 7.5], and 1 mM EDTA) at -80°C before use. 
Primary hepatocyte isolation and treatment 
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Primary hepatocytes from Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice 
were isolated as described previously (Ding et al., 2010). After isolation, cells were 
plated in 12-well plates (1×105 cells per well) and cultured in Williams’ Medium E 
(Invitrogen Corporation, Carlsbad, CA) containing 10% fetal bovine serum, 100 U/mL 
penicillin/streptomycin, and 2 mM glutamate. The plates were placed in a humidified, 5% 
CO2 and 95% air incubator at 37°C. After 3 h, cells were washed with PBS and 
adherent hepatocytes were allowed to acclimate to culture conditions overnight. Cells 
were then cultured with fresh medium containing 0, 30, 100, or 300 mM ethanol, or 0, 
10, 30, or 100 µM cadmium, or 0, 10, 30, or 100 µM diquat for 0, 3, 6, or 24 h.  
Measurement of ROS Production 
For general oxidative stress detection, cells were loaded with 2′,7′-
dichlorodihydrofluoresein diacetate (H2DCFDA; Invitrogen Corporation, Carlsbad, CA) 
for 30 min, and then washed with PBS, and incubated with Hanks′ Balanced Salt 
Solution (HBSS, with calcium and magnesium) for another 30 min. Images were taken 
using an Olympus B×41 microscope (Olympus Optical, Tokyo, Japan). Images were 
captured using an Olympus DP70 camera (×40) with DP Controller software. For 
quantification, cells were scraped and lysed using a lysis buffer (25 mM HEPES, 5 mM 
EDTA, and 0.1% CHAPS), and the fluorescence intensity of the DCF formed was 
determined with a Synergy 2 Multi-Detection Microplate Reader interfaced with a Gen5 
Reader Control and Data Analysis Software (Biotek, Winoosky, VT) at excitation and 
emission wavelengths of 480 nm and 530 nm, respectively. 
Triglyceride and free fatty acid concentrations in liver and serum 
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Table 3.1. Oligonucleotide sequences for primers for RT-PCR analysis. 
Gene Forward Reverse 
β-actin tgaccgagcgtggctacag gggcaacatagcacagcttct 
Nqo1 tatccttccgagtcatctctagca tctgcagcttccagcttcttg 
Gclc tggccactatctgcccaatt gtctgacacgtagcctcggtaa 
G6pdx agtgggtgaaccctcacaag agctgggtttactggtggtg 
Me1 gggattgctcacttggttgt gttcatgggcaaacacctct 
Pgd gggcactttgtgaagatggt aacagctctttgccgtcagt 
Srebp1 gtgagcctgacaagcaatca ggtgcctacagagcaagagg 
Scd1 gcgatacactctggtgctca cccagggaaaccaggatatt 
MT-1 ctccgtagctccagcttcac aggagcagcagctcttcttg 
MT-2 ccgatctctcgtcgatcttc aggagcagcagcttttcttg 
Ho-1 cctcactggcaggaaatcatc cctcgtggagacgctttacata 
Trxn1 gccaaaatggtgaagctgat tgatcattttgcaaggtcca 
Gpx2 cagcttccagaccatcaaca cactgagccctgaggaagac 
Srxn1 cccactggaccaacttctgt gtggctagctcagaccaagg 
Prdx1 cacccaagaaacaaggagga aaaaaggcccctgaaagaga 
Txnrd1 gcagaccaatgtgccttacat acggctttttcttcagagagg 
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Cell growth and maintenance 
The AREc32 cell line was obtained from CRX biosciences (Dundee, Scotland). 
The AREc32 are a stable cell line derived from human MCF7 breast carcinoma cells. 
AREc32 cells were constructed by a luciferase gene construct that under the control of 
eight copies of rat Gsta2 AREs in the promoter region (Wang et al., 2006). AREc32 
cells were maintained at University of Kansas High Throughput Center in Dulbecco’s 
Modified Eagle’s medium (DMEM) containing glutamax supplemented with 10% fetal 
calf serum and the antibiotic G418 (Life Technologies Corporation, Carlsbad, CA).  The 
cell line was grown at 37ºC in the presence of 5% CO2. 
AREc32 cells were seeded into 384-well plates (flat-bottom white, opaque, sterile, 
with lids).  Cells were seeded at a density of 3,500 cells/well using a Wellmate bulk 
dispenser (Thermo Fisher Scientific, Waltham, MA) in 50µL complete media per well.  
Cell plates were incubated at room temperature for 30 min following seeding to allow for 
even cell settling.  Cell plates were then incubated at 37ºC, 5% CO2 in a 95% humidified 
incubator for 20 hrs. 
Murine hepatoma Hepa1c1c7 cells were obtained from ATCC (Manassas, VA) 
and maintained in DMEM with glutamate, supplemented with 10% (v/v) heat-inactivated 
FBS, penicillin (100 units/mL), and streptomycin (100 µg/ml). The cell line was grown at 
37ºC in the presence of 5% CO2. 
Compound Libraries and preparation 
Four libraries of compounds were screened for Nrf2 activation in the present 
study: MicroSource Discovery Systems (www.msdiscovery.com/spectrum.html) 
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containing 2000 compounds, Prestwick Chemical Library (Prestwick Chemical, 
Washington, DC) containing 1120 compounds, 1920 compounds  from the University of 
Kansas Center of Excellence in Chemical Methodologies & Library Development (KU-
CMLD) containing, and ChemBridge Small Molecule Library (ChemBridge Corporation, 
San Diego, CA) containing 41,888 compounds. The chemical names, CAS-numbers, 
and sources of all the natural chemicals are summarized in Table 3.2. 
The four libraries of compounds  were stored at 2859 µM in 100% DMSO, and 
175 nL from each compound well  was transferred to the 50 µL cell culture medium in 
the receiving well.  Chembridge library compounds were dispensed by the Matrix 
PlateMate Plus automated nanoliter capacity liquid handler (Thermo Fisher Scientific, 
Waltham, MA), followed by three gentle mixings. Compounds from MicroSource, 
Prestwick, and CMLD libraries, as well as the compounds for the concentration-
response validation, were dispensed by Labcyte Echo 550 Compound Reformatter 
(Labcyte Inc., Sunnyvale, CA), which allows the accurate transfer of small volumes of 
liquid.  The final concentration of each chemical in the full library screen was 10.0 µM, 
with a DMSO content of 0.35%.  
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Table 3.2. Chemical names, CAS-numbers and sources of all the test natural chemicals. 
Compound CAS Source 
CDDO-Im NA Sporn a 
tBHQ 1948-33-0 Sigma b 
Andrographolide 5508-58-7 Sigma 
Trans-chalcone 614-47-1 Acros c 
Sulforaphane 4478-93-7 Sigma 
Curcumin 458-37-7 Acros 
Flavone 525-82-6 Sigma 
Kahweol 6894-43-5 LKT d 
Cafestol 469-83-0 LKT 
Carnosol 5957-80-2 Cayman e 
Caffeic acid 331-39-5 Cayman 
Caffeic acid phenethyl ester 104594-70-9 Sigma 
Chlorogenic acid 327-97-9 LKT 
Allyl disulfide 2179-57-9 Sigma 
Chrysin 480-40-0 Sigma 
Caffeic acid phenethyl ester 104594-70-9 Sigma 
Myricetin 529-44-2 Sigma 
Apigenin 520-36-5 Sigma 
(s,s)-(+)-Tetrandrine 518-34-3 Sigma 
Quercetin 117-39-5 Sigma 
Luteolin 491-70-3 Cayman 
Berberine 2086-83-1 Sigma 
Fisetin 528-48-3 Sigma 
Resveratrol 501-36-0 Sigma 
Baicalin 21967-41-9 Sigma 
Kaempferol 520-18-3 Sigma 
Galangin 548-83-4 Sigma 
(-)-Epicatechin 490-46-0 Sigma 
Hesperetin 520-33-2 Sigma 
Genistein 446-72-0 Acros 
Indole-3-carbinol 700-06-1 Acros 
Chlorophyllin 15611-43-5 Sigma 
Daidzein 486-66-8 Sigma 
Lupeol 545-47-1 Sigma 
Glycitein 40957-83-3 LKT 
Daidzin 552-66-9 Cayman 
Evodiamine 5956-87-6 Sigma 
Quercitrin 522-12-3 Sigma 
Zebularine 3690-10-6 Sigma 
Naringenin 480-41-1 LKT 
Silymarin 65666-07-1 LKT 
Matrine 519-02-8 INDOFINE f 
Oleanolic acid 508-02-1 Quality g 
Sennoside B 128-57-4 Quality 
Crocin 42553-65-1 Sigma 
Morin 480-16-0 Sigma 
Oxymatrine 16837-52-8 INDOFINE 
Chrysophanic acid 481-74-3 Sigma 
Icariin 489-32-7 Sigma 
Silibinin 22888-70-6 Sigma 
Glycyrrhetinic acid 471-53-4 Acros 
Synephrine 94-07-5 Quality 
Rutin 153-18-4 Sigma 
Epigallocatechin 3-gallate 989-51-5 Sigma 
Naringin 10236-47-2 Sigma 
(+)-Catechin 7295-85-4 Sigma 
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a: generous gift from Dr. Michael Sporn (Dartmouth College, Hanover, New Hampshire) 
b: Sigma-Aldrich (St. Louis, MO) 
c: Acros Organics (Geel, Belgium) 
d: LKT Laboratories (St. Paul, MN) 
e: Cayman Chemicals (Ann Arbor, MI) 
f: INDOFINE Chemical Company (Hillsborough, NJ). 
g: Quality Phytochemicals, LLC (Edison, NJ) 
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Quantification of ARE activation by Promega Steady-Glo luciferase assay system. 
The AREc32 cell line was exposed to library compounds for 24 hrs at 37ºC, 5% 
CO2 in a 95% humidified incubator, then the plates were removed from the incubator 
and left at room temperature for 20 min to equilibrate the plate and its contents to room 
temperature.  The Matrix Wellmate dispensed Steady-Glo luciferase assay reagent 
(Promega, Madison, WI) to all cells, 10 µL per well, and plates were shaken for 1 min at 
1600 rpm. The luminescence intensities were read 30 min later on a Tecan Safire2 
microplate reader (Männedorf, Switzerland).  The Steady-Glo reagent produces cell 
lysis and generation of a luminescent signal, which is proportional to ARE activation, 
through the luciferase reporter in the AREc32 cell line.   
Four controls were used on each plate of cells: (1) cells treated with tBHQ, a 
known ARE activator (positive control), (2) cells treated with CDDO-Im, a very potent 
activator of Nrf2/ARE (positive control), (3) cells in media containing 0.35% DMSO 
(vehicle control), and (4) cells in media containing no DMSO (fully healthy cells) to 
measure background luminescence.  
Z’ factor for Pass/Fail Criterion 
The positive and negative controls were required to assure uniformity from plate 
to plate, and from screening batch to batch.  The controls were used to calculate a Z’ 
factor value for each plate, a measure of assay robustness and variability popularly 
used for high throughput screening.  The Z’ factor compares the baseline background 
(minimum ARE signal) from the DMSO vehicle control, and the maximum signal of 
response of the positive controls tBHQ and CDDO-Im (Zhang et al., 1999; Iversen et al., 
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previous step. Compounds that had not originally been selected to a given cluster but 
containing the cluster's characteristic conserved substructure were then added to the 
cluster. 
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Chapter 4 : BENEFICIAL ROLE OF NRF2 IN REGULATING NADPH GENERATION 
AND CONSUMPTION 
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Abstract 
Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that 
promotes the transcription of cytoprotective genes in response to oxidative and 
electrophilic stresses. Most functions of Nrf2 were identified by studying biological 
models with Nrf2 deficiency, however, little is known about the effects of graded Nrf2 
activation. In the present study, genomic gene expression profiles by microarray 
analysis were characterized with a ‘gene dose-response’ model in livers of Nrf2-null 
mice, wild-type mice, Keap1-knockdown (Keap1-KD) mice with enhanced Nrf2 
activation, and Keap1-hepatocyte knockout (Keap1-HKO) mice with maximum hepatic 
Nrf2 activation. Hepatic nuclear Nrf2 protein, glutathione concentrations, and known 
Nrf2 target genes were increased in a dose-dependent manner. In total, 115 genes 
were identified to be constitutively induced and 80 genes suppressed with graded Nrf2 
activation. Messenger RNA of genes encoding enzymes in the pentose phosphate 
pathway and enzyme were low with Nrf2 deficiency and high with Nrf2 activation, 
indicating that Nrf2 is important for NADPH production. NADPH is the major reducing 
resource to scavenge oxidative stress, including regenerating glutathione and 
thioredoxin, and is also used for anabolic pathways including lipid synthesis. HPLC-UV 
analysis confirmed that hepatic NADPH concentration was lowest in Nrf2-null mice and 
highest in Keap1-HKO mice. In addition, genes involved in fatty acid synthesis and 
desaturation were down-regulated with graded Nrf2 activation. In conclusion, the 
present study suggests that Nrf2 protects against environmental insults by promoting 
the generation of NADPH, which is preferentially consumed by aiding scavenging of 
oxidative stress rather than fatty acid synthesis and desaturation. 
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Introduction 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that 
induces a battery of cytoprotective genes in response to oxidative/electrophilic insults. 
Under physiological conditions, Nrf2 is bound to its repressor, Kelch-like ECH 
associating protein 1 (Keap1), in the cytosol. Keap1 functions as an adapter protein that 
retains Nrf2 in the cytoplasm by interacting with the cytoskeleton, and it facilitates 
degradation of Nrf2 by binding with Cullin 3-based E3 ligase, a protein-protein complex 
that ubiquitinates Nrf2 protein (Cullinan et al., 2004). With the negative regulatory 
system of Keap1, Nrf2 protein has a very rapid turnover, with a half-life less than 20 min 
(Kobayashi et al., 2004), and thus Nrf2 protein is minimally detectable in unstressed 
conditions. There are numerous cysteine residues in Keap1 protein: murine and rat 
Keap1 have 25 cysteine residues, and human Keap1 has 27 cysteine residues. The 
high cysteine content of Keap1 makes it an excellent sensor for oxidative/electrophilic 
stress. Yamamoto and coworkers, therefore, proposed that Nrf2-activating compounds 
directly modify the sulfhydryl groups of cysteines in Keap1 by oxidation, reduction, or 
alkylation, which would alter the conformation of Keap1 and cease  the ubiquitination of 
Nrf2 (Kobayashi and Yamamoto, 2006). Once released from Keap1, Nrf2 translocates 
into the nucleus, heterodimerizes with a small musculo-aponeurotic fibrosarcoma (Maf) 
protein, and promotes transcription of its target genes (Itoh et al., 1997). Consistent with 
this hypothesis, a number of Nrf2 activators have been reported to react with different 
cysteine residues of Keap1 (Hong et al., 2005b; Luo et al., 2007). 
After the Keap1-Nrf2 signal pathway was discovered, a number of natural and 
synthetic compounds were shown to activate Nrf2, and protect against oxidative stress-
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induced toxicity through Nrf2 activation. Potential therapeutic applications of Keap1-Nrf2 
pathway have therefore been investigated. For example, curcumin was shown to protect 
against focal ischemia of cerebrum through upregulation of Nrf2, indicating Nrf2 may be 
suitable target for therapy of cerebral ischemia (Yang et al., 2009).  Resveratrol was 
shown to increase transcription of GSH synthesis enzymes through activating Nrf2 
(Zhang et al., 2009). Oltipraz was shown to protect against Alpha-
naphthylisothiocyanate (ANIT)-induced cholestasis through Nrf2 activation, which 
indicated that pharmacological activation of Nrf2 may represent a therapeutic option for 
intrahepatic cholestasis (Tanaka et al., 2009). 2-Cyano-3,12-dioxooleana-1,9-dien-28-
oic imidazolide (CDDO-Im), a synthetic triterpenoid, was shown to activate Nrf2 and 
protect against acetaminophen-induced liver injury (Reisman et al., 2009b). However, 
pharmacological activation of Nrf2 by chemicals is problematic, for they often have 
many off-target effects. For example, curcumin also activates AP-1, a transcription 
factor that promotes cell proliferation (Anand et al., 2008); Resveratrol also activates 
SIRT-1 (Baur, 2010); oltipraz activates CAR, and induces Cyp2b10 through CAR 
activation (Merrell et al., 2008); CDDO-Im activates Smad and ERK, and induces cell 
differentiation (Ji et al., 2006).  
Nrf2-null mice have served as a valuable model to examine the Keap1-Nrf2 
pathway. Compared to wild-type mice, Nrf2-null mice are more susceptible to liver injury 
by oxidative and electrophilic stress (Aleksunes and Manautou, 2007), acetaminophen 
(Enomoto et al., 2001), ethanol (Lamle et al., 2008), pentachlorophenol (Umemura et al., 
2006), and high-fat diet (Tanaka et al., 2008). To investigate the effect of increased Nrf2 
activation, Keap1-null mice were engineered. However, Keap1-null mice died at about 
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20 days of age (Wakabayashi et al., 2003), and thus a Keap1-hepatocyte knockout 
mouse (Keap1-HKO mouse) was engineered, utilizing the albumin-Cre loxP system. 
The Keap1-HKO mice have maximal activation of Nrf2 and Nrf2-target genes in liver, 
and are more resistant to acetaminophen hepatotoxicity (Okawa et al., 2006). Later it 
was discovered that mice homozygous for Keap1 loxP sites (no Albumin-Cre transgene) 
have decreased or a “knockdown” of Keap1 (Keap1-KD), resulting in an intermediate 
activation of Nrf2 in multiple organs(Okada et al., 2008). Taking advantage of the fact 
that floxed Keap1 allele is hypomorphic, an animal of graded reduction of Keap1 
expression in adult mice was generated (Taguchi et al., 2010).  
Gene transcription profiles have been performed on the effect of Nrf2 in mouse 
macrophages (Woods et al., 2009), lung tissue (Blake et al., 2010), and embryonic 
fibroblasts (Malhotra et al., 2010), but there is a significant gap in our understanding of 
Nrf2 on genomic gene expression in liver. Liver is the primary organ for the 
detoxification of environmental chemicals, drugs, and endogenous toxicants. Thus, 
studying the function of Nrf2 in liver is of great importance. In the present study, we 
have utilized a “gene dose-response” approach including Nrf2-null mice lacking any 
functional Nrf2, wild-type mice having normal Nrf2 activation, Keap1-KD mice having 
enhanced Nrf2 activation, and Keap1-HKO mice having the highest Nrf2 activation in 
liver. Hepatic phenotypes as well as genomic gene expression profile were analyzed in 
this “gene dose-response” approach.  
 
 
 
 
Results 
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Characterization of “gene dose-response” model for Nrf2 activation 
To confirm differential Nrf2 activation of the “gene dose-response” model, nuclear 
Nrf2 concentration, relative liver weight, hepatic GSH concentration, as well as mRNA 
expression of known Nrf2-target genes were characterized in livers of Nrf2-null, wild-
type, Keap1-KD, and Keap1-HKO mice. Nuclear Nrf2 protein was undetectable in Nrf2-
null mice, 1.4-fold higher in Keap1-KD mice, and 2.3-fold higher in Keap1-HKO mice 
than wild-type mice (Fig. 4.1A). The relative liver weight in Nrf2-null mice tended to be 
lower than wild-type mice but not statistically significant. The relative liver weight in 
Keap1-KD and Keap1-HKO mice was 11% and 24% higher than in wild-type mice, 
respectively (Fig.4.1B). GSH concentrations in livers of Nrf2-null mice were 18% lower 
than in wild-type mice. In livers of Keap1-KD and Keap1-HKO mice, GSH 
concentrations were 7% and 14% higher than wild-type mice, respectively (Fig.4.1C). 
Compared to wild-type mice, mRNA expression of Nqo1, a prototypical Nrf2 target gene, 
was 88% lower in Nrf2-null mice, and 167% and 1262% higher in Keap1-KD and 
Keap1-HKO mice, respectively (Fig.4.1D, upper panel). Compared to wild-type mice, 
mRNA of Gclc, another known Nrf2 target gene, was 36% lower in Nrf2-null mice, and 
49% and 138% higher in Keap1-KD and Keap1-HKO mice, respectively (Fig.4.1.D, 
lower panel). In summary, Nrf2 activation was low in Nrf2-null mice, normal in wild-type 
mice, enhanced in Keap1-KD mice, and greatest in Keap1-HKO mice. 
 
 
 
 
53 
 
 
Figure 4.1. Characterization of “gene dose-response” model. (A) Nuclear Nrf2 protein 
levels by western blot analysis, (B) relative liver weight, (C) hepatic GSH concentrations 
by UPLC-MS/MS analysis, and (D) mRNA concentrations of known Nrf2 target genes 
by RT-PCR analysis in livers of Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice. 
Data are presented as Mean ± S.E.M of 3 animals per group for Fig 1A, and 5 animals 
per group for Fig 1B, 1C and 1D.  Asterisks (*) indicate statistically significant 
differences from wild-type mice (p < 0.05).  
Transcriptional profiling of “gene dose-response” model 
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To investigate the effect of Nrf2 on gene transcription profiles in livers of mice, 
genomic mRNA expression was characterized by microarray. With approximately 45101 
probes, 8021 were detected with signal intensity higher than the threshold and were 
selected for further analysis. In the pool of 8021 probe sets, 1519 probes were identified 
to be differentially expressed among the “gene-dose response” groups based on LIMMA. 
Specifically, 310 probe sets were expressed higher in wild-type mice than in Nrf2-null 
mice, 294 were higher in Keap1-KD mice than in wild-type mice, and 550 were higher in 
Keap1-HKO mice than Keap1-KD mice. Focusing on the intersection of the three sets, 
115 probes were identified to have dose-response behavior and were constitutively 
induced by Nrf2. In contrast, the signal intensity of 362 probe sets were lower in wild-
type mice than in Nrf2-null mice, 263 were lower in Keap1-KD mice than in wild-type 
mice, and 612 were lower in Keap1-HKO mice than Keap1-KD mice. Focusing on the 
intersection of the three sets, 80 probe sets were identified to have dose-response 
behavior and were constitutively suppressed by Nrf2 (Fig.4.2).  
Pathway analysis of genes constitutively induced or suppressed with Nrf2 
activation 
To categorize the functions of genes induced or suppressed by Nrf2, 
constitutively up-regulated and down-regulated probes sets were submitted separately 
to Ingenuity Pathway Analysis (IPA) and the Database for Annotation, Visualization, and 
Integrated Discovery (DAVID). From the list of probe sets that were up-regulated by 
Nrf2, core analysis using IPA revealed enrichment of Nrf2-mediated oxidative stress 
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Figure 4.2. Transcriptional profiling of “gene dose-response” model to reveal Nrf2-
dependent transcriptional targets. (A) Venn diagram of probe sets that had higher 
expression in wild-type mice than in Nrf2-null mice (WT>Nrf2-null), in Keap1-KD mice 
than in wild-type mice (Keap1-KD>WT), and in Keap1-HKO mice than in Keap1-KD 
mice (Keap1-HKO>Keap1-KD). (B) Venn diagram of probe sets that had lower 
expression in wild-type mice than in Nrf2-null mice (WT<Nrf2-null), in Keap1-KD mice 
than in wild-type mice (Keap1-KD<WT), and in Keap1-HKO mice than in Keap1-KD 
mice (Keap1-HKO<Keap1-KD).  
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Category Count %* P-Value 
Clusters of genes induced through Nrf2 activation 
    Nrf2-mediated oxidative stress response 14 7.7 5.84E-12 
    Glutathione metabolism 10 10 2.78E-11 
    Xenobiotic metabolism signaling 15 5.2 6.58E-10 
Clusters of genes suppressed through Nrf2 activation 
    PPARα/RXRα activation 4 2.2 5.05E-03 
 
Table 4.1. Functional clustering of genes constitutively induced or suppressed with Nrf2 
activation using Ingenuity Pathway Analysis. A canonical pathway–based analysis was 
conducted using the IPA (Ingenuity Systems, www.ingenuity.com) to identify the 
pathways enriched in genes constitutively induced or suppressed with Nrf2 activation. 
 *: The ratio of the number of genes that were differentially regulated by Nrf2 and map to 
the pathway (for example, 14 genes induced by Nrf2 were mapped to “Nrf2-mediated 
oxidative stress response pathway”), divided by the total number of genes that map to 
the same pathway (for example, 182 genes were mapped to “Nrf2-mediated oxidative 
stress response pathway” in total), was calculated(14/182=7.7%)  Fisher’s exact test 
was used to calculate the p value determining that the probability of the association 
between the genes differentially regulated by Nrf2 and the canonical pathway was 
random.  
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Term 
Enrichment 
Score 
Gene Symbols 
Top annotation cluster for the set of genes induced through Nrf2 activation 
Glutathione transferase and 
glutathione metabolism 
8.2 
Gstm1, Gss, Gsta2, Gstm2, Gsta3, 
Gstm3, Gclc, Gstm4, Gsta4, Gpx4, Gstm6 
Oxidation reduction and NADPH 
bind enzymes 
6.0 
Cyp2g1, Xdh, Ptgr1, Htatip2, Ugdh, Coq7, 
Fth1, Akr1c13, Akr1a4, Cryl1, Fmo1, 
Gpx4, Aox1, Cyp2a5, Txnrd1, Nqo1, 
Srxn1 
Carboxylesterase 3.9 Ces2, Ces1, BC015286, Ces5 
Chemical and iron homeostasis 3.2 
Xdh, Ftl1, Gclc, Fech, Ftl2, Hexa, Hexb, 
Bnip3, Afg3l2, Fth1, Abcg8, Anxa7 
Cofactor biosynthetic process 2.4 Gss, Fech, Gclc, Coq7, Gch1 
Top annotation cluster for the set of genes suppressed through Nrf2 activation 
Response to nutrient and 
extracellular stimulus 
2.3 Avpr1a, Adipor2, Cp, Apom, Cbs 
 
Table 4.2. Annotation clustering of genes constitutively induced or suppressed with Nrf2 
activation using DAVID analysis. Database for Annotation, Visualization and Integrated 
Discovery (DAVID) (http://david.abcc.ncifcrf.gov) database was used to identify the 
pathways enriched in genes constitutively induced or suppressed with Nrf2 activation. 
Pathway enrichment was determined by the enrichment score > 2. 
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response, glutathione metabolism, and xenobiotic metabolism pathways (Table 4.1, 
upper panel). Down-regulated pathways included PPARα/RXRα activation (Table 4.1, 
lower panel). Annotation clustering using DAVID analysis revealed enrichment of 
glutathione transferases, NADPH mediated oxidation reduction, carboxylesterase, 
chemical and iron homeostasis, and cofactor biosynthesis in genes induced by Nrf2.  
The only annotation cluster enriched in genes suppressed by Nrf2 was involved in 
response to extracellular stimulus and nutrient (Table 4.2). 
Regulation of antioxidant system genes by Nrf2 
Figure 4.3 summarizes the antioxidant-associated enzymes that were 
significantly increased in the “gene dose-response” model. As shown in Fig.4.3A, Nrf2 
activation increased transcription of genes involved in GSH biosynthesis (glutamate-
cysteine ligase, Gclc; and glutathione synthase, Gss) as well as GSH regeneration 
(glutathione reductase, Gsr). Compared to wild-type mice, mRNA of Gclc was induced 
58% in Keap1-KD mice and 210% in Keap1-HKO mice, and mRNA of Gss was induced 
18% in Keap1-KD mice and 91% in Keap1-HKO mice. mRNA of Gsr increased 110% in 
Keap1-HKO mice over wild-type mice. Figure 4.3B indicates that Nrf2 activation 
increased the mRNA of genes involved in reduction of superoxide using GSH 
(glutathione peroxidase: Gpx2 and Gpx4) as well as using NADPH (peroxiredoxin, 
Prdx6). Especially, mRNA of Gpx2 and Gpx4 were increased in Keap1-HKO mice by 
2260% and 105%, respectively. Figure 4.3C shows that Nrf2 activation increased 
transcription of genes involved in reduction of disulfide bonds between protein and GSH 
(glutaredoxin: Glrx1 and Glrx5), disulfide bonds with oxidized protein (sulfiredoxin:  
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Srxn1), and disulfide bonds in oxidized thioredoxin (thioredoxin reductase: Txnrd1). The 
mRNA of Srxn1 increased 743% and Txnrd1 221% in Keap1-HKO mice. Figure 4.3D 
shows that Nrf2 activation increased transcription of genes involved in heme 
metabolism (biliverdin reductase B: Blvrb; and ferrochelatase: Fech) and free ion 
storage (ferritin heavy chain: Fth1; and ferritin light chain: Ftl1 and Ftl2). In particular, 
the mRNA of Blvrb was increased in Keap1-HKO mice by 270% and Ftl2 171%.  
Regulation of NADPH production genes by Nrf2 
Figure 4.4 summarizes the effect of Nrf2 in producing NADPH in the Nrf2 “gene 
dose-response” model. The pentose phosphate pathway produces NADPH, and 
generates 90% of the NADPH in the body. Figure 4A shows hierarchical clustering of 
genes involved in the pentose phosphate pathway. Of the 16 genes examined, 12 were 
highly expressed in Keap1-HKO mice, and only one gene was highly expressed in Nrf2-
null mice. In addition, the expression of the gene that encodes malic enzyme (Me1) was 
low in Nrf2-null mice, and high in wild-type, Keap1-KD, and Keap1-HKO mice (Fig.4B). 
To validate the role of Nrf2 in increasing NADPH production, hepatic NADPH 
concentrations were determined by HPLC-UV analysis. As shown in Figure 4C, NADPH 
concentrations tended to be lower in livers of Nrf2-null mice and were 24% higher in 
Keap1-HKO mice than wild-type mice.  
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Figure 4.3. Antioxidant genes that were induced in “gene dose-response” model. 
Messenger RNA expression of genes involve in (A) GSH synthesis and regeneration, (B) 
reduction of protein disulfide bond, (C) reduction of hydrogen peroxide, and (D) bilirubin 
synthesis and ion storage in “gene dose-response” model. Data are presented as Mean 
± S.E.M of 3 animals per group.  Asterisks (*) indicate statistically significant differences 
from wild-type mice (p < 0.05). 
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Figure 4.4. NADPH production was induced in “gene dose-response” model. (A) 
Hierarchical clustering of genes involved in pentose phosphate pathway. Shading is 
based on the fold-induction of mRNA of each gene compared to the wild-type mice. 
Genes involved in pentose phosphate pathway were selected according to KEGG 
category (KEGG: 00030). (B) Messenger RNA expression of Me1, G6pdx, and Pgd by 
RT-PCR analysis and (C) hepatic NADPH concentration by HPLC-UV analysis in “gene 
dose-response” model. Data are presented as Mean ± S.E.M 3 animals per group for 
Fig 4A, and 5 animals per group for Fig 4B and 4C.  Asterisks (*) indicate statistically 
significant differences from wild-type mice (p < 0.05). 
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Regulation of lipid biosynthesis genes by Nrf2 
Figure 5A indicates hierarchical clustering of genes involved in lipid biosynthesis. 
Of 52 genes examined, 36 genes were expressed at higher levels in Nrf2-null mice and 
at lower levels in Keap1-HKO mice. In contrast, 7 genes were expressed at higher 
levels in Keap1-HKO mice and lower levels in Nrf2-null mice. Specifically, Figure 5B 
shows hierarchical clustering of genes involved in fatty acid synthesis. Of 21 genes 
examined, 14 genes were expressed at higher levels in Nrf2-null mice and lower levels 
in Keap1-HKO mice. In contrast, only one gene was expressed at lower level in Nrf2-
null mice and at higher level in Keap1-HKO mice. Figure 5C shows that genes involved 
in fatty acid desaturation were suppressed with Nrf2 activation. Fatty acid desaturase 
(Fads1 and Fads2) and Stearoyl-CoA desaturase (Scd1) are desaturases that catalyze 
the addition of a double bond utilizing NADPH as the cofactor. The abundance of Fads1 
mRNA was 54% higher in Nrf2-null mice and 46% lower in Keap1-HKO mice than wild-
type mice. Similarly, the abundance of Fads2 mRNA was 52% higher in Nrf2-null mice 
and 30% lower in Keap1-HKO mice than wild-type mice, and the abundance of Scd1 
mRNA was 81% higher in Nrf2-null mice and 73% lower in Keap1-HKO mice than wild-
type mice. 
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Figure 4.5.Lipid biosynthesis and fatty acid desaturation were suppressed in gene 
dose-response” model. (A) Hierarchical clustering of genes involved in lipid biosynthesis. 
Genes were selected according to Gene Ontology category (GO:0008610). (B) 
Hierarchical clustering of genes involved in fatty acid biosynthesis. Shading is based on 
the fold-induction of mRNA of each gene compared to the wild-type mice. Genes were 
selected according to Gene Ontology category (GO:0006633). (C) Messenger RNA 
expression of genes involved in fatty acid desaturation. Data are presented as Mean ± 
S.E.M of 3 animals per group.  Asterisks (*) indicate statistically significant differences 
from wild-type mice (p < 0.05). 
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Discussion 
Liver is an organ in responsible for multiple vital functions, including protein 
synthesis (e.g., albumin and clotting factors), glucose homeostasis, and lipid 
metabolism. Liver also plays the major role in detoxication of environmental chemicals, 
drugs, and endogenous toxicants. Nrf2 is the central regulator for increasing expression 
of genes that protect against oxidative and electrophilic stress. Thus, studying the 
function of Nrf2 in liver is of great importance. The present study used a “gene dose-
response” model characterized by graded Nrf2 activation in livers of mice to 
systematically study the functions of Nrf2 in liver. 
Continuous efforts have been made to identify Nrf2 target genes and thus the 
function of Nrf2. However, varied conclusions have been drawn using different models. 
For example, by comparing transcription profiles of the prostate of control mice and 
mice treated with soy isoflavones, which are natural Nrf2 inducers, Nrf2 was shown to 
be primarily involved in induction of phase-I and phase-II drug metabolism genes (Barve 
et al., 2008).  By comparing transcription profiles of lung tissues in wild-type mice and 
Clara-cell specific Keap1-KO mice, Nrf2 was shown to be important in induction of 
antioxidant genes (Blake et al., 2010). Chromatin-immunoprecipitation (ChIP-seq)  of 
Nrf2 binding sites utilizing parallel sequencing of mouse embryonic fibroblasts of Nrf2-
null mice and wild-type mice showed that Nrf2 is essential for basal expression of genes 
involved in cell proliferation (Malhotra et al., 2010). In the same study, by comparing 
mouse embryonic fibroblasts of wild-type mice and Keap1-null mice, genes induced by 
Nrf2 were enriched in anti-oxidative stress pathways.  A proteomic expression profile of 
livers of Nrf2-null mice and wild-type mice, found that the most profound changes were 
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observed in proteins involved in lipid catabolism (Kitteringham et al., 2010). In the 
present study, by comparing genomic gene transcription profile in livers utilizing a “gene 
dose-response” model, it was determined that Nrf2-inducible genes are most enriched 
in protection against oxidative stress, glutathione metabolism, and xenobiotic 
metabolism. The observations in these various studies may result from different 
biological samples used for comparison (cell lines versus animal tissues), or different 
models to modulate Nrf2 activation (pharmacological versus genetic).  
With few exceptions, previously identified Nrf2-target genes involved in protection 
against oxidative stress were identified to be inducible in the “gene dose-reponse” 
model. GSH is a tripeptide that serves as the predominant cellular thiol resource, and 
protects against oxidative and electrophilic stress by either directly scavenging reactive 
oxygen species or conjugating with electrophiles. It is well-documented that Nrf2 
activation can increase GSH content in both cell line models (Gao et al., 2010) and 
animal models (Reisman et al., 2009a). Consistent with the previous study, hepatic 
GSH concentrations increased in the “gene dose-response” model in a dose-dependent 
manner (Fig.4.1C). GSH is mainly synthesized in liver, by a two-step reaction. The first 
and rate-limiting step is catalyzed by glutamate-cysteine ligase (Gcl), which is made up 
of a catalytic and a modifier subunit (Gclc and Gclm), that combine glutamate and 
cysteine into a dipeptide. The second step is catalyzed by glutathione synthase (Gss), 
which adds a glycine to the glutamate-cysteine dipeptide. In addition to de novo 
biosynthesis, GSH can be regenerated from GSSG by GSH reductase (Gsr). It is known 
that Gclc, Gss, and Gsr are Nrf2 target genes (Chan et al., 2001; Li et al., 2009), and 
the present study also shows that these genes were induced by Nrf2 in the “gene dose-
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response” model (Fig.3A). Once hydrogen peroxide is formed, it can be detoxified 
through peroxiredoxin (Prdx), or reduced by GSH through GSH peroxidase (Gpx). In the 
present study, Prdx6, Gpx2, and Gpx4 were increased with Nrf2 activation (Fig.3B). 
Similarly, induction of Gpx2 and Prdx6 are reported to be induced by Nrf2 in lung (Blake 
et al., 2010), and inorganic arsenic activated Nrf2 and increased Gpx4 expression in 
mouse embryonic stem cells (Chan et al., 2001). Failure to scavenge reactive oxygen 
species leads to oxidation of proteins and abnormal enzyme activity. Oxidized thiol 
groups in proteins can be reduced by glutaredoxin (Glrx) and thioredoxin. Oxidized 
thioredoxin can be regenerated by thioredoxin reductase (Txnrd), and oxidized 
peroxireduction can be regenerated by sulfiredoxin (Srxn). In the present study, Glrx1, 
Glrx5, Srxn1, and Txnrd1 were induced with Nrf2 activation, whereas only mRNA of 
Srxn1 and Txnrd1 were decreased in the absence of Nrf2 (Fig.4.3C). 
Bilirubin is another endogenous antioxidant, and has been shown to efficiently 
scavenge peroxyl radicals (Stocker et al., 1987). Heme degradation generates biliverdin, 
and bilverdin reductase (Blvrb) converts the pro-oxidant biliverdin to the antioxidant 
bilirubin.  Ferrochelatase (Fech) catalyzes the final step of heme biosynthesis. Both 
Blvrb and Fech are induced in the “gene dose-response model” (Fig.4.3D), suggesting a 
role for Nrf2 in bilirubin metabolism. Ferritin is an iron-sequestering protein that prevents 
uncontrolled surges in the free intracellular concentration of ferric iron (Goven et al., 
2010). The reduction of ferric ion by superoxide can generate reactive hydroxyl radicals 
via the Fenton reaction. Ferritin is composed of ferritin heavy chains (Fth) and ferritin 
light chains (Ftl). Fth1, Ftl1, and Ftl2 are induced by Nrf2 (Fig.4.4), indicating an 
important role of Nrf2 in ferric ion scavenging.  
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The central role of Nrf2 in inducing genes encoding enzymes that directly 
synthesize GSH and scavenge oxidative stress is well recognized, however, its role in 
promoting NADPH production has received less attention. NADPH serves as the major 
reducing resource in the body, and many oxido-reduction reactions, including reducing 
oxidized GSH and thioredoxin, are performed by oxidizing NADPH into NADP+. Most of 
the cellular NADPH is generated by the pentose phosphate pathway, and small 
amounts of NADPH are generated by malic enzyme. In an earlier study, microarray 
analysis comparing intestinal gene expression profile between control mice and mice 
treated with sulforaphane identified glucose 6-phosphate dehydrogenase (G6pd), 6-
phosphogluconate dehydrogenase (Pgd), and malic enzyme (Me1) as Nrf2 target genes, 
and linked NADPH production to the Nrf2 signal pathway (Kirby et al., 2005). The effect 
of Nrf2 on these NADPH generating enzymes was later confirmed in mouse lung 
(Goven et al., 2010) and liver (Reisman et al., 2009e). Consistent with these 
observations, Pgd and Me1 were induced in mouse liver with Nrf2 activation in the 
present study. More importantly, the present study shows that the majority of genes 
encoding enzymes involved in the pentose phosphate pathway are induced by Nrf2.  
The induction of the mRNA of multiple genes, including Aldoa (aldolase A, fructose-
bisphosphate), Taldo1 (transaldolase 1), Tkt (transketolase), Prps1 (phosphoribosyl 
pyrophosphate synthetase 1), and Dera (putative deoxyribose phosphate aldolase) 
strongly correlated with Nrf2 activation in the “gene dose-response” model (Fig.4A), 
indicating these genes are novel Nrf2 target genes. To further confirm the role of Nrf2 in 
promoting NADPH production, hepatic NADPH concentrations were quantified in the 
“gene dose-response” model. Nrf2-null mice have less, whereas Keap1-HKO mice have 
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more hepatic NADPH than wild-type mice (Fig.4.4C). Higher NADPH concentrations in 
the Keap1-HKO mouse increase the availability of the cellular reducing resource. In 
contrast, lower NADPH concentrations render Nrf2-null mice less capable of reducing 
oxidative stress. 
In contrast to the role of Nrf2 in reducing oxidative stress, conflicting data have 
been reported on the role of Nrf2 in lipid metabolism. One study reported that 
pharmacological activation of Nrf2 by CDDO-Im effectively prevented high-fat diet-
induced increases in body weight, adipose mass, and hepatic lipid accumulation in wild-
type mice but not in Nrf2-disrupted mice, indicating that the Nrf2 pathway is a novel 
target for the prevention of obesity (Shin et al., 2009). In contrast, another study showed 
that Nrf2-null mice have lower adipose tissue mass, greater formation of small 
adipocytes, and protects against weight gain and obesity by a high fat diet (Pi et al., 
2010), indicating that intact Nrf2 signaling facilitates obesity. Proteomic analysis 
comparing livers of wild-type mice and Nrf2-null mice showed that the majority of 
proteins up-regulated in Nrf2-null mice are primarily involved in lipid metabolism with 
particular respect to lipogenesis (Kitteringham et al., 2010).  Consistent with this, the 
present study shows that most genes involved in lipid biosynthesis were induced in 
Nrf2-null mice, and suppressed in Nrf2 activated mice, suggesting that Nrf2 negatively 
regulates lipogenesis (Fig. 4.5A). In addition, the mRNA expression of most genes 
involved in fatty acid synthesis and desaturation are much higher in Nrf2-null mice than 
the other 3 genotypes of mice, indicating that Nrf2 strongly suppresses the basal level 
of fatty acid synthesis and desaturation. It should be noted that NADPH, the major 
reducing power in the body, is used to reduce oxidative stress, and also provides the 
69 
 
reducing equivalents for biosynthetic reactions, including lipid synthesis and fatty acid 
desaturation (Kuhajda et al., 1994; Shimomura et al., 1998). Specifically, expression of 
Fasn (fatty acid synthase) and Scd1 (stearoyl-CoA desaturase), which encode enzymes 
that use NADPH as the cofactor (Ntambi et al., 1988; Kuhajda et al., 1994), are 
suppressed by Nrf2 in a dose-dependent manner. Thus, Nrf2 regulation favors the use 
of NADPH to reduce oxidative stress rather than the biosynthesis of lipids (Fig.4.6). 
In conclusion, the present study shows that Nrf2 induces expression of genes 
involved in antioxidant defense as well as NADPH generation. In addition, the absence 
of Nrf2 results in decreased expression of genes involved in lipid synthesis and fatty 
acid desaturation. Thus, Nrf2 activation increases the availability of NADPH for reducing 
oxidative stress decrease NADPH consumption for lipid biosynthesis.  
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Figure 4.6. Proposed regulatory model for the role of Nrf2 in NADPH production and 
consumption. In Nrf2 activated cells, NADPH generation was promoted through pentose 
phosphate pathway and malic enzyme. Genes involved in antioxidant defense by using 
NADPH were induced, and genes involved in lipid biosynthesis by using NADPH were 
suppressed. 
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Chapter 5 : EFFECT OF GRADED NRF2 ACTIVATION ON PAHSE-I AND –II DRUG 
METABOLIZING ENZYMES AND TRANSPORTERS 
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Abstract 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that 
induces a battery of cytoprotective genes in response to oxidative/electrophilic stress. 
Kelch-like ECH associating protein 1 (Keap1) sequesters Nrf2 in the cytosol. The 
purpose of this study was to investigate the role of Nrf2 in regulating the mRNA of 
genes encoding drug metabolizing enzymes and xenobiotic transporters. Microarray 
analysis was performed in livers of Nrf2-null, wild-type, Keap1-knockdown mice with 
increased Nrf2 activation, and Keap1-hepatocyte knockout mice with maximum Nrf2 
activation. In general, Nrf2 did not have a marked effect on uptake transporters, but the 
mRNAs of organic anion transporting polypeptide 1a1, sodium taurocholate 
cotransporting polypeptide, and organic anion transporter 2 were decreased with Nrf2 
activation. The effect of Nrf2 on cytochrome P450 (Cyp) genes was minimal, with only 
Cyp2a5, Cyp2c50, Cyp2c54, and Cyp2g1 increased, and Cyp2u1 decreased with 
enhanced Nrf2 activation. However, Nrf2 increased mRNA of many other phase-I 
enzymes, such as aldo-keto reductases, carbonyl reductases, and aldehyde 
dehydrogenase 1.  Many genes involved in phase-II drug metabolism were induced by 
Nrf2, including glutathione S-transferases, UDP- glucuronosyltransferases, and UDP-
glucuronic acid synthesis enzymes. Efflux transporters, such as multidrug resistance-
associated proteins, breast cancer resistant protein, as well as ATP-binding cassette g5 
and g8 were induced by Nrf2. In conclusion, Nrf2 markedly alters hepatic mRNA of a 
large number of drug metabolizing enzymes and xenobiotic transporters, and thus Nrf2 
plays a central role in xenobiotic metabolism and detoxification. 
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Introduction 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that 
induces a battery of cytoprotective genes in response to oxidative/electrophilic stress. 
The role of Nrf2 in protecting against oxidative and electrophilic stress has been well 
established, and the majority of genes involved in antioxidant defense have been 
identified as Nrf2 target genes in various models. For example, genes that are involved 
in direct reduction of reactive oxygen species (ROS), including superoxide dismutase, 
catalase, and glutathione peroxidases are induced by Nrf2 (Kensler et al., 2007). Genes 
involved in reduction of oxidized proteins, such as thioredoxin-1, thioredoxin reductase-
1, and sulfuredoxin, are also Nrf2-target genes (Wu et al., 2011a). Genes encoding 
enzymes that synthesize glutathione (GSH), the most abundant cellular thiol resource, 
namely γ-glutamate-cysteine ligase catalyze subunit (Gclc) and the modifier subunit 
(Gclm), as well as glutathione synthase (Gss), are known to be Nrf2 target genes. In 
addition, genes involved in generation of NADPH, the co-substrate to reduce oxidized 
GSH, such as glucose-6-phosphate dehydrogenase (G6pd) and malic enzyme (Me1), 
are induced upon Nrf2 activation (Klaassen and Reisman, 2010; Wu et al., 2011a). 
There is increasing recognition of the role of Nrf2 in regulating drug metabolizing 
enzymes as well as uptake and efflux transporters, which alter the kinetics and 
disposition of xenobiotics (Cheng et al., 2011). For example, Nrf2 has been shown to 
increase the mRNA of phase-I drug-metabolizing genes, such as NAD(P)H quinone 
oxidoreductase 1 (Nqo1) and Cyp2a5 (Lamsa et al., 2010), as well as phase-II drug-
metabolizing enzymes, such as glutathione S-transferase and UDP-
glucuronosyltransferase (Kwak et al., 2004). In addition, efflux transporters, such as 
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Mrp3 and Mrp4, can be induced by Nrf2 (Maher et al., 2007). Nrf2 deficiency results in 
decreased, whereas Nrf2 activation results in increased elimination of acetaminophen 
from the liver (Reisman et al., 2009c), and Nrf2 activation increased biliary excretion of 
sulfobromophthalein by inducing glutathione-S-transferase activity (Reisman et al., 
2009d).  
Liver is the primary organ in the metabolism and detoxification of drugs and 
environmental toxicants. Whereas Nrf2 is known to regulate a few drug metabolizing 
enzymes and xenobiotic transporters, there has not been a systematic study to 
determine the role of Nrf2 in regulating all drug metabolizing enzymes and xenobiotic 
transporters in liver. In the present study, a “gene dose-response” model with graded 
hepatic Nrf2 activation was generated by using Nrf2-null, wild-type, Keap1-knockdown 
(Keap1-KD) mice with enhanced Nrf2 activation in all tissues, and Keap1-hepatocyte 
knockout (Keap1-HKO) mice with maximum Nrf2 activation in liver. Microarray analyses 
of livers of the “gene dose-response” model were performed to obtain genomic gene 
expression profiles to determine the role of Nrf2 in regulating each individual drug 
metabolizing enzyme and xenobiotic transporter.  
 
Results 
Uptake transporters 
Maximum activation of Nrf2 in Keap1-HKO mice resulted in a marked decrease 
in mRNA of organic anion-transporting polypeptide 1 (Oatp1a1) and organic anion 
transporter 2 (Oat2), and a slight decrease in the mRNA of sodium taurocholate 
cotransporting polypeptide (Ntcp) (Fig. 5.1). The mRNA of other uptake transporters, 
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namely Oatp1a4, Oatp1b2, organic cation transporter 1 (Oct1), and organic 
cation/carnitine transporter 2 (Octn2) were not changed with graded Nrf2 activation. 
Cytochrome P450 phase-I drug-metabolizing enzymes 
Cyp1, Cyp2, and Cyp3 gene families are the major cytochrome P450 enzymes 
that catalyze phase-I drug metabolism in humans. Compared to wild-type mice, mRNA 
of Cyp2a5 was 76% lower in Nrf2-null mice, 139% higher in Keap1-KD mice, and 969% 
higher in Keap1-HKO mice (Fig. 5.2). The mRNA of Cyp2c50 and Cyp2c54 in Nrf2-null 
mice was 45 and 65% lower than in wild-type mice, respectively, but in Keap1-KD and 
Keap1-HKO mice the mRNA of Cyp2c50 and Cyp2c54 tended to be higher than in wild-
type mice, although this was not statistically significant. Compared to wild-type mice, the 
mRNA of Cyp2g1 was 36% lower in Nrf2-null mice, moderately higher with a 91% 
increase in Keap1-KD mice, and markedly higher with a 850% increase in Keap1-HKO 
mice.  In contrast, Cyp2u1 mRNA decreased with increased Nrf2 activation. More 
specifically, mRNA of Cyp2u1 was 81% higher in Nrf2-null mice and 48% lower in 
Keap1-HKO mice. The mRNA of the other 22 genes encoding cytochrome P450 
enzymes of the 1-4 families, including Cyp1a2, Cyp2b10, Cyp2c29, Cyp3a11, and 
Cyp3a13, were not altered with various expression of Nrf2. 
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Figure 5.1. Messenger RNA expression of uptake transporters in a “gene dose-
response” model. Data of Nrf2-null, Keap1-KD, and Keap1-HKO mice are normalized by 
the value of wild-type mice and presented as Mean ± S.E.M.  Asterisks (*) indicate 
statistically significant differences from wild-type mice (p < 0.05). 
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Figure 5.2.  Messenger RNA expression of Cytochrome P450 phase-I drug metabolism 
enzymes in a “gene dose-response” model. Data of Nrf2-null, Keap1-KD, and Keap1-
HKO mice are normalized by the value of wild-type mice and presented as Mean ± 
S.E.M.  Asterisks (*) indicate statistically significant differences from wild-type mice (p < 
0.05). 
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Non-p450 phase-I drug-metabolizing enzymes 
Aldo-keto reductases (gene name: Akr) catalyze NADPH-dependent reduction of 
endogenous and xenobiotic substrates. Figure 5.3 illustrates the mRNA expression of 
the aldo-keto reductases that were significantly increased in the “gene dose-response” 
model. Compared to wild-type mice, mRNA of Akr1a4 was 29% lower in Nrf2-null mice, 
14% higher in Keap1-KD mice, and 43% higher in Keap1-HKO mice. Messenger RNA 
of Akr1c13 was 22% lower in Nrf2-null mice and 39% higher in Keap1-HKO mice. 
Akr1b3 and Akr1c19 mRNA were increased 75 and 142% in Keap1-HKO mice over 
wild-type mice, respectively. The mRNA of Akr7a5 tended to be lower in Nrf2-null mice, 
higher in Keap1-KD mice, and highest in Keap1-HKO mice, but these alterations were 
not statistically significant. Other genes in the Akr gene family, namely Akr1c6, Akr1c12, 
Akr1c14, Akr1d1, and Akr1e1, were not altered with graded Nrf2 activation. 
Carbonyl reductase 1 (Cbr1) was induced in Keap1-KD and Keap1-HKO mice 76 and 
1,110%, respectively. Similarly, Cbr3 was induced 430% in Keap1-KD mice and 1318-
fold in Keap1-HKO mice (Fig. 5.4A). Cbr4 mRNA was not changed with graded Nrf2 
activation. Carboxylesterase 1 (Ces1) and Ces2 mRNAs were lower in Nrf2-null mice, 
higher in Keap1-KD mice (71 and 61% higher, respectively), and highest in Keap1-HKO 
mice (216 and 219% higher, respectively). Although Ces5 mRNA tended to be lower in 
Nrf2-null mice, higher in Keap1-KD mice, and highest in Keap1-HKO mice, these 
changes were not statistically significant (Fig. 5.4B). Ces3 and Ces6 mRNA were not 
changed with graded Nrf2 activation. 
79 
 
Of the 13 mRNA of aldehyde dehydrogenases (Aldh1a1, Aldh1a7, Aldh1b1, Aldh1l1, 
Aldh2, Aldh3a2, Aldh5a1, Aldh6a1, Aldh7a1, Aldh8a1, Aldh9a1, and Aldh16a1) 
detected in the microarray, only Aldh1a1 mRNA was altered in the “gene dose-response” 
model, with Nrf2-null lower and Keap1-HKO higher than wild-type mice. The mRNA of 
aldehyde oxidase (gene name: Aox1) was 85% lower in Nrf2-null mice, and 63% higher 
in Keap1-KD mice, and 191% higher in Keap1-HKO mice (Fig. 5.4C). Compared to wild-
type mice, mRNA of epoxide hydrolase 1 (Ephx1) was 64% lower in Nrf2-null mice, 73% 
higher in Keap1-KD mice, and 218% higher in Keap1-HKO mice than wild-type mice. 
The mRNA of Ephx2 was not changed with graded Nrf2 activation. The mRNA of Nqo1 
was 52% lower in Nrf2-null mice, 335% higher in Keap1-KD mice, and 3860% higher in 
Keap1-HKO mice than wild-type mice. The mRNA of Nqo2 was not changed with 
graded Nrf2 activation. The mRNA of Fmo1 and Xdh was slightly increased in Keap1-
HKO mice over that in wild-type mice (Fig. 5.4D), whereas the mRNA of Fmo5 was not 
altered with graded Nrf2 activation.  
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Figure 5.3. Messenger RNA expression of aldo-keto reductase in a “gene dose-
response” model. Data of Nrf2-null, Keap1-KD, and Keap1-HKO mice are normalized by 
the value of wild-type mice and presented as Mean ± S.E.M.  Asterisks (*) indicate 
statistically significant differences from wild-type mice (p < 0.05). 
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Figure 5.4. Messenger RNA expression of (A) Carbonyl reductase; (B) 
Carboxylesterase; (C) Aldehyde dehydrogenase and aldehyde oxidase; (D) Other non-
P450 phase-I drug metabolism enzymes in “gene dose-response” model.  Data of Nrf2-
null, Keap1-KD, and Keap1-HKO mice are normalized by the value of wild-type mice 
and presented as Mean ± S.E.M.  Asterisks (*) indicate statistically significant 
differences from wild-type mice (p < 0.05). 
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Phase-II drug metabolizing enzymes and transporters 
Of the 25 mouse glutathione S-transferases (Gst), 18 Gsts were detected in the 
microarray, and 11 of them were decreased in the absence of Nrf2, and/or induced with 
Nrf2 activation (Fig. 5.5A). The most marked changes in Nrf2-null mice were the 87% 
decrease in Gsta2, 76% decrease in Gstm1, and 81% decrease in Gstm3. In 
comparison to wild-type mice, the most marked inductions of Gsts were the 890% 
increase of Gsta2, 3,000% increase of Gstm3, and 820% increase of Gstm4 in Keap1-
HKO mice. Graded Nrf2 activation had no effect on the other 7 Gsts, namely Gstk1, 
Gstm5, Gstm7, Gsto1, Gstt1, Gstt2, Gstz1.   
Graded Nrf2 activation had less of an effect on mRNA profile of UDP-
glucuronosyltransferases (Ugt).  Of the 21 mouse Ugts, 13 Ugts were detected in the 
microarray, and 6 were lower without Nrf2, and/or increased with Nrf2 activation (Fig. 
5.5B). The most marked changes in the Ugts in Nrf2-null mice were the 80% lower 
expression of Ugt2b35, 51% lower Ugt2b36, and 55% lower Ugt2b5 than in the wild-
type mice. The most marked increase was 87% of Ugt2b35 in Keap1-HKO mice. UDP-
glucose pyrophosphorylase 2 (Ugp2) and UDP-glucose dehydrogenase (Ugdh) are the 
two enzymes that synthesize UDP-glucuronic acid from glucose. Although Ugp2 mRNA 
tended to be lower in Nrf2-null mice, higher in Keap1-KD mice, and highest in Keap1-
HKO mice, the changes were not statistically significant. In contrast, Ugdh mRNA was 
significantly lower in Nrf2-null mice (56%), higher in Keap1-KD mice (48%), and highest 
in Keap1-HKO mice (214%). The solute carrier family 35 member D1 (Slc35d1) is the 
transporter that imports UDP-glucuronic acid into the endoplasmic reticulum for  
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Figure 5.5. Messenger RNA expression of genes encoding (A) Glutathione S-
transferase; (B) UDP- glucuronosyltransferase and related enzymes and transproters; 
(C) Sulfotransferases in a “gene dose-response” model.  Data of Nrf2-null, Keap1-KD, 
and Keap1-HKO mice are normalized by the value of wild-type mice and presented as 
Mean ± S.E.M.  Asterisks (*) indicate statistically significant differences from wild-type 
mice (p < 0.05). 
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glucuronidation of substrates. Slc35d1 mRNA was 110% higher in Keap1-HKO mice 
than in wild-type mice. For the sulfotransferases (Sults), Sult1b1 was higher, whereas  
Sult1a1 was lower with graded Nrf2 activation (Fig. 5.5C). Messenger RNA of Sult1d1 
and Sult5a1 did not change with graded Nrf2 activation. 
Efflux transporters 
For efflux transporters, Nrf2 activation increased 5 out of 6 ATP-binding cassette 
sub-family C (Mrp, Abcc) members detected by microarray. The most marked changes 
were the 108- and 21-fold higher Mrp4 and Mrp9 mRNA in Keap1-HKO mice, 
respectively. The mRNA of Breast cancer resistance protein (Bcrp, Abcg2) was 19% 
lower in Nrf2-null mice, 40% higher in Keap1-KD mice, and 63% higher in Keap1-HKO 
mice than in wild-type mice. Similarly, Abcg5 and Abcg8 were constitutively higher with 
graded Nrf2 activation (Fig. 5.6). Other efflux transporters, namely Mrp6, multiple drug 
resistant 1a (Mdr1a/Abcb1a), Mdr2, bile salt export pump (Bsep/Abcb11), and multidrug 
and toxin extrusion 1 (Mate1/Slc47a1) remained unchanged with graded Nrf2 activation. 
Expression of chemical-sensing xenobiotic transcription factors 
Compared to wild-type mice, constitutive androstane receptor (CAR, Nr1i3) 
mRNA was 64% lower in Nrf2-null mice, 41% higher in Keap1-KD mice, and 166% 
higher in Keap1-HKO mice (Fig. 5.7). Other genes encoding transcription factors that 
are involved in drug metabolism, namely pregnane X receptor (PXR, Nr1i2), liver X 
receptor (LXR, Nr1h3), farnesoid X activated receptor (FXR, Nr1h4), aryl-hydrocarbon 
receptor (AhR), and hepatic nuclear factor 4, alpha (HNF4α) remained unchanged with 
graded Nrf2 activation. 
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Figure 5.6. Messenger RNA of efflux transporters in a “gene dose-response” model. 
Data of Nrf2-null, Keap1-KD, and Keap1-HKO mice are normalized by the value of wild-
type mice and presented as Mean ± S.E.M.  Asterisks (*) indicate statistically significant 
differences from wild-type mice (p < 0.05). 
 
 
 
 
 
 
 
 
86 
 
 
 
 
 
Figure 5.7. Messenger RNA of CAR in “gene dose-response” model.  Data of Nrf2-null, 
Keap1-KD, and Keap1-HKO mice are normalized by the value of wild-type mice and 
presented as Mean ± S.E.M.  Asterisks (*) indicate statistically significant differences 
from wild-type mice (p < 0.05). 
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Motif analyses of the 5’ region of drug processing genes 
The 5’ region (up to 10kb upstream of TSS) of drug processing genes that are 
induced (47 genes), not changed (72 genes), and suppressed (5 genes) with graded 
Nrf2 activation were searched for the core sequence of ARE (TGACnnnGC) as putative 
Nrf2 binding sites. In the 5’ region up to 2kb upstream from the TSS, 47 AREs were 
found in 62% of the genes (29 genes) that were induced with Nrf2 activation, 43 AREs 
were in 47% of the genes (34 genes) that were not changed with Nrf2 activation, and 
one ARE was found in 20% of the genes (one gene) suppressed with Nrf2 activation 
(Table 5.1). In the 5’ region up to 10kb upstream from the TSS, 163 AREs were found in 
94% of the genes (44 genes) that were induced with Nrf2 activation, 201 AREs were in 
86% of the genes (62 genes) that were not changed with Nrf2 activation, and 11 AREs 
were in the five genes suppressed with Nrf2 activation. 
Transcription factor-binding site over-representation 
The transcription factor binding site enrichment profile was investigated around 
the transcription start site of the drug processing genes that were induced by Nrf2. As 
shown in Table 2, the putative binding site of Nrf2 was greatly enriched in genes that 
were induced with graded Nrf2 activation. In addition, the putative binding sites for other 
transcription factors, namely C/EBPα, CTCF, NFATC2, Max, NFkB, USF1, Arnt, PPARγ, 
and Lhx3, were also enriched in genes that were induced with graded Nrf2 activation. 
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Table 5.1. Summary of total number of AREs in the 5’ region of drug processing genes 
that were induced, not changed, and suppressed in the Nrf2 “gene dose-response” 
model. The core sequence of ARE (TGACnnnGC) was searched for using Genamics 
Expression DNA Sequence Analyses Software. 
 
Gene 
category 
Number 
of 
genes 
Number of 
AREs up to 
2kb upstream 
of TSS 
Number of 
genes that 
contain at 
least one 
ARE up to 
2kb 
upstream of 
TSS 
Number of 
AREs up to 
10kb 
upstream of 
TSS 
Number of 
genes that 
contain at 
least one 
ARE up to 
10kb 
upstream of 
TSS 
Induced 47 47 29 (62%) 163 44 (94%) 
No change 72 43 34 (47%) 201 62 (86%) 
Suppressed 5 1 1 (20%) 11 5 (100%) 
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Table 5.2. Putative binding sites of transcription factors in drug processing genes 
induced by Nrf2 using the oPOSSUM system. 
TF TF Class 
Target 
gene 
hits 
Background 
gene hits 
Target 
TFBS 
nucleotide 
rate1 
Background 
TFBS 
nucleotide 
rate2 
Z-
score 
Fisher 
score 
Nrf2 Zipper-Type 17 4 0.0134 0.003 37.007 5.173 
C/EBPα Zipper-Type 32 18 0.0431 0.024 21.456 3.129 
CTCF 
Zinc-
coordinating 
8 1 0.00489 0.001 19.468 3.432 
Nfatc2 Ig-fold 32 22 0.0493 0.031 18.409 1.477 
Max Zipper-Type 17 8 0.0129 0.005 17.872 2.309 
Nfkb1 Ig-fold 11 2 0.00495 0.001 17.531 3.94 
Usf1 Zipper-Type 21 10 0.0169 0.008 16.307 2.76 
Arnt Zipper-Type 24 11 0.0158 0.008 15.637 3.43 
PPARγ::
RXRα 
Zinc-
coordinating 
21 8 0.0227 0.014 13.93 3.959 
Lhx3 
Helix-Turn-
Helix 
15 9 0.0155 0.009 13.089 1.285 
1The rate of occurrence of this transcription factor binding sites (TFBS) within the searched 
regions of the genes induced by Nrf2. 
2The rate of occurrence of this TFBS within the searched regions of the set of background 
genes (genes not induced by Nrf2). 
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Discussion 
The present data indicate that Nrf2 plays a critical role in regulating mRNA of 
numerous phase-I and phase-II drug-metabolizing genes as well as a number of efflux 
transporters that are important for the hepatic disposition of xenobiotics (Fig. 5.8). 
Although the role of Nrf2 in regulating some of the drug metabolizing genes were 
investigated previously through comparing wild-type mice with Nrf2-null or Keap1-HKO 
mice (Reisman et al., 2009e; Cheng et al., 2011), the present study is among the first 
reports to make a systematic comparison in four lines of mice with a Nrf2 “gene dose-
response”. Taking advantage of microarray analysis, which determines global gene 
transcription profiles, the present study also systematically compared the importance of 
Nrf2 in basal and inducible expression of each individual gene involved in drug 
metabolism and disposition. For example, the present study compared fold-induction of 
glutathione S-transferase (Gst) gene family by Nrf2 and showed that the mRNA of 
Gsta3 was increased 20%, whereas the mRNA of Gstm3 was increased 3000% in 
Keap1-HKO mice. In addition, we also report the mRNA of the drug metabolizing genes 
that are expressed in liver and not changed with absence of Nrf2 or with Nrf2 activation. 
For example, although the majority of the Gsts are induced by Nrf2, we report seven 
Gsts (Gstk1, Gstm5, Gstm7, Gsto1, Gstp1, Gstt1, Gstt2) are not changed with graded 
Nrf2 activation, indicating that Nrf2 is not qualitatively or quantitatively equally important 
in induction of this family of enzymes. It is also interesting to note that the mRNA of 
some genes, such as Fmo1, Xdh, and Aldh1a1, decreased slightly (less than 20%) with 
the absence of Nrf2, and increased slightly (less than 20%) with maximum Nrf2 
activation. However, the mRNA of another battery of genes, including Cyp2a5, Ces1, 
Ces2, and Gstm3, was almost absent with no Nrf2 in the Nrf2-null mice, and markedly 
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increased (more than 30-fold) with maximum Nrf2 activation in Keap1-HKO mice. This 
observation suggests that Nrf2 is critical in both the basal and inducible expression of 
these genes. 
In contrast to the minor impact of Nrf2 on mRNA of uptake transporters, Nrf2 has 
a major effect on the abundance of mRNAs of efflux transporters, with most Mrps, Bcrp, 
and Abcg5/Abcg8 induced in Nrf2 activated mice (Fig. 5.6). Mrp2 transports GSH and 
GSH-conjugated xenobiotics from hepatocytes into bile, whereas Mrp3 and Mrp4 
transport glucuronated and GSH conjugates, bile acids, and nucleoside analogues from 
hepatocytes into blood (Klaassen and Lu, 2008; Klaassen and Aleksunes, 2010). Bcrp 
is an efflux transporter that mediates the biliary excretion of sulfate metabolites as well 
as glucuronated conjugates (Zamek-Gliszczynski et al., 2006). Abcg5 and Abcg8 
function as a heterodimer and transport cholesterol as well as dietary plant sterols into 
bile (Jansen et al., 2006). Taken together, the increase of multiple Mrp isoforms, Bcrp, 
and Abcg5/Abcg8 probably results in enhanced elimination of xenobiotics from 
hepatocytes by increased transport into bile and blood. 
Nrf2 has a minor role in regulating cytochrome P450s drug metabolizing genes, 
with only Cyp2a5 and Cyp2g1 induced with Nrf2 activation. The human ortholog of 
mouse Cyp2a5 is CYP2A6, which is the major CYP that catalyzes the initial metabolism 
of nicotine, and is also involved in the metabolism of drugs (e.g. valproic acid and 
pilocarpine) as well as environmental toxicants (e.g. nitrosamines and aflatoxin B1). The 
present study as well as previous reports show that both human CYP2A6 (Yokota et al., 
2010) and mouse Cyp2a5 (Abu-Bakar et al., 2007) are induced by Nrf2, indicating Nrf2 
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may play a role in nicotine metabolism. Cyp2g1 metabolizes exogenous compounds 
including coumarin and acetaminophen in vitro (Gu et al., 1998), and there is little 
information about the regulation of Cyp2g1. The present study shows that Cyp2g1 
mRNA was lower in the absence of Nrf2 and markedly higher with Nrf2 activation, 
indicating the novel role of Nrf2 in activating Cyp2g1 transcription.  
In contrast to the minor role of Nrf2 in regulating cytochrome P450s, most 
isoforms of aldo-keto reductases (AKR), including Akr1a4, Akr1b3, Akr1c13, and 
Akr1c19, were induced with Nrf2 activation (Fig. 5.3), indicating these genes are novel 
Nrf2 target genes. Akr1a4 (human ortholog: AKR1A1) plays a key role in ascorbic acid 
synthesis (Gabbay et al., 2010), reduction of trans-muconaldehyde, a cytotoxic 
metabolite of benzene (Short et al., 2006), and scavenges free radicals (Singh et al., 
2010). The human ortholog of mouse Akr1b3 is AKR1B1, the most extensively studied 
AKR (Barski et al., 2008), catalyzes the reduction of a wide range of aldehydes and 
their glutathione conjugates, including  lipid peroxidation products 4-hydroxy-trans-2-
nonenal (HNE) and acrolein (Vander Jagt et al., 1995). Akr1b3 is induced by Nrf2 in 
vitro (Nishinaka and Yabe-Nishimura, 2005), and human AKR1B10, AKR1C1 and 
AKR1C2 are induced by Nrf2 in keratinocytes (MacLeod et al., 2009). However, the 
mRNA of the mouse orthologs of human AKR1B10 (Akr1b10) and AKR1C1 (Akr1c21) 
remained unchanged with Nrf2 activation (data not shown). This difference may be due 
to the model used (cell culture versus whole animal), and/or the species (human versus 
mouse). The AKR7 family catalyzes the reduction of many toxic aldehydes, such as 
acrolein, methylglyoxal, and especially aflatoxin B1 dialdehyde (Gardner et al., 2004). 
Rat Akr7a1 is highly inducible (up to 15-fold) in liver in response to antioxidants 
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(McLellan et al., 1994), whereas mouse Akr7a5 was not induced by antioxidants 
(Hinshelwood et al., 2002). Similarly, in the present study, the mRNA of Akr7a5 tended 
to increase with graded Nrf2 activation, but was not statistically significant (Fig. 5.2).  
           In addition to the aldo-keto reductases, the 2 isoforms of carbonyl reductases 
(Cbr1, Cbr3) were highly inducible by Nrf2. CBR1 is the major enzyme that reduces 
doxorubicin (Kassner et al., 2008) in humans, and is involved in the detoxification of 
reactive aldehydes, such as 4-oxonon-2-enal and its GSH conjugate (Doorn et al., 
2004). Human CBR3 catalyzes similar reactions as CBR1 but with narrower substrate 
specificity, indicating a minor role in xenobiotic metabolism (Pilka et al., 2009). Keap1-
knockdown and then Nrf2 activation resulted in dramatic induction of human CBR3 in 
cancer cell lines (Ebert et al., 2010). In parallel with the human cell line study, the 
present study shows that Cbr3 mRNA was increased more than 1000 fold in livers of 
Keap1-HKO mice. In addition, Cbr1 was also induced markedly with Nrf2 activation (Fig. 
5.4A), indicating that Nrf2 is an important regulator of Cbr and carbonyl detoxification. 
           Aldehyde dehydrogenase (Aldh1a1), epoxide hydrolase (Ephx1), and NAD(P)H 
quinone oxi-reductase (Nqo1) are a group of enzymes that reduce electrophilic 
substrates into nucleophilic products. Nrf2 is known to be the central regulator that 
promotes transcription of antioxidant genes. Thus, it is not surprising that Aldh1a1, Eh1, 
and Nqo1 were induced by Nrf2 in the present study (Fig. 5.4C and Fig.5. 4D) and 
many other studies (Yates et al., 2006; Alnouti and Klaassen, 2008; Reisman et al., 
2009a). Aldehyde oxidase (Aox1) and xanthine dehydrogenase (Xdh) catalyze the 
generation of reactive oxygen species during oxidation of their substrates, and flavin 
monooxygenases (Fmo1) catalyze thiobenzamide into an electrophilic intermediate that 
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causes tissue damage (Nunoya et al., 1995). In the present study, Aox1, Xhd, and 
Fmo1 are induced by Nrf2 (Fig.5. 4C and Fig.5.4D), indicating that whereas most of the 
enzymes that Nrf2 increases result in decreasing electrophiles and oxidative stress, a 
few of its target genes can increase electrophiles and oxidative stress. 
Nrf2 has a major impact on inducing numerous phase-II drug metabolism genes, 
with induction of most isoforms of glutathione S-transferases, and multiple isoforms of 
UDP-glucuronosyltransferases. Ugp2 and Ugdh synthesize UDP-glucuronic acid, the 
substrate for UDP-glucuronosyltransferases catalyzed conjugation, from glucose in the 
cytosol. Slc35d1 is the transporter that imports UDP-glucuronic acid into the 
endoplasmic reticulum (ER) and provides the co-substrates for UGT catalyzed 
conjugation (Muraoka et al., 2001). Nrf2 increases the mRNA of Ugdh and Slc35d1, and 
tended to increase the mRNA of Ugp2 (Fig. 5.5B), suggesting that Nrf2 increases the 
availability of UDP-glucuronic acid in the ER as well as the amount of enzyme for UDP-
glucuronic acid conjugation.  
           In addition to Nrf2, multiple nuclear receptors and other transcription factors, 
such as AhR, CAR, PXR, PPARα, and FXR, are known to play an important role in 
regulating the expression of phase-I and -II drug metabolizing enzymes, as well as 
uptake and efflux transporters (Klaassen and Aleksunes, 2010). In addition, there are 
known interactions between Nrf2 and other drug metabolism-related nuclear receptors 
and transcription factors. For example, a number of AhR target genes are induced by 
the activation of Nrf2 (Yeager et al., 2009). The mRNA of Nrf2 is increased in livers of 
HNF-4α knockout mice (Lu et al., 2010). The present study indicates that the mRNA of 
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CAR is almost absent in Nrf2-null mice, and markedly increased in Nrf2 enhanced mice 
(Fig. 5.6A), indicating that Nrf2 regulates CAR expression at the mRNA level. 
Using in silico analyses to search for putative ARE binding sites showed that 44 
out of 47 genes induced by Nrf2 in the present study have at least one ARE core 
sequence (5’-TGACnnnGC-3’) within 10kb upstream from their transcription start sites. 
The total number of AREs is larger in the set of genes induced by Nrf2 than in the set of 
genes where mRNAs are not changed or suppressed with Nrf2 activation (Table 5.1), 
suggesting that genes are induced in Nrf2 activated mice through direct binding of Nrf2 
to promote their transcription. However, it should be noted that 18 out of 47 genes that 
are induced by Nrf2 do not contain ARE up to 2kb upstream of the TSS, and three 
genes (Gsta2, Bcrp, and Abcg8) Nrf2 do not contain ARE up to 2kb upstream of the 
TSS. Thus, more experiments (e.g. ChiP-Seq) are needed to confirm the binding of Nrf2 
to these putative AREs, and thus whether these genes are direct Nrf2 target genes. In 
addition to the enrichment of Nrf2 binding sites in the genes responsive to Nrf2 
activation, transcription factor over-representation analyses revealed co-existence of 
ARE and binding sites for other transcription factors, including C/EBPα, NFkB, Arnt:AhR, 
and PPARγ:RXRα (Table 5.2), indicating the potential cross-talk between Nrf2 and 
these transcription-factor signal pathways. 
For some of the drug processing genes (example: Nqo1), the mRNA abundance 
is positively correlated to the enzyme activity (Reisman et al., 2009e). A battery of drug 
processing genes (example: Cyp2e1) are regulated mainly at post-translational level 
(Novak and Woodcroft, 2000). However, the mRNA abundance - enzyme activity 
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correlation of most drug processing genes is unknown. Thus, it is not plausible to 
extrapolate the protein expression or enzyme activity level by comparing mRNA 
abundance of the genes. Due to the limitations of antibody specificity and availability of 
in vivo enzyme activity assays, the present study only provides the systemic 
comparison of mRNA abundance of the drug metabolism genes. Western blot and 
activity assays should be performed to further study the effect of Nrf2 on protein 
abundance and activity of a specific drug processing enzyme or transporter. 
In conclusion, the present study demonstrates that Nrf2, the key transcription 
factor in protecting against oxidative and electrophilic stress, is also important in 
regulating hepatic mRNA of phase-I and -II drug metabolizing enzymes as well as 
uptake and efflux transporters (Fig. 5.8). Activation of Nrf2 has a minor effect on uptake 
transporters and P450 phase-I enzymes that activate xenobiotics into toxicants, 
markedly increased mRNA of other phase-I enzymes and phase-II enzymes that 
detoxify toxicants, and also increased mRNA of efflux transporters that facilitate the 
elimination of toxicants. 
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Figure 5.8. Proposed regulatory model for the role of Nrf2 on drug metabolizing genes 
in liver. Activation of Nrf2 had a minor effect on uptake transporters and P450 phase-I 
enzymes that activate xenobiotics into toxicants, markedly induces genes encoding 
other phase-I enzymes and phase-II enzymes that detoxify toxicants, and also induces 
efflux transporters that facilitate the elimination of toxicants. 
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Chapter 6 : ROLE OF NRF2 IN PREVENTING ETHANOL-INDUCED OXIDATIVE 
STRESS AND LIPID ACCUMULATION 
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Abstract 
Oxidative stress and lipid accumulation play important roles in alcohol-induced 
liver injury. Previous reports showed that, in livers of nuclear factor erythroid 2-related 
factor 2 (Nrf2)-activated mice, genes involved in antioxidant defense are induced, 
whereas genes involved in lipid biosynthesis are suppressed.  To investigate the role of 
Nrf2 in ethanol-induced hepatic alterations, Nrf2-null mice, wild-type mice, kelch-like 
ECH-associated protein 1-knockdown (Keap1-KD) mice with enhanced Nrf2, and 
Keap1-hepatocyte knockout (Keap1-HKO) mice with maximum Nrf2 activation, were 
treated with ethanol (5 g/kg, po). Blood and liver samples were collected 6 h thereafter. 
Ethanol increased alanine aminotransferase and lactate dehydrogenase activities as 
well as thiobarbituric acid reactive substances in serum of Nrf2-null and wild-type mice, 
but not in Nrf2-enhanced mice. After ethanol administration, mitochondrial glutathione 
concentrations decreased markedly in Nrf2-null mice but not in Nrf2-enhanced mice. 
H2DCFDA staining of primary hepatocytes isolated from the four genotypes of mice 
indicate that oxidative stress was higher in Nrf2-null cells, and lower in Nrf2-enhanced 
cells than in wild-type cells. Ethanol increased serum triglycerides and hepatic free fatty 
acids in Nrf2-null mice, and these increases were blunted in Nrf2-enhanced mice. In 
addition, the basal mRNA and nuclear protein levels of sterol regulatory element-binding 
protein 1(Srebp-1) were decreased with graded Nrf2 activation.  Ethanol further induced 
Srebp-1 mRNA in Nrf2-null mice but not in Nrf2-enhanced mice. In conclusion, Nrf2 
activation prevented alcohol-induced oxidative stress and accumulation of free fatty 
acids in liver by increasing genes involved in antioxidant defense and decreasing genes 
involved in lipogenesis. 
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Introduction 
Ethanol in fermented drinks is consumed widely across the world, and causes 
global health problems. Alcohol consumption is related to more than 60 medical 
conditions, and has been suggested to be responsible for 25% of liver cancer as well as 
32% of liver cirrhosis worldwide (Room et al., 2005).  
The predominant factor causing ethanol-associated liver damage is the 
generation of oxidative stress. Liver is the major organ responsible for metabolizing 
ethanol in the body, mainly through alcohol dehydrogenase in the cytosol, cytochrome 
P450 2E1 (CYP2E1) in the endoplasmic reticulum, and catalase in peroxisomes 
(Zakhari, 2006). More specifically, alcohol dehydrogenase serves as the primary 
pathway to metabolize alcohol in liver, producing acetaldehyde as the major product. 
Acetaldehyde is highly reactive, and interacts with proteins to form acetaldehyde 
adducts. In addition, acetaldehyde interacts with endogenous antioxidants (cytosolic 
and mitochondrial glutathione), induces mitochondrial dysfunction, and sensitizes 
hepatocytes to oxidative damage (Farfan Labonne et al., 2009). Another enzyme that 
metabolizes ethanol is CYP2E1. CYP2E1 also oxidizes ethanol to acetaldehyde, and 
generates reactive oxygen species by transferring electrons to oxygen (Jimenez-Lopez 
and Cederbaum, 2005). Although catalase reduces hydrogen peroxide into water, the 
role of catalase in ethanol metabolism is minor (Handler and Thurman, 1990). Thus, an 
overall consequence of ethanol metabolism in liver is oxidative stress.  
Another consequence of ethanol metabolism is lipid accumulation in liver. During 
ethanol metabolism, large amounts of nicotinamide adenine dinucleotide (NAD+) are 
reduced into NADH by alcohol dehydrogenase and aldehyde dehydrogenase. The 
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increased NADH/NAD+ ratio promotes lipid accumulation by stimulating fatty acid 
synthesis and opposing degradation (Lieber, 2004). In addition, inflammation provoked 
by oxidative stress promotes the production of proinflammatory cytokine tumor necrosis 
factor-alpha (TNF-α) in Kupffer cells and hepatocytes, leading to stimulation of collagen 
synthesis by hepatic stellate cells (Enomoto et al., 2007). Collectively, imbalanced lipid 
homeostasis, together with generation of oxidative stress, promotes alcohol-induced 
fatty liver into inflammation, fibrosis, and finally cirrhosis.  
Several compounds have been studied to prevent the development of alcoholic liver 
disease, and the proposed mechanisms of the protective effects of some of these 
chemicals are focused on ameliorating oxidative stress. For example, S-adenosyl-L-
methionine (SAMe), a precursor in glutathione biosynthesis, was shown to attenuate 
alcohol-induced liver injury in both animal models and human studies (Lu and Mato, 
2005). The protective effect of poly-enyl-phosphatidylcholine on alcohol-induced toxicity 
is partially due to inhibition of CYP2E1 (Lieber, 2000). Other direct antioxidants, such as 
vitamin C and vitamin E, have also been used to treat ethanol-induced liver injury. 
However, the therapeutic results are not consistent (Yanardag et al., 2007; Chung et al., 
2009). 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that 
induces a battery of cytoprotective genes in response to oxidative/electrophilic insults 
(Klaassen and Reisman, 2010). Transcription profiling in the Nrf2 “gene dose-response” 
model by microarray analysis revealed that genes involved in lipid biosynthesis are 
suppressed with Nrf2 activation in a “gene dose-response” manner (Wu et al., 2011b), 
indicating that Nrf2 may play a role in preventing lipid accumulation. 
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The antioxidant and anti-lipogenesis activities of Nrf2 make it a promising target 
for therapy of alcoholic liver disease. It was reported that loss of Nrf2 results in 
aggravated steatosis, inflammation, and mortality in Nrf2-null mice exposed to ethanol 
(Lamle et al., 2008). It is more important to know whether Nrf2 activation protects 
against ethanol-induced liver toxicity. In the present study, the Nrf2 “gene dose-
response” model was used to characterize the role of the Keap1-Nrf2 pathway in liver in 
maintaining redox as well as lipid homeostasis in response to ethanol administration. 
Results 
 
Serum LDH and ALT 
By 6h after ethanol administration, ethanol-induced acute hepatotoxicity was 
indicated by serum lactate dehydrogenase (LDH) and alanine aminotransaminase (ALT). 
Ethanol increased serum LDH activity in Nrf2-null and wild-type mice, but not in Keap1-
KD or Keap1-HKO mice (Fig. 6.1A). After ethanol administration, serum ALT activities 
were increased in Nrf2-null, wild-type, and Keap1-KD mice, and the increase was 
similar in Nrf2-null mice but 40% lower in Keap1-KD mice than wild-type mice (Fig. 
6.1B). Ethanol did not increase serum ALT activities in Keap1-HKO mice. Histological 
analysis indicated that livers of wild-type, Nrf2-null, Keap1-KD, and Keap1-HKO mice 
appeared normal in both control and ethanol-administrated groups (data not shown). 
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Figure 6.1. Blood biochemistry. Serum lactate dehydrogenase and serum alanine 
transaminase (ALT) levels in wild-type, Nrf2-null, Keap1-KD and Keap1-HKO mice 6 h 
after ethanol administration (5 g/kg, p.o.). Units are in International Units/Liter (IU/L) 
expressed as mean ± S.E.M of 5 mice per group.  Asterisks (*) indicate statistically 
significant differences from control mice of the same genotype (p < 0.05). Daggers (†) 
indicate statistically significant differences from wild-type mice after ethanol 
administration (p < 0.05). 
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Lipid peroxidation 
To determine the effect of ethanol on inducing oxidative stress, and whether Nrf2 
activation protects against ethanol-induced oxidative stress, lipid peroxidation products 
were quantified in serum samples of mice using the TBARS assay. In wild-type mice, 
TBARS concentrations in the serum increased 65% after ethanol administration. In 
Nrf2-null mice, the basal TBARS concentration tended to be higher than wild-type mice, 
and increased after ethanol administration. Ethanol did not have any effect on TBARS 
concentrations in Keap1-KD and Keap1-HKO mice (Fig. 6.2A).  
Cytosolic and mitochondrial GSH concentrations in liver 
In an attempt to determine the mechanism of how Keap1-Nrf2 signaling pathway 
prevents ethanol-induced oxidative stress, cytosolic and mitochondrial GSH 
concentrations were quantified in livers. Basal cytosolic GSH concentrations were 7% 
lower in Nrf2-null mice, and 15% higher in Keap1-HKO than wild-type mice. After 
ethanol administration, GSH concentrations decreased 31% in Nrf2-null mice, 21% in 
wild-type mice, 11% in Keap1-KD mice, and remained unchanged in Keap1-HKO mice 
(Fig. 6.2B). Basal mitochondrial GSH concentrations were 12% lower in Nrf2-null mice, 
and 39% higher in Keap1-HKO mice than in wild-type mice. After ethanol administration, 
GSH concentrations decreased 52% in Nrf2-null mice, 39% in wild-type mice, 
unchanged in Keap1-KD mice, and decreased 27% in Keap1-HKO mice (Fig. 6.2C).  
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Figure 6.2. Ethanol-induced oxidative stress in vivo. Serum thiobarbituric acid reactive 
substances (TBARS), cytosolic glutathione (GSH) in livers, and mitochondrial GSH in 
livers of Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice 6 h after ethanol 
administration (5 g/kg, p.o.). Data are expressed as mean ± S.E.M of 5 mice per group.  
Asterisks (*) indicate statistically significant differences from control mice of the same 
genotype (p < 0.05). Daggers (†) indicate statistically significant differences from wild-
type mice after ethanol administration (p < 0.05). 
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Gclc and Nqo1 mRNA and protein concentrations in liver 
Compared with the wild-type mice, the basal mRNA of Nqo1 was 72% lower in 
Nrf2-null mice, 120% higher in Keap1-KD mice, and 820% higher in Keap1-HKO mice. 
Six hrs after ethanol administration, mRNA of Nqo1 decreased in Keap1-HKO mice (Fig. 
6.3A). The protein levels of Nqo1 were consistent with the mRNA, which was increased 
with graded Nrf2 activation in a gene dose-response manner, and decreased after 
ethanol administration in Keap1-HKO mice (Fig. 6.3B). Compared with the wild-type 
mice, the basal level of Gclc mRNA was 55% lower in Nrf2-null mice, 28% higher in 
Keap1-KD mice, and 148% higher in Keap1-HKO mice. Six hours after ethanol 
administration, mRNA of Gclc decreased in wild-type, Keap1-KD, and Keap1-HKO mice 
(Fig. 6.3C). Consistent with the mRNA data, Gclc protein was increased with graded 
Nrf2 activation in a “gene dose-response” manner, and decreased after ethanol 
administration in wild-type, Keap1-KD, and Keap1-HKO mice (Fig. 6.3D). 
Dose-response and time course of ROS generation 
To characterize ethanol-induced oxidative stress in vitro, primary hepatocytes 
from Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice were isolated and stained 
with H2DCFDA, a general ROS indicator, as described in the Methods. The basal ROS 
were 83% higher in Nrf2-null cells, and 37 and 44% lower in Keap1-KD and Keap1-HKO 
cells than wild-type mice, respectively. After the addition of ethanol, ROS increased 
moderately in wild-type mice, and increased markedly in Nrf2-null mice. In contrast, 
ROS in Keap1-KD and Keap1-HKO slightly increased at 3 h, and decreased below 
basal levels at later time points. Ethanol increased ROS in wild-type and Nrf2-null cells  
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Figure 6.3. Effects of ethanol on the mRNA and protein of prototypical Nrf2-target 
genes. (A) mRNA of Nqo1, (B) protein of Nqo1, (C) mRNA of Gclc, and (D) protein of 
Gclc in livers of Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice 6 h after ethanol 
administration (5 g/kg, p.o.). Data are expressed as mean ± S.E.M of 5 animals per 
group.  Asterisks (*) indicate statistically significant differences from control mice of the 
same genotype (p < 0.05). Daggers (†) indicate statistically significant differences from 
wild-type mice after ethanol administration (p < 0.05). 
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Figure 6.4. Ethanol-induced oxidative stress in vitro. (A) DCFDA fluorescence in primary 
hepatocytes 6 h after ethanol exposure. Primary hepatocytes were isolated and treated 
with ethanol for 24 h and subjected to live cell imaging. (B) Time-response and (C) 
dose-response of ROS production after ethanol administration of primary hepatocytes 
from Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice. Data are presented as 
Mean ± S.E.M. of 3 mice per group in Fig 4B and Fig 4C.  Asterisks (*) indicate 
statistically significant differences from wild-type cells of the same time point (p < 0.05). 
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in a dose-dependent manner. However, ethanol did not increase ROS in Keap1-KD or 
Keap1-HKO mice even at high concentrations (Fig. 6.4). 
Triglyceride and free fatty acid concentrations in serum and liver 
To determine the effect of ethanol on increasing lipid accumulation in serum and 
liver, and whether Nrf2 activation attenuates ethanol-induced lipid accumulation, 
triglycerides and free fatty acid concentrations were quantified. Ethanol increased 
triglyceride contents in serum of only in Nrf2-null mice but not in wild-type, Keap1-KD, or 
Keap1-HKO mice (Fig. 6.5A). In contrast, ethanol increased triglyceride contents livers 
of in all groups of mice, with no difference among genotypes (Fig. 6.5B). Ethanol also 
increased free fatty acid contents serum of wild-type and Keapq-KD mice, but not in 
Nrf2-null or Keap1-HKO mice (Fig. 6.5C). Ethanol After ethanol administration, free fatty 
acid concentrations in livers were increased markedly in Nrf2-null mice, moderately in 
wild-type mice, slightly in Keap1-HKO mice, and remained unchanged in Keap1-KD 
mice (Fig. 6.5D). 
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Figure 6.5. Ethanol administration induced lipid accumulation. (A) Serum triglyceride, (B) 
hepatic triglyceride, (C) serum free fatty acid, and (D) hepatic free fatty acid 
concentrations in Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice after ethanol 
administration (5 g/kg, p.o.).  Data are expressed as mean ± S.E.M of 5 mice per group.  
Asterisks (*) indicate statistically significant differences from control mice of the same 
genotype (p < 0.05). Daggers (†) indicated statistically significant differences from wild-
type mice after ethanol administration. 
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Srebp1 and its target gene expression in liver 
To determine the mechanism of how Keap1-Nrf2 signaling pathway is protective 
against ethanol-induced lipid accumulation, the mRNA and protein of Srebp1, the 
transcription factor that induces genes involved in lipid biosynthesis, were quantified. 
Compared to wild-type mice, basal Srebp1 mRNA was 41% higher in Nrf2-null mice, 8% 
lower in Keap1-KD mice, and 59% lower in Keap1-HKO mice. After ethanol 
administration, Srebp1 mRNA increased 135% in Nrf2-null mice, 160% in wild-type mice, 
28% in Keap1-KD mice, and 115% in Keap1-HKO mice. Compared to wild-type mice, 
the basal level of Srebp1 protein was 28% higher in Nrf2-null mice, 48% lower in 
Keap1-KD mice, and 51% lower in Keap1-HKO mice. Ethanol did not have any effect on 
nuclear Srebp1 protein levels in the four genotypes of mice, and Srebp1 protein was 
maintained in a gene dose-response manner after ethanol administration. To further 
evaluate the role of Nrf2 in Srebp1 activation, the mRNA of Scd1, a Srebp1-target gene, 
was quantified in the gene dose-response model. Compared to wild-type mice, the 
basal level of Scd1 mRNA was 17% higher in Nrf2-null mice, 9% lower in Keap1-KD 
mice, and 52% lower in Keap1-HKO mice. After ethanol administration, Scd1 mRNA 
increased 70% in Nrf2-null mice, 37% in wild-type mice, decreased 20% in Keap1-KD 
mice, and remained unchanged in Keap1-HKO mice (Fig. 6.6).  
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Figure 6.6. Effects of ethanol on the mRNA and protein of the Srebp1 signal pathway. 
(A) mRNA of Srebp1, (B) protein of Srebp1, and (C) mRNA of Scd1 in livers of Nrf2-null, 
wild-type, Keap1-KD, and Keap1-HKO mice 6 h after ethanol administration (5 g/kg, 
p.o.). Data are expressed as mean ± S.E.M of 5 mice per group.  Asterisks (*) indicate 
statistically significant differences from control mice of the same genotype (p < 0.05). 
Daggers (†) indicate statistically significant differences from wild-type mice after ethanol 
administration. 
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Discussion 
It is well established that acute and chronic ethanol intoxication causes lipid 
peroxidation, as evidenced by increased lipid peroxidation products in liver and serum 
of laboratory animals and humans. For example, chronic feeding of an ethanol-
containing diet resulted in production of 4-hydroxynonenal (4-HNE), a product 
generated in the oxidation of polyunsaturated lipids, and subsequently production of 4-
HNE modified proteins in rats and mice (Smathers et al., 2011). A reduction in alcohol 
consumption in humans was associated with reduced plasma F2-isoprostanes, a 
product from non-enzymatic oxidation of arachidonic acid (Barden et al., 2007). 
Malondialdehyde (MDA), another product generated from oxidation of polyunsaturated 
fatty acids, was increased after acute (Kim et al., 2009) and chronic (Khanal et al., 2009) 
ethanol feeding to mice. Consistent with these previous studies, the present study using 
the TBARS assay, illustrate that acute ethanol intoxication resulted in increased lipid 
peroxidation products in serum of wild-type mice. TBARS were increased more in Nrf2-
null mice, an indication of exaggerated oxidative stress in the absence of Nrf2. In 
addition, ethanol had no effect on thiobarbituric acid reactive substances in Keap1-KD 
and Keap1-HKO mice (Fig. 6.2), which indicates that Nrf2 activation blunted the 
ethanol-induced oxidative stress. 
Ethanol enhanced ROS in a dose-dependent manner in primary hepatocytes of 
Nrf2-null mice and wild-type mice, but not in Nrf2-enhanced mice. This indicates that 
ethanol induces oxidative stress, and the absence of Nrf2 increases ethanol-induced 
oxidative stress, whereas Nrf2 activation decreases oxidative stress in vitro. Under 
physiological conditions, reactive oxygen species (ROS) are generated from multiple 
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sources, including the electron transport chain in mitochondria (Droge, 2002).  The 
basal level of ROS was higher in primary hepatocytes from Nrf2-null mice, and lower in 
primary hepatocytes from Nrf2-enhanced mice, indicating that Nrf2 decreases oxidative 
stress even in the absence of an exogenous challenge. In primary hepatocytes of 
Keap1-KD and Keap1-HKO mice, ROS increased rapidly (3 h) after ethanol exposure 
(Fig. 6.4B). The increase in ROS may be due to higher CYP2E1 activities in Keap1-KD 
and Keap1-HKO mice (data not shown). However, ROS in Keap1-KD and Keap1-HKO 
hepatocytes were low, and remained low after ethanol exposure, indicating that Nrf2 
activation-induced antioxidants are efficient in scavenging the ROS generated.  
In addition to the formation of lipid peroxidation products, acute and chronic 
ethanol intoxication also results in a decrease in endogenous antioxidants (GSH in 
particular) in liver. For example, after a single dose of ethanol to mice, hepatic GSH 
content was decreased the most 6 h after administration (Vogt and Richie, 2007). In the 
present study, ethanol tended to decrease GSH in wild-type mice at 6 h. However, the 
decrease was not statistically significant. The different observations in the two studies 
may be due to the difference in nutrient status (fasted versus feed) or age difference of 
the animals (6-month old versus 3-month old). In the present study, cytosolic GSH 
concentrations in Nrf2-null mice were the most sensitive to ethanol, which indicates that 
Nrf2 is critical for maintenance of cellular GSH following ethanol consumption. 
Mitochondria, through the electron transport chain, is the major cellular organelle that 
generates ROS (Droge, 2002), and the redox status of mitochondria is crucial in 
ethanol-induced oxidative stress. GSH in mitochondria is a key regulator in the cell 
survival/death decision (Mari et al., 2009). In livers of wild-type mice, ethanol slightly 
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decreased cytosolic GSH concentrations, but depleted 52% of the mitochondrial GSH 
(Fig.6. 2). After ethanol administration, the GSH concentrations in mitochondria were 
lower in Nrf2-null mice than wild-type mice, indicating a role of Nrf2 in maintaining redox 
homeostasis in mitochondria. 
In contrast with the consistent observation of oxidative stress by ethanol, the 
pattern of transcriptional activation of Nrf2 battery genes has not always been 
consistent between acute and chronic ethanol intoxication models. For example, chronic 
feeding of ethanol induced the mRNAs of heme oxygenase 1 (Ho-1) and NAD(P)H 
quinone dehydrogenase 1 (Nqo1) in rat livers (Yeligar et al., 2010). In another study, 
chronic feeding of ethanol also induced mRNA of sulfiredoxin (Sxn) and peroxiredoxin 1 
(Prx1) in livers of mice (Bae et al., 2011). In contrast, acute ethanol intoxication 
decreases mRNA and activity of proteins involved in antioxidant defense. For example, 
acute ethanol decreased markedly the enzyme activities of catalase, glutathione 
reductase, glutathione peroxidase, and glutathione-S-transferase in livers of rats (Khan 
et al., 2011). Acute ethanol exposure inhibits Nrf2 activation in the cerebellum of rats 
(Kumar et al., 2011a), and acute ethanol administration decreased mRNA and protein 
levels of thioredoxin 1(Trx1) (Cohen et al., 2009) and peroxiredoxin 6 (Prx6) (Roede et 
al., 2008) in livers of mice. Consistent with the previous observations, the present study 
shows that Gclc mRNA and protein are decreased after ethanol administration. 
However, it should be noted that after ethanol administration, mRNA and protein 
concentrations of Nqo1 and Gclc increased with Nrf2 activation in a gene dose-
response manner (Fig. 6.3).  
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In the present study, ethanol had minor effects on increasing serum triglyceride 
and hepatic free fatty acid concentrations in wild-type mice. Ethanol treatment resulted 
in more profound increases in free fatty acid concentrations in livers of Nrf2-null mice, 
whereas Nrf2 activation blunted such an increase in livers of ethanol-treated Keap1-KD 
and Keap1-HKO mice (Fig. 6.5). However, activation of Nrf2 did not prevent ethanol-
induced increase in triglyceride concentrations in liver, which were increased in all 
genotypes of mice.  Sterol regulatory element binding protein 1 (Srebp1) is an 
endoplasmic reticulum (ER) membrane-bound transcription factor that translocates into 
the nucleus to promote transcription of genes involved in cholesterol and fatty acid 
synthesis (Horton et al., 2002). Srebp1 mRNA and protein were decreased with graded 
Nrf2 activation before and after ethanol administration. The basal mRNA level of Scd1, 
an Srebp1-target gene, was also decreased with graded Nrf2 activation, and increased 
markedly after ethanol administration in Nrf2-null mice, but not in Nrf2-enhanced mice 
(Fig. 6.6). These observations indicate that Srebp1 expression and activity are 
suppressed by Nrf2 activation. Srebp1 is regulated by multiple nuclear receptors and 
endogenous signaling molecules, including Liver X receptor (Yoshikawa et al., 2001), 
insulin, and glucagon (Raghow et al., 2008). Recently, oxidative stress was shown to 
facilitate Srebp1 activation (Waris et al., 2007). Thus, increased Scd1 mRNA as well as 
increased fatty acid concentrations in livers of Nrf2-null mice were partially due to 
ethanol-induced oxidative stress. 
In summary, the present study shows that Keap1-Nrf2 signaling pathway plays 
an important role in protecting against ethanol-induced hepatic alterations in vitro and in 
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vivo, and this protective effect may result from Nrf2-regulated elevation of cellular GSH 
concentrations and suppression of the Srebp1 signaling pathway.  
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Chapter 7 : NRF2 ACTIVATION PREVENTS CADMIUM-INDUCED ACUTE LIVER 
INJURY 
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Abstract 
Oxidative stress plays an important role in cadmium-induced liver injury. Nuclear 
factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that up-regulates 
cytoprotective genes in response to oxidative stress. To investigate the role of Nrf2 in 
cadmium-induced hepatotoxicity, Nrf2-null mice, wild-type mice, kelch-like ECH-
associated protein 1-knockdown (Keap1-KD) mice with enhanced Nrf2, and Keap1-
hepatocyte knockout (Keap1-HKO) mice with maximum Nrf2 activation were treated 
with cadmium (3.5 mg/kg, i.p.). Blood and liver samples were collected 8 h thereafter. 
Cadmium increased serum alanine aminotransferase (ALT) and lactate dehydrogenase 
(LDH) activities, and caused extensive hepatic hemorrhage and necrosis in the Nrf2-null 
mice. In contrast, Nrf2-enhanced mice had lower serum ALT and LDH activities and 
less morphological alternations in the livers than wild-type mice. H2DCFDA (2′,7′-
dichlorodihydrofluoresein diacetate) staining of primary hepatocytes isolated from the 
four genotypes of mice indicated that oxidative stress was higher in Nrf2-null cells, and 
lower in Nrf2-enhanced cells than in wild-type cells. To further investigate the 
mechanism of the protective effect of Nrf2, mRNA of metallothionein (MT) and other 
cytoprotective genes were determined. Cadmium markedly induced MT-1 and MT-2 in 
livers of all four genotypes of mice. In contrast, genes involved in glutathione synthesis 
and reducing reactive oxygen species, including glutamate-cysteine ligase (Gclc), 
glutathione peroxidase-2 (Gpx2), and sulfiredoxin-1 (Srxn-1) were only induced in Nrf2-
enhanced mice, but not in Nrf2-null mice. In conclusion, the present study shows that 
Nrf2 activation prevents cadmium-induced oxidative stress and liver injury through 
induction of genes involved in antioxidant defense rather than genes that scavenge Cd. 
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Introduction 
Cadmium (Cd) is a heavy metal that causes dose- and route-dependent toxicity 
in multiple organs in humans and laboratory animals. Acute Cd exposure via inhalation 
causes pneumonitis, bronchitis, and pulmonary edema (Liu et al., 2007). Chronic Cd 
exposure through inhalation or by oral ingestion results in renal dysfunction, anemia, 
osteoporosis, and bone fractures (Liu et al., 2009). Cd is identified as a category-I 
human carcinogen, due to its potential to induce pulmonary tumors (Waalkes, 2003). 
In animal studies, liver injury is the major toxic effect after an acute dose of Cd. 
The mechanisms of Cd-induced acute hepatotoxicity have been studied and appear to 
be a biphasic process (Rikans and Yamano, 2000).  The first phase of damage is 
initiated by the binding of Cd to sulfhydryls of glutathione (GSH) and proteins, resulting 
in the generation of reactive oxygen species (ROS) and protein inactivation. Cd-induced 
ROS in turn produces lipid peroxidation, and results in DNA damage (Hassoun and 
Stohs, 1996). Damage to the vascular endothelium also disrupts the microcirculation, 
causing ischemia and subsequent liver injury (Liu et al., 1992). The second phase of 
damage is initiated by the activation of Kupffer cells in response to endothelial and 
parenchymal cell injury. The activated Kupffer cells release inflammatory mediators 
such as cytokines, chemokines, and adhesion molecules to recruit neutrophils to the 
sites of injury. Kupffer cells, together with neutrophils, release cytotoxic mediators, such 
as ROS, reactive nitrogen species (RNS), bioactive lipids, and hydrolytic enzymes to 
cause further liver injury (Yamano et al., 2000). 
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The mechanism of Cd detoxification in cells is dependent mainly on the induction 
of metallothionein (MT). MT is a family of cysteine-rich, low-molecular-weight proteins. 
MT has a high capacity to bind both physiological (such as zinc, copper, selenium) as 
well as xenobiotic (such as cadmium, mercury, silver, arsenic) heavy metals through the 
thiol group of the cysteine residues of MT, and it is highly inducible by metals (Klaassen 
and Liu, 1998; Klaassen et al., 1999). MT-null mice are more susceptible to Cd-induced 
hepatotoxicity than wild-type mice, whereas MT-transgenic mice are protected from Cd-
induced hepatotoxicity (Liu et al., 1995b). Antioxidants, such as quercetin, α-tocopherol 
(Prabu et al., 2010), and diallyl tetrasulfide (Ponnusamy and Pari, 2011) also decrease 
Cd-induced oxidative stress and subsequent tissue injury in rats. 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that 
promotes transcription of a battery of cytoprotective genes in response to 
oxidative/electrophilic stress. Recently, a Nrf2 “gene dose-response” model was 
generated using Nrf2-null mice, wild-type mice, Keap1-knockdown (Keap1-KD) mice 
with enhanced Nrf2 activation, and Keap1-hepatocyte knockout (Keap1-HKO) mice with 
maximum Nrf2 activation. Transcription profiling in the Nrf2 “gene dose-response” 
model by microarray analysis showed that mRNA of MT-1 and MT-2 were induced by 
Nrf2 activation in a “gene dose-response” manner (Wu et al., 2011a), indicating that 
Nrf2 may play a role in preventing Cd-induced acute liver injury. 
The antioxidant properties of Nrf2 target genes make Nrf2 a promising target in 
preventing Cd-induced toxicity. Suppression of Nrf2 resulted in greater sensitivity, 
whereas over-expression of Nrf2 results in resistance to Cd-induced apoptosis in rat 
kidney cells (Chen and Shaikh, 2009). However, it is not known whether Nrf2 activation 
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protects against Cd-induced toxicity in vivo. In the present study, the Nrf2 “gene dose-
response” model was used to characterize the protective effect of Nrf2 in maintaining 
redox equilibrium in response to Cd exposure. 
Results 
Serum ALT and LDH 
Cd-induced acute hepatotoxicity was indicated by enzyme activities of alanine 
transaminase (ALT) and lactate dehydrogenase (LDH) in serum. In saline-treated mice, 
serum ALT activities in Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice were low 
and with no differences between genotypes. Cd increased serum ALT activities 24-fold 
in Nrf2-null mice, 16-fold in wild-type mice, 4-fold in Keap1-KD mice, but not in Keap1-
HKO mice (Fig. 1A). Serum LDH activities of Nrf2-null, wild-type, Keap1-KD, and 
Keap1-HKO mice were also low, and with no differences among the four genotypes of 
mice. Cd increased serum ALT activities 16-fold in Nrf2-null mice, 3-fold in wild-type 
mice, but not in Keap1-KD and Keap1-HKO mice (Fig. 7.1B). 
Liver histopathology 
There were no observable abnormalities in the livers of Nrf2-null, wild-type, 
Keap1-KD, and Keap1-HKO mice (data not shown).  However, Cd produced severe 
hemorrhage and necrosis in Nrf2-null mice (under low magnification), and extensive 
nuclear condensation (under high magnification). Cd produced severe hemorrhage and 
moderate necrosis in wild-type mice, but mild hemorrhage and no necrosis in Keap1-KD 
and Keap1-HKO mice (Fig. 7.2).  
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Figure 7.1.  (A) Serum alanine transaminase (ALT) and (B) lactate dehydrogenase 
(LDH) activities in Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice (n=5) 
administered saline (10 mL/kg, i.p.) or Cd (3.5 mg/kg, i.p.). ALT and LDH activities are 
expressed as International Units/Liter. Values are expressed as mean ± S.E.M. 
Asterisks (*) indicate a statistically significant difference from saline pretreated mice of 
the same genotype (p ≤ 0.05). Daggers (†) indicate a statistically significant difference 
from wild-type mice treated with Cd (p ≤ 0.05). 
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Figure 7.2. Histological analysis of livers from Nrf2-null, wild-type, Keap1-KD, and 
Keap1-HKO mice treated with Cd (3.5 mg/kg, i.p.). Left panel, low magnification (20×). 
Right panel, high magnification (40×). 
  
(100X) (200X) 
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Dose-response and time course of ROS generation 
To characterize Cd-induced oxidative stress, primary hepatocytes from Nrf2-null, 
wild-type, Keap1-KD, and Keap1-HKO mice were isolated and stained with H2DCFDA, 
an general indicator of ROS. H2DCFDA enters cells by simple diffusion, then is 
deacetylated by cellular esterase and trapped within the cells. It is further oxidized by 
ROS into DCF to emit a green fluorescence. Without Cd, there was slight green 
fluorescent staining in the Nrf2-null cells but not in wild-type or Nrf2-activated cells, 
indicating more ROS were in Nrf2-null cells than wild-type and Nrf2 activated cells. After 
the addition of Cd, ROS staining was most evident in Nrf2-null cells, but not in Nrf2-
activated cells (Fig. 7.3A). Quantitatively, without Cd, the basal levels of ROS were 68% 
higher in Nrf2-null cells, and 41 and 53% lower in Keap1-KD and Keap1-HKO cells than 
wild-type cells, respectively. After the addition of Cd, ROS increased 3-fold in Nrf2-null 
cells and 2.8-fold in wild-type cells. In contrast, ROS in Keap1-HKO cells remained low 
at all time points (Fig. 7.3B). Cd increased ROS in wild-type and Nrf2-null cells in a 
concentration-dependent manner, but had no effect on ROS in Keap1-HKO cells (Fig. 
7.3C). 
mRNA of MT-1, MT-2, and Ho-1 in liver 
To determine the mechanism of how Nrf2 protects against Cd-induced toxicity, 
MT-1 and MT-2 mRNA were quantified in livers of Nrf2-null, wild-type, Keap1-KD, and 
Keap1-HKO mice (Fig. 7.4). Without Cd, the basal level of MT-1 was 66% higher in 
Nrf2-null mice, 43% higher in Keap1-KD mice, and 490% higher in Keap1-HKO mice 
than wild-type mice. Eight h after Cd administration, mRNA of MT-1 increased more 
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than 200-fold in the four genotypes of mice, with no statistical significance among the 
genotypes (Fig. 7.4A). Similarly, without the addition of Cd, the basal level of MT-2 was 
41% higher in Nrf2-null mice, 65% higher in Keap1-KD mice, and 12-fold higher in 
Keap1-HKO mice than wild-type mice. Eight h after injection of Cd, mRNA of MT-2 
increased more than 500-fold in the four genotypes of mice, with no statistical 
significance among the genotypes (Fig. 7.4B). The basal level of Ho-1 was 72 and 55% 
higher in Keap1-KD and Keap1-HKO mice than wild-type mice, respectively. At 8 h of 
Cd exposure, the mRNA of Ho-1 increased more than 15-fold in Nrf2-null, wild-type, and 
Keap1-KD mice, and 60-fold in Keap1-HKO (Fig. 7.4C). 
mRNA of genes involved in antioxidant defense 
The mRNA of certain genes involved in antioxidant defense, including Gpx2, 
Prdx1, Gclc, Txnrd1, Srxn1, and Txn1 were lowly expressed in Nrf2-null mice, but were 
induced with graded Nrf2 activation in wild-type, Keap1-KD, and Keap1-HKO mice (Fig. 
5). Specifically, the mRNA of Gpx2 was 160-fold more abundant in Keap1-HKO mice 
than wild-type mice. After Cd administration, Gpx2 mRNA was increased in wild-type 
and Keap1-KD mice but not in Keap1-HKO mice. However, the abundance of Gpx2 
mRNA was 24-fold higher than in Nrf2-null mice, 14-fold higher than in wild-type mice, 
and 8-fold higher than in Keap1-KD mice. Cd increased Gclc and Srxn-1 mRNA in wild-
type mice and Nrf2-activated mice, but not in Nrf2-null mice. In contrast, Cd markedly 
increased mRNA of Prdx1, Txnrd1, and Txn1 in both Nrf2-null and Nrf2-activated mice 
(Fig. 7.5).  
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Figure 7.3.  Figure 7.4. Cd-induced oxidative stress in vitro. (A) DCFDA fluorescence in 
primary hepatocytes 6 h after ethanol exposure. Primary hepatocytes were isolated and 
treated with ethanol for 24 h and subjected to live cell imaging. (B) Time-response and 
(C) dose-response of ROS production after ethanol administration of primary 
hepatocytes from Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice. Data are 
presented as Mean ± S.E.M. of 3 mice per group in Fig 4B and Fig 4C.  Asterisks (*) 
indicate statistically significant differences from wild-type cells of the same time point (p 
< 0.05). 
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Figure 7.5. (A) MT-1, (B) MT-2, and (C) Ho-1 mRNA in livers of Nrf2-null, wild-type, 
Keap1-KD, and Keap1-HKO mice after Cd treatment (3.5 mg/kg, i.p.). Livers were 
removed 8 h after dosing and mRNA quantified by the RT-PCR. Asterisks (*) indicate a 
statistically significant difference from saline pretreated mice of the same genotype (p ≤ 
0.05). Number signs (#) indicate a statistically significant difference from wild-type mice 
treated with saline (p ≤ 0.05). Daggers (†) indicate a statistically significant difference 
from wild-type mice treated with Cd (p ≤ 0.05). 
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Figure 7.6. (A) Gpx2, (B) Gclc, (C) Srxn, (D) Prdx1, (E) Trxnrd1, and (F) Trxn1 mRNA 
in livers of Nrf2-null, wild-type, Keap1-KD, and Keap1-HKO mice after Cd treatment (3.5 
mg/kg, i.p.). Livers were removed 8 h after dosing and mRNA quantified by RT-PCR. 
Asterisks (*) indicate a statistically significant difference from saline pretreated mice of 
the same genotype (p ≤ 0.05). Number signs (#) indicate a statistically significant 
difference from wild-type mice before Cd treatment (p ≤ 0.05). Daggers (†) indicate a 
statistically significant difference from wild-type mice after Cd treatment (p ≤ 0.05). 
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DISCUSSION 
In the present study, liver injury was the primary toxic effect observed after an 
acute dose of Cd (3.5 mg/kg). After administration, Cd is distributed via the blood, 
where it is bound to red blood cells and plasma proteins, mainly albumin. Albumin-
bound Cd is readily distributed to various organs, with the majority going to the liver, 
where Cd is primarily bound to MT (Liu et al., 2001). After a single injection of Cd to rats, 
the highest concentration of Cd is in the liver, followed by kidney, spleen, and heart 
(Goering and Klaassen, 1983). The distribution of Cd changes with time; the 
concentration of Cd in the liver decreases as it redistributes to the kidney, resulting in 
nephrotoxicity after chronic Cd exposure (Klaassen and Liu, 1997).  
The present study, together with other reports, indicates excessive generation of 
ROS after Cd exposure. For example, a concentration-response study of Cd (50 -100 
µM) in mouse embryonic fibroblasts (MEF) demonstrated the presence of ROS 5 h after 
incubation using dihydroethidium, a staining technique used to quantify ROS. In addition, 
MEF derived from Nrf2-null mice showed elevated basal and Cd-induced ROS 
generation (He et al., 2008). Similarly, the present study demonstrates increases in 
ROS in mouse primary hepatocytes by Cd in a concentration- (10-100 µM) and time-
dependent (3-24 h) manner. The Nrf2-null hepatocytes also have higher basal ROS as 
well as Cd-induced ROS generation.  In addition, the present study further shows that 
Keap1-HKO hepatocytes not only have the maximum activation of Nrf2, but also a lower 
basal level of ROS, and protect against Cd-induced generation of ROS at all tested 
concentrations (Fig. 7.3).  
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Cd activates the Keap1-Nrf2 pathway through multiple mechanisms. For example, 
Cd delays the ubiquitin-proteasome mediated degradation of Nrf2, and increase its half-
life from 13 to 100 min in mouse hepatoma (Hepa) cells (Stewart et al., 2003). Cd also 
enhances the nuclear export of BTB and CNC homology 1 (Bach1), which competes 
with Nrf2 for DNA binding, to promote Nrf2 target gene transcription (Suzuki et al., 
2003). The most extensively studied Nrf2 target gene that is induced by Cd is heme 
oxygenase-1 (Ho-1). For example, Ho-1 is induced by Cd in mouse MCF-7 mammary 
epithelial cells (Alam et al., 2000), mouse Hepa cells (Stewart et al., 2003), and HeLa 
cells (Andoh et al., 2006). However, the present study shows that cadmium produces a 
marked (over 180-fold) increase of Ho-1 mRNA in livers of Nrf2-null mice, which 
indicates that additional transcription factors or signaling pathways are involved in the 
induction of Ho-1 by Cd. Thioredoxin reductase (Trxnrd1) is induced by Cd in bovine 
arterial endothelial cells (BAEC) through Nrf2 activation (Sakurai et al., 2005), and in the 
present study, both thioredoxin (Trxn1) and Trxnrd1 are induced by Cd in livers of Nrf2-
null mice. The mRNA of Trxn1 and Trxnrd1 tended to be higher in Nrf2-activated mice, 
but was not statistically different (Fig. 7.5).  
The critical roles of MT in Cd detoxification are well-established (Klaassen et al., 
2009), and there is increasing knowledge about the protective role of Nrf2 against Cd 
toxicity. However, little is known about whether Nrf2 protects against Cd-induced toxicity 
through inducing MT. Four major MT isoforms have been identified (MT-1 to MT-4). MT-
1 and MT-2 are expressed in all organs, especially in liver, intestine, pancreas, and 
kidney. MT-3 is mainly expressed in brain and kidney, and MT-4 is most abundant in 
stratified epithelium (Vesey, 2010). It is estimated that one molecule of MT can bind to 
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seven molecules of Cd, and MT-bound Cd is generally considered non-toxic (Liu et al., 
1996). The present study showed that the mRNA of MT-1 and MT-2 are higher in 
Keap1-HKO mice than in wild-type mice (5-fold and 11-fold, respectively), indicating 
MT-1 and MT-2 are potential Nrf2 target genes in vivo. However, following Cd treatment, 
MT-1 and MT-2 in Nrf2-null mice were markedly increased (more than 200-fold), and 
there was no difference in the quantities of MT-1 or MT-2 mRNA among the four 
genotypes of mice. This finding indicates that induction of MT-1 and MT-2 mRNA by Cd 
is through Nrf2-independent mechanism.  
In contrast to MT-1, MT-2, and Ho-1, the present study shows that Cd increased 
the mRNA of Gpx2, Gclc, and Srxn1 in wild-type and Nrf2-activated mice, but not in 
Nrf2-null mice (Fig. 7.5). Glutathione peroxidase is a family of enzymes that reduces 
hydrogen peroxide to H2O and oxidizes glutathione (GSH) to GSSG. There are five 
isoforms in the Gpx family: cytosolic Gpx (Gpx1), gastrointestinal Gpx (Gpx2), plasma 
Gpx (Gpx3), phospholipid hydroperoxide Gpx (Gpx4), and olfactory epithelium-specific 
Gpx (Gpx5) (Margis et al., 2008). Gpx2 is localized in the cytosol and was originally 
detected in the rodent gastrointestinal tract. In humans, Gpx2 is expressed in the liver 
and large intestine (Chu et al., 1993). The present study shows that Gpx2 mRNA is 
almost absent in livers of Nrf2-null mice, and Cd increased 160-fold more Gpx2 mRNA 
in Keap1-HKO mice than wild-type mice (Fig. 7.5). This observation indicates that Gpx2 
is present and highly inducible in mouse liver, and its induction is highly dependent on 
Nrf2. Gclc is the rate limiting enzyme that synthesizes GSH, the essential substrate for 
Gpx2 to reduce hydrogen peroxide (Yang et al., 2011). The basal level of Gclc mRNA 
increased with graded Nrf2 activation, and Cd exposure further induced Gclc in Nrf2-
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containing mice but not in Nrf2-null mice (Fig. 7.5). Collectively, the present study 
shows that Nrf2-Gclc-Gpx2 serves as a novel mechanism to protect against Cd-induced 
oxidative stress and tissue injury. In addition to Gpx, peroxiredoxin (Prx-SH) is another 
family of enzymes that directly reduces hydrogen peroxide. Oxidized peroxiredoxin (Prx-
SO2H) under excessive oxidative stress, can only be reduced by surfiredoxin (Srxn) 
(Lowther and Haynes, 2011). The present study shows that Nrf2 is essential for both the 
basal and Cd-induced adaptive response of Srxn1 transcription. 
In conclusion, the present study shows that Nrf2 activation prevents cadmium-
induced oxidative stress and liver injury. The protective effect of Nrf2 is dependent on 
induction of genes involved in antioxidant defense rather than genes that scavenge Cd. 
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Chapter 8 : NRF2 ACTIVATION PROTECTS AGAINST DIQUAT-INDUCED LIVER 
AND LUNG INJURY 
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Abstract 
Diquat is a herbicide that generates superoxide anions through redox cycling. Nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor that up-regulates 
cytoprotective genes in response to oxidative stress. To investigate the protective effect 
of Nrf2 against diquat-induced toxicity, wild-type, Nrf2-null, and Kelch-like ECH-
associated protein 1-knockdown (Keap1-KD) mice with enhanced Nrf2 activity were 
treated with diquat dibromide (125 mg/kg, i.p.). Blood and tissues were collected at 1, 2, 
4, and 6 h after treatment. Administration of diquat resulted in lipid peroxidation and 
lethality in wild-type mice, which were more in Nrf2-null mice and less in Keap1-KD 
mice. Diquat produced liver injury in Nrf2-null mice, as evidenced by increased serum 
ALT activity and extensive hepatic necrosis, but not in wild-type and Keap1-KD mice. 
Diquat produced more severe lung injury in Nrf2-null than in wild-type mice, as 
evidenced by increased lung weight and alveolar collapse. In contrast, Keap1-KD mice 
had attenuated lung edema and no histopathological alterations. To further investigate 
the mechanism of the protective effects of Nrf2, lung and liver glutathione (GSH) 
concentrations were quantified. Diquat decreased GSH in lung and liver in wild-type 
mice, and the decrease was more in Nrf2-null mice, and less in Keap1-KD mice. After 
diquat treatment, the mRNA of the GSH synthesis enzyme Gclc was increased in 
Keap1-KD, but not in Nrf2-null mice. Collectively, Nrf2 plays an important role in 
preventing diquat-induced liver and lung injury, and this protective effect results from 
Nrf2-regulated elevation of cellular GSH and expression of GSH synthetic genes.  
Introduction 
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One of the major challenges in a biological system is to maintain redox cellular 
homeostasis through balancing the rate and magnitude of oxidant generation and 
oxidant detoxification. An imbalanced ratio between reactive oxygen species (ROS) 
production and adaptive antioxidant capacity will result in oxidative stress, a pathogenic 
state that is both a cause and consequence of numerous acute toxicity and chronic 
diseases. ROS are free radicals with one or more unpaired electrons, which make them 
highly reactive. Most common cellular oxidative stress are generated from oxygen 
metabolism, such as the superoxide radical (O.-) and the hydroxyl radical (OH.) as well 
as reactive nitrogen species, such as nitric oxide (NO) and the peroxynitrite radical 
(ONOO.).  
The immediate outcomes of oxidative stress include DNA damage (Bertram and 
Hass, 2008), protein adduction (Filippin et al., 2008), and lipid peroxidation (Cejas et al., 
2004), leading to nuclear damage, mitochondrial damage, proteasome inhibition, and 
endoplasmic reticulum (ER) stress. ROS can damage the enzymes that maintain low 
intracellular Ca2+ (Malhotra and Kaufman, 2007). In addition, mitochondrial damage 
results in both ROS leakage from the electron transport system and Ca2+ release, and 
impaired ATP generation further disrupts ion homeostasis (Lemasters et al., 2009). 
Nuclear damage induces p53 activation, Bax activation, and Bcl-2 inhibition, followed by 
a release of cytochrome c into the cytosol that initiates the caspase signal pathway and 
apoptosis (Bursch et al., 2008). Oxidative stress also sensitizes cells to pro-
inflammatory cytokines, recruits immune cells, and subsequent inflammatory response 
leads to further injury (Filippin et al., 2008). Thus, oxidative stress and ROS play an 
integral role in ageing, xenobiotic-induced toxicity, and numerous diseases. 
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Diquat is a contact herbicide that undergoes oxidation/reduction cycling, resulting 
in the generation of superoxide (Smith, 1987). It is a pure redox cycler that is minimally 
metabolized, thus diquat-induced injury serves as a typical model to study ROS 
generation and oxidative stress. A cell line based study revealed that mouse embryonic 
fibroblasts derived from Nrf2-deficient mice were more sensitive to diquat-induced 
toxicity, with impaired capacity to restore endogenous antioxidants (Osburn et al., 2006). 
However, there is no information on the importance of the Nrf2 in protecting the intact 
animal from diquat toxicity. In the present study, Nrf2-null, wild-type, and Keap-KD mice 
were used to characterize the role of the Keap1-Nrf2 signaling pathway on maintaining 
redox homeostasis after diquat treatment, and whether Nrf2 activation protects against 
diquat-induced toxicity. 
Results 
Survival 
Wild-type mice treated with diquat dibromide (125 mg/kg, i.p.) began to die 3 h 
after injection, and 40% died by 6 h (Fig.8.1). Nrf2-null mice began to die at 2 h, and 40 
and 60% died by 4 h and 6 h after diquat injection, respectively. In contrast, constitutive 
Nrf2 activation in the Keap1-KD mice resulted in 100% survival during the 6 h-
observation period. 
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Figure 8.1. Survival rates of wild-type, Nrf2-null, and Keap1-KD mice after treatment 
with diquat dibromide (125 mg/kg, i.p.).  
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TBARS 
To determine the effect of diquat on oxidative stress and whether Nrf2 activation 
protects against diquat-induced oxidative stress, lipid peroxidation products were 
quantified in serum samples of wild-type, Nrf2-null, and Keap1-KD mice using the 
TBARS method. In wild-type mice, TBARS increased after diquat treatment, and 
peaked at 4 h, which was 140% higher than before diquat administration. In Nrf2-null 
mice treated with diquat, TBARS also increased slightly more than wild-type mice during 
the 6 h-observation period. TBARS in Keap1-KD mice treated with diquat was much 
lower than in wild-type and Nrf2-null mice (Fig. 8.2).  
Serum ALT and liver histology 
Diquat-induced hepatotoxicity was detected by serum alanine transaminase (ALT) 
and histopathology. Diquat increased serum ALT in all genotypes of mice throughout 
the 6 h-observation period. In the Nrf2-null mice, diquat produced higher serum ALT at 
all time intervals than in the wild-type mice. Keap1-KD mice tended to have lower ALT 
after diquat administration, and ALT was statistically lower at 6 h (Fig. 8.3A). 
Histological analysis showed that livers of wild-type, Nrf2-null, and Keap1-KD mice 
treated with saline appeared normal. There were no morphological changes in livers of 
wild-type and Keap1-KD mice after diquat administration. However, in the Nrf2-null mice 
administered diquat, extensive areas of necrosis were concentrated around the central 
veins (Fig.8. 3B). 
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Figure 8.2. Time course of serum thiobarbituric acid-reactive substances (TBARS) in 
wild-type, Nrf2-null, and Keap1-KD mice after treatment with diquat dibromide (125 
mg/kg, i.p.). Data are presented as malondialdehyde equivalences (nmol/L) ± S.E.M.  
Asterisks (*) indicate statistically significant differences from wild-type mice of the same 
time point (p < 0.05).  
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Figure 8.3. (A) Time course of serum alanine transaminase (ALT) levels in wild-type, 
Nrf2-null, and Keap1-KD mice after treatment with diquat dibromide (125 mg/kg, i.p.). 
Units are in International Units/Liter (IU/L) expressed as mean ± S.E.M.  Asterisks (*) 
indicate statistically significant differences from wild-type mice of the same time point (p 
< 0.05). (B) Histopathological analysis of liver stained with hematoxylin and eosin in 
wild-type, Nrf2-null, Keap1-KD mice treated with saline (left panel) and diquat dibromide 
(125 mg/kg, i.p., right panel). 
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Glutathione and GSSG concentrations in liver 
In an attempt to determine the mechanism of how the Keap1-Nrf2 signaling 
pathway protects against diquat-induced toxicity, GSH and GSSG concentrations were 
quantified in livers. The basal concentration of GSH in Nrf2-null mice was 26% lower, 
and in Keap1-KD mice was 20% higher than in wild-type mice. After diquat injection to 
wild-type mice, GSH concentrations decreased gradually to 64% of the basal level at 6 
h. After diquat injection to Nrf2-null mice, GSH concentrations tended to be lower than 
in wild-type mice given diquat. In Keap1-KD mice, diquat did not markedly alter GSH 
concentrations in liver (Fig. 8.4A). The basal GSSG concentrations in livers of wild-type, 
Nrf2-null, and Keap1-KD mice were similar, but after diquat administration, GSSG 
increased in wild-type mice, but not in Nrf2-null or Keap1-KD mice (Fig. 8.4B).  
Gclc mRNA expression in liver 
To study the role of the Keap1-Nrf2 pathway in GSH synthesis after diquat, 
mRNA expression of Gclc, the rate limiting enzyme in GSH synthesis, was quantified in 
livers of wild-type, Nrf2-null, and Keap1-KD mice at the 6 h time point. After diquat 
administration, Gclc mRNA increased in both wild-type and Keap1-KD mice (52 and 
75%, respectively), but not in Nrf2-null mice (Fig. 8.5). 
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Figure 8.4. (A) Glutathione and (B) GSSG concentrations in livers of wild-type, Nrf2-null, 
and Keap1-KD mice after treatment with diquat dibromide (125 mg/kg, i.p.). Data are 
presented as μmol/g tissue or concentrations relative to wild-type controls as mean ± 
S.E.M. Asterisks (*) indicate statistically significant differences from wild-type mice of 
the same time point (p < 0.05). 
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Figure 8.5. Messenger RNA expression of Gclc in livers of wild-type, Nrf2-null, and 
Keap1-KD mice 6h after treatment with diquat dibromide (125 mg/kg, i.p.). Data are 
presented as RLU ± S.E.M.  Asterisks (*) indicate statistically significant differences 
from wild-type controls (p < 0.05). 
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Concentration-response and time course of ROS generation by diquat in vitro 
To characterize diquat-induced oxidative stress in vitro, primary hepatocytes from 
Nrf2-null, wild-type, and Keap1-KD mice were isolated and stained with H2DCFDA, a 
general indicator of ROS. Basal ROS were 58% higher in Nrf2-null hepatocytes, and 53% 
lower in Keap1-KD cells than wild-type hepatocytes. After administration of diquat, ROS 
moderately increased in wild-type cells, but markedly increased in Nrf2-null hepatocytes. 
In contrast, ROS in Keap1-KD cells remained at basal levels after the addition of diquat. 
Diquat increased ROS in hepatocytes from wild-type and Nrf2-null mice in a 
concentration-dependent manner. However, diquat did not increase ROS in Keap1-KD 
cells, even at the highest concentration of diquat (Fig.8. 6). 
Lung histology 
Typical photomicrographs of lung parenchyma from wild-type, Nrf2-null, and 
Keap1-KD mice treated with saline or diquat dibromide are shown in Fig 8.7. Lungs 
from wild-type and Keap1-KD mice treated with saline appeared normal, whereas lungs 
of Nrf2-null mice treated with saline appeared to have slight enlargement of the alveolar 
walls. By 6 h after diquat injection, there are structural alterations of lung parenchyma in 
wild-type mice, including moderate alveolar edema, intra-alveolar hemorrhage, and 
interstitial infiltrates; in Nrf2-null mice, severe perivascular and interstitial infiltrates, 
marked alveolar collapse and enlargement of alveolar walls were evident; however, 
there was no apparent pathology in Keap1-KD mice (Fig. 8.7). 
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Figure 8.6. Diquat-induced oxidative stress in vitro. (A) DCFDA fluorescence in primary 
hepatocytes after diquat exposure. Primary mouse hepatocytes were isolated and 
treated with diquat for 24h and subjected to live cell imaging. (B) Time-response and (C) 
dose response of ROS production after diquat exposure in primary hepatocytes from 
Nrf2-null, wild-type, and Keap1-KD mice. Data are presented as Mean ± S.E.M. 3 
animals per group for Fig 4B and Fig 4C.  Asterisks (*) indicate statistically significant 
differences from wild-type cells in the same time point or concentration (p < 0.05).  
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Figure 8.7. Histopathological analysis of lung parenchyma stained with hematoxylin and 
eosin in wild-type, Nrf2-null, Keap1-KD mice treated with saline (left panel) and diquat 
dibromide (125 mg/kg, i.p., right panel). 
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Glutathione and GSSG concentrations in lung 
The basal concentration of GSH in lungs of Nrf2-null mice tended to be lower 
than in wild-type and Keap1-KD mice. Within 1 h of diquat exposure, GSH in lungs was 
decreased 40% in wild-type mice, and decreased 50% in Nrf2-null mice. In Keap1-KD 
mice, GSH concentrations in lungs increased 17% during the first h after diquat 
administration, and decreased gradually thereafter (Fig. 8.8A). GSSG concentrations in 
lungs of wild-type mice were higher than in Nrf2-null and Keap1-KD mice before diquat 
administration, and even higher 1 h after administration, and decreased 67% at the end 
of 6 h. GSSG concentrations in Keap1-KD mice remained unchanged at all time points 
(Fig.8.8B).  
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Figure 8.8. (A) Glutathione and (B) GSSG concentrations in lungs of wild-type, Nrf2-null, 
and Keap1-KD mice after treatment with diquat dibromide (125 mg/kg, i.p.). Data are 
presented as μmol/g tissue or concentrations relative to wild-type controls as mean ± 
S.E.M. Asterisks (*) indicate statistically significant differences from wild-type mice of 
the same time point (p < 0.05). 
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Discussion 
In the present study, the protective role of Nrf2 against oxidative stress was 
investigated using diquat-induced injury as a model of excess ROS. Diquat receives a 
single electron from NADPH by cytochrome P450 reductase. The diquat radical formed 
in this step is highly unstable and transfers an electron to molecular oxygen to form a 
superoxide anion radical. By this mechanism, a small amount of diquat is cycled in a 
continuous process of receiving electrons from NADPH and donating electrons to 
oxygen to form large amounts of superoxide anion radicals (Fu et al., 1999). The 
superoxide anion radicals react with each other, forming hydrogen peroxide and 
molecular oxygen, either spontaneously or via the enzyme superoxide dismutase. Once 
protective mechanisms, such as catalase, the glutathione peroxidase system, and the 
thioredoxin system that detoxify hydrogen peroxide become overwhelmed, oxidative 
stress results, leading to cellular dysfunction and injury. Consistent with previous reports, 
the present study shows that diquat induces oxidative stress in vitro and in vivo, as 
demonstrated by increased lipid peroxidation products in serum (Fig. 8.2), decreased 
GSH content in livers and lungs (Fig. 8.4 and Fig. 8.8), and increased ROS staining in 
primary hepatocytes (Fig. 8.5).  
Diquat produced more mortality in Nrf2-null mice than in wild-type mice, and no 
mortality in Keap1-KD mice (Fig.8.1). Enhanced susceptibility to diquat-induced toxicity 
in Nrf2-deficient cells has been reported previously (Osburn et al., 2006). Specifically, 
Nrf2-deficiency in embryonic fibroblasts resulted in a 5-fold increase in cell death 
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caused by diquat. The present study indicates that Nrf2 also protects from diquat 
toxicity in intact mice.  
The bipyridyl herbicides, paraquat and diquat, both generate ROS in vivo, but 
they produce different target-organ toxicity as a result of a difference in tissue 
distribution. Paraquat distributes mainly to the lung by an active transport process 
(Waddell and Marlowe, 1980; Dinis-Oliveira et al., 2006), whereas diquat distributes 
mainly to the liver, but also to other organs (Spalding et al., 1989). The present study 
indicates that diquat is hepatotoxic, as indicated by increased serum ALT and 
histopathology of mouse liver.  In addition, the presence of interstitial edema from 
pathological analysis confirmed acute lung injury produced by diquat. 
One of the earliest targets of oxidative stress are the lipids in biological 
membranes. Lipid peroxidation by ROS is initiated at the polyunsaturated fatty acid 
side-chains, which are present in cellular membrane phospholipids (Porter et al., 1995), 
forming lipid hydroperoxides and resulting in reduced membrane fluidity and disturbed 
functions of membrane proteins.  Lipid hydroperoxides can undergo iron-mediated 
reduction to form alkoxy radicals and iron-mediated oxidation to form peroxyl radicals, 
which triggers further lipid peroxidation to form cytotoxic aldehydes (Girotti, 1998). 
Aldehydes attack proteins and DNA, thereby propagating the initial damage in cellular 
membranes to other macromolecules (Dargel, 1992). Therefore, inhibiting lipid 
peroxidation is crucial for cells to survive from oxidative stress. In the present study, 
diquat-induced oxidative stress increased TBARS, a biomarker of lipid peroxidation, at 
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early time points in all three genotypes of mice. However, the increase of TBARS was 
less in Keap-KD mice, indicating Nrf2 protects against diquat-induced lipid peroxidation. 
To further understand the mechanism of how Nrf2 activation reduces diquat-
induced mortality and lipid oxidation, GSH and GSSG concentrations were quantified in 
the three genotypes of mice.  GSH is the most abundant cellular thiol and provides 
direct protection from hydrogen peroxide. In the presence of glutathione peroxidase 
(Gpx), hydrogen peroxide is reduced to water at the expense of oxidizing GSH to its 
disulfide (GSSG). GSSG is reduced to GSH by glutathione reductase, using NADPH. 
The Gpx-GSH pathway is also a major intracellular antioxidative mechanism that 
reduces lipid peroxidation (Imai and Nakagawa, 2003), DNA fragmentation (Higuchi, 
2004), and protein adduction (Filippin et al., 2008). Accordingly, free radical reactions, 
which can cause apoptosis and necrosis, accelerate as a consequence of GSH 
depletion. In addition, GSH also decreases inflammation at the site of injury (Biswas 
and Rahman, 2009). In the present study, diquat reduced hepatic GSH concentrations 
in wild-type mice, and even more in Nrf2-null mice, but not in Keap1-KD mice, indicating 
a strong correlation between Nrf2 activation and cellular GSH concentrations. The major 
organ that synthesizes GSH is the liver, which has the highest enzyme activity for GSH 
synthesis and the most abundant substrates for GSH biosynthesis (Meister and 
Anderson, 1983). After diquat administration, the GSH concentrations in livers of 
Keap1-KD mice are higher than in wild-type and Nrf2-null mice, indicating that Nrf2 
activation is important to maintain intracellular GSH concentrations. GSH concentrations 
were decreased more in lung than liver in all genotypes of mice, and failed to recover to 
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basal levels during the observation period. However, GSH concentrations in lung did 
correlate with the activity of Nrf2 in the three genotypes of mice.   
It is well-documented that Nrf2-null mice are more susceptible to many oxidative 
stress- and electrophile-induced toxicity models, such as acetaminophen- (Enomoto et 
al., 2001), pentachlorophenol- (Umemura et al., 2006), and carbon tetrachloride- (Xu et 
al., 2008) induced hepatotoxicity, as well as bleomycin- (Cho et al., 2004) and tobacco 
smoke- (Rangasamy et al., 2004) induced lung toxicity. However, there is conflicting 
data on the role of the Keap1-Nrf2 pathway on basal expression of anti-oxidative genes 
and redox state in animal models without a chemical challenge. Microarray analyses 
showed that constitutive expression of some of the genes that provide direct anti-
oxidative protection, such as Cat, Txn2, Txnrd1, and Sod1, are similar in wild-type and 
Nrf2-null mice (Thimmulappa et al., 2002). Additionally, oxidative stress biomarkers, 
such as aconitase activity and TBARS, as well as GSH concentrations in embryonic 
fibroblasts derived from Nrf2-null mice were similar to embryonic fibroblasts derived 
from wild-type mice (Osburn et al., 2006). In contrast, expression of other anti-oxidative 
genes, such as Gpx, Gst, and Nqo1, as well as genes involved in GSH synthesis were 
higher in livers of wild-type mice than Nrf2-null mice (Reisman et al., 2009e).  In the 
present study, the basal ROS of primary hepatocytes in vitro as well as serum TBARS 
concentrations in vivo were highest in Nrf2-null mice, and lowest in Keap1-KD mice. In 
addition, the basal levels of hepatic GSH were lowest in Nrf2-null mice and highest in 
Keap1-KD mice, indicating that Nrf2 is not only essential for the adaptive response 
under oxidative stress, but also critical in maintaining redox homeostasis under basal 
conditions.  
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In conclusion, the present study shows that the Keap1-Nrf2 signaling pathway 
plays an important role in protecting against oxidative stress-induced liver and lung 
injury in vivo, and this protective effect appears to result from Nrf2-regulated elevation of 
basal cellular GSH concentration and constitutive expression of GSH synthetic genes.  
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Chapter 9 : IMPLEMENTATION OF HIGH-THROUGHPUT SCREEN FOR 
INDENTIFYING SMALL MOLECULES TO ACTIVATE THE KEAP1-NRF2-ARE 
PATHWAY 
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Abstract 
 
Nuclear factor erythroid 2–related factor 2 (Nrf2) is a transcription factor that induces a 
battery of cytoprotective genes involved in antioxidant defense through binding to 
Antioxidant Response Elements (ARE) located in the promoter regions of these genes. 
To identify Nrf2 activators for the treatment of oxidative/electrophilic stress-induced 
diseases, the present study developed a high-throughput assay to evaluate Nrf2 
activation using AREc32 cells that contain a luciferase gene under the control of ARE 
promoters. Of the 47,000 compounds screened, 238 (top 0.5% hits) of the chemicals 
increased the luminescent signal more than 14.4-fold and were retested at eleven 
concentrations in a range of 0.01-30 µM. Of these 238 compounds, 231 (96%) 
increased the luminescence signal in a concentration-dependent manner. Chemical 
structure relationship analysis of these 231 compounds indicated enrichment of four 
chemical scaffolds (diaryl amides and diaryl ureas, oxazoles and thiazoles, pyranones 
and thiapyranones, and pyridinones and pyridazinones). In addition, 30 of these 231 
compounds were extremely effective and/or potent in activating Nrf2, with more than a 
80-fold increase in luminescence, or an EC50 lower than 1.6 µM. These top 30 
compounds were also screened in Hepa1c1c7 cells for an increase in Nqo1 mRNA, the 
prototypical Nrf2-target gene. Of these 30 compounds, 17 increased Nqo1 mRNA in a 
concentration-dependent manner. In conclusion, the present study documents the 
development, implementation, and validation of a high-throughput screen to identify 
activators of the Keap1-Nrf2-ARE pathway.  Results from this screening identified Nrf2 
activators, and provide novel insights in chemical scaffolds that might prevent 
oxidative/electrophilic stress-induced toxicity and carcinogenesis. 
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Introduction 
 
Oxidative stress is the consequence of imbalanced production of reactive oxygen 
species (ROS) and the ability of cells to detoxify these ROS, which can result in ROS-
induced tissue damage. In humans, oxidative stress is involved in the pathogenesis of 
numerous clinical conditions, including atherosclerosis (Sugamura and Keaney, 2011), 
Alzheimer’s disease (Axelsen et al., 2011), and rheumatoid arthritis (Filippin et al., 
2008). In addition, ROS, together with other electrophiles, are capable of attacking DNA 
in the nucleus and become carcinogens (Jeffrey, 1985).  
Data from the previous Chapters suggest potential therapeutic applications of the 
Keap1-Nrf2 pathway, and thus Nrf2 activators are promising drug candidates in the 
treatment of oxidative/electrophilic stress-induced diseases. A quantitative bioassay 
evaluating the induction of NAD(P)H:quinone oxidoreductase 1 (NQO1), the prototypical 
Nrf2 target gene, in Hepa1c1c7 murine hepatoma cells was developed and still remains 
a major screening tool for potential activators of the Keap1-Nrf2 pathway (Baird and 
Dinkova-Kostova, 2011). To date, a number of compounds with diverse chemical 
structures have been shown to activate Keap1-Nrf2, including oxidizable diphenols 
(tBHQ), dithiolethiones (oltipraz), isothiocyanates (sulforaphane), and Michael acceptors 
(curcumin, cinnamates, and chalcones) (Copple et al., 2010). In an effort to develop 
more potent and effective activators of the Keap1-Nrf2 pathway, chemical derivatives of 
known active compounds were synthesized and screened. The most potent known Nrf2 
activator, 2-cyano-3,12-dioxoolean-1,9-bien-28-oic acid imidazole (CDDO-Im), is a 
semisynthetic triterpenoid derived from oleanolic acid (Dinkova-Kostova et al., 2005). 
Based on the structure-activity relationship analyses of the oleanolic triterpenoids, (±)-
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(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-
octahydrophenanthrene-2,6-dicarbonitrile (TBE-31), was synthesized. Both CDDO-Im 
and TBE-31 have been shown to activate Keap1-Nrf2 pathway at nano-molar 
concentrations in vitro and in vivo (Dinkova-Kostova et al., 2010).  
Despite the discovery of a few potent Nrf2 activators (CDDO compounds and 
TBE-31), there is limited information about the chemical scaffolds that can potentially 
activate Nrf2. Recently, AREc32 cells were engineered, which are MCF7 human breast 
cancer cells stably transfected with a luciferase reporter gene construct under the 
control of eight copies of rat Gsta2 AREs in the promoter region (Natsch and Emter, 
2008). The ARE-promoted luciferase reporter method provides a rapid and convenient 
quantification of Nrf2-ARE induction by chemicals, and made large scale-screening of 
Nrf2 activators possible.  
The aim of the present study was to develop a high-throughput assay to evaluate 
Nrf2 activation using the AREc32 cells, screen a library of 47,000 compounds, and to 
find compounds that are potent and effective activators of Nrf2. In addition, through 
structural activity relationship analyses, the present study also aimed to discover novel 
chemical scaffolds that are highly likely to activate the Keap1-Nrf2-ARE pathway. 
Results from this screening identified extremely strong Nrf2 activators, and provide 
novel insights into chemical scaffolds that might detoxify oxidative/electrophilic stress 
and prevent oxidative/electrophilic stress-induced toxicity and carcinogenesis. 
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Results 
Luciferase assay signal stability 
Batch processing of 384-well plates for the HTS library screen requires the 
readout signal to be steady for 30 min, and preferably one hr to minimize timing effects.  
To test the luciferase assay signal stability of AREc32 cells, they were seeded at 3000 
cells/well in a 384-well plate, and tBHQ, the typical Nrf2 activator, was added to cells to 
make final concentrations of 0, 10, 20, or 80 µM.  All wells had a final DMSO 
concentration of 0.5%. Twenty-four hrs after treatment, luciferase activity was assessed 
using the Steady-Glo luciferase assay with luminescence readout. The luminescence 
signal was recorded 30 min after cell lysis, and was quantified repeatedly every 30 min 
for six hrs.  As shown in Fig 9.1A, the luminescent signal was strong and stable for over 
one and a half hrs after adding the luciferase reagent.   
Optimization of AREc32 cells seeding density 
To determine the optimal seeding density of AREc32 cells under screening 
conditions, cells were seeded at a range of 1,000-10,000 cells/well in a 384-well plate, 
and were treated with tBHQ or DMSO vehicle (0-50µM tBHQ, 0.5% DMSO).  Twenty-
four hrs after treatment, luciferase activity was assessed with luminescence readout.  
The luminescent signal was quantified 30 min after adding the luciferase reagent to the 
cells.  Data are presented as fold increase in luminescence by tBHQ over vehicle 
control. As shown in Fig 9.1B, 3000-3500 cells/well provided optimal activation of the 
ARE-luciferase construct by tBHQ. 
The effect of DMSO on cell viability and assay sensitivity 
Because the compounds are maintained in 100% DMSO, the effect of DMSO on 
viability and assay sensitivity of AREc32 cells was investigated. Cell viability was 
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unaffected by DMSO below 0.75% (data not shown). To test the effect of DMSO on 
assay sensitivity, cells were seeded at 3000 cells/well in a 384-well plate and a mixture 
of media and DMSO was added to each well to achieve a final DMSO content of 0%-
10%.  Additionally, 5 µL of media with or without tBHQ was added immediately following 
addition of DMSO.  Twenty-four hrs after treatment, luciferase activity was assessed 
with the luminescence readout. As shown in Fig 9.1C, the ability of tBHQ to activate the 
luciferase reporter construct was hindered by DMSO concentrations above 1%. To 
avoid cell stress that may activate undesired molecular pathways, 0.5% DMSO was 
selected as the maximum tolerable concentration of DMSO in the cell culture medium. 
Dose-response activation of ARE-luciferase reporter construct in AREc32 cells by 
known Nrf2 activators 
To validate the ARE-luciferase reporter assay, tBHQ and CDDO-Im, two 
prototypical Nrf2 activators were tested in the AREc32 cells. Cells were seeded at 3000 
cells/well in a 384-well plate and treated with DMSO vehicle or compound (0-100 µM for 
tBHQ and 0-2 µM for CDDO-Im). Twenty-four hrs after treatment, luciferase activity was 
assessed by quantifying the luminescent intensity. As shown in Fig 9.2A, both tBHQ 
and CDDO-Im increased the luminescence signal in a dose-dependent manner, with 
over a 70-fold increase in luminescence at 100 µM (tBHQ) or 300 nM (CDDO-Im). 
Other known Nrf2 activators, namely curcumin, sulfuraphene, and genistein, also 
increased the luminescence signal in AREc32 cells in a concentration-dependent 
manner (data not shown). 
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Pilot screening of 5040 compounds from the Microsource, Prestwick, and CMLD 
libraries 
To further validate the ARE-luciferase reporter assay in a high-throughput 
manner, Prestwick library containing 1120 compounds was screened in the AREc32 
cells at seven concentrations and within a range of 0.25-16 µM. Twenty-one compounds 
(top 1.9%) increased the luminescence signal in a concentration-dependent manner, 
with the maximum fold-induction value higher or comparable to tBHQ (data not shown).  
Microsource library containing 2000 compounds, and CMLD library containing 1920 
compounds were screened at a final concentration of 10 µM. The fold-induction of the 
luminescent signals of the tested compounds are shown in Fig. 9.2B, with the fold-
induction values of positive controls for comparison. Specifically, the fold-induction 
values of compounds in Microsource and CMLD libraries were tested in a final 
concentration of 10 µM, and compounds in the Prestwick library were treated at 8 µM.  
The Z’ factor measure of assay robustness and variability was plotted for the 16 
validation library plates (Fig. 9.2C).  Z’ score of each plate was greater than 0.6, 
confirming the quality of the assay methodology. 
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Full screening of 47,000 compounds from the Microsource, Prestwick, and 
Chembridge Libraries 
After the luciferase-based reporter assay was validated in a high-throughput 
system, the full library containing 47,000 compounds was screened using this assay. 
The fold increase in luminescence, indicative of Nrf2 activation by compounds in 
AREc32 cells, was plotted against each individual well of the libraries (Fig. 9.3A). The 
majority of compounds did not activate Nrf2, and were densely packed at the bottom of 
the scatterplot. Only the top 0.5% hits (238 compounds) increased the luminescence 
more than 14.4-fold. A histogram summarizing the frequency distribution of the ability of 
the compounds to increase luminescence over the DMSO control was shown in Fig 
9.3B. The majority of the compounds did not activate Nrf2. The top 1% hits (485 
compounds) increased the luminescence more than 9-fold, the top 0.5% hits (238 
compounds) increased the luminescence more than 14.4-fold, the top 0.25% hits (119 
compounds) increased the luminescence more than 20-fold, and the top 0.1% hits (48 
compounds) increased the luminescent signal more than 28-fold.  
Dose-response curves for the 4 compounds with the highest maximal ARE 
activation 
The most active 238 compounds (top 0.5% hit) from the full library screening 
were retested at multiple concentrations, and 91% of them (216 compounds) activated 
the Nrf2 pathway in a concentration-dependent manner. Among those 216 validated hits, 
18 compounds were shown to be extremely effective and each produced a maximum 
fold-activation higher than did CDDO-Im. The concentration-response curves of the top  
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4 compounds were shown in Fig 9.4A. Compound KU0006807 increased the 
luminescence signal 125-fold at 18 µM, KU 0105510 increased the luminescence signal 
119-fold at 18 µM, KU0103737 increased the luminescence signal 115-fold at 3.9 µM, 
and KU0017619 increased the luminescence signal 111-fold at 18 µM. The chemical 
structure of KU0006807, KU 0105510, KU0103737, and KU0017619 are shown in Fig 
9.4B. 
Dose-response curves for the 4 compounds with the lowest EC50 for Nrf2-ARE 
activation. 
Among those 247 validated hits from screening the full library, 6 compounds 
were shown to be extremely potent and had EC50 values lower than 1 µM. However, 
none of the compounds tested had an EC50 value lower than CDDO-Im. The 
concentration-response curves of the top 4 compounds are shown in Fig 9.4C. 
KU0009102 had an EC50 value of 0.7 µM, and the highest Nrf2 activation was 74-fold; 
KU0008241 had an EC50 value of 0.9 µM, and the highest Nrf2 activation was 46-fold; 
KU0025955 had an EC50 value of 0.9 µM, and the highest Nrf2 activation was 72-fold; 
and KU0012935 had an EC50 value of 1 µM, with the highest Nrf2 activation was 47-fold. 
The chemical structure of KU0009102, KU0008241, KU0025955, and KU0012935 are 
shown in Fig 9.4D. 
Structure clusters of hits from the primary screening 
The chemical structures of the top 238 hits fall into four clusters. The chemical 
scaffolds of the clusters, as well as the compound numbers were noted in Fig. 9.5. 
Cluster 1 contains 80 structures that were related diaryl amides and diaryl ureas, and 10 
of them were very potent with EC50 values lower than 2 µM. Cluster 2 contains 22  
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structure-related oxazoles and thiazoles, and eight of them were highly potent with EC50 
values lower than 2 µM. Cluster 3 contains 23 structure-related pyranones and 
thiapyranones, including one highly potent compound with an EC50 lower than 2 µM. 
Cluster 4 contains 22 structure-related pyridinones, pyridazinones, and pyrimidones, but 
none had EC50 values lower than 2 µM. 
Induction of Nqo1 by the top 30 hits from the primary screening in Hepa1c1c7 
cells 
To validate the active compounds using a different technique than the ARE-
luciferase assay, and to determine the ability of active compounds to induce 
cytoprotective genes, a secondary screen assay was developed to quantify Nqo1 
mRNA in Hepa1c1c7 cells. As shown in Fig 9.6A, both tBHQ and CDDO-Im increased 
Nqo1 mRNA in a concentration-dependent manner, with over a 7-fold increase in Nqo1 
mRNA with 30 µM tBHQ or 100 nM CDDO-Im. 
Nineteen compounds with the lowest EC50 values and 14 compounds with the 
highest maximum increase of luminescence signal from the primary screen were 
selected for the secondary screen. Three compounds (KU0002640, KU0003452, and 
KU0013654) were shown to activate Nrf2 at both the lowest EC50 concentrations and 
the highest maximum increase of luminescence. Thus, 30 compounds were screened in 
Hepa1c1c7 cells at six concentrations (0-3 µM). Among those 30 compounds, 17 of 
them increased Nqo1 mRNA in a concentration-dependent manner, and the 
concentration-response curves of the most effective four compounds are shown in Fig 
9.6B. Specifically, KU002640, which has both lowest EC50 and highest Nrf2 activation in 
the primary screen, also increased Nqo1 mRNA the most in the secondary screen.  
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DISCUSSION 
The present study describes the development, implementation, and validation of 
a high-throughput screen to identify activators of the Keap1-Nrf2-ARE pathway. Using a 
luciferase-based assay driven by AREs in the promoter region of the luciferase gene, 
the AREc32 cells provided a rapid and convenient quantification of Nrf2-ARE induction 
by small molecules, and made the large scale-screening for Nrf2 activators possible.  
In contrast to many focused-screenings for Nrf2 activators in previous reports, 
which compared the efficacy and potency of potential Nrf2 activators that were derived 
from a single chemical scaffold (Lee et al., 2010a; Tanaka et al., 2010; Kumar et al., 
2011b), the present study screened 47,000 chemicals with diverse sources and 
chemical structures. This increased the chances of identifying novel chemical scaffolds 
for analogs to further improve potency, efficacy, and pharmacokinetics. The present 
study summarized four novel chemical scaffolds that clustered in the top 0.5% hits: (1) 
diaryl amides and diaryl ureas, (2) oxazoles and thiazoles, (3) pyranones and 
thiapyranones, and (4) pyridinones and pyridazinones. Among these four chemical 
clusters, cluster 1 contains the largest number of the top 0.5% hits (80 hits in cluster 1, 
22 hits in cluster 2, 23 hits in cluster 3, and 22 hits in cluster 4), and contains the most 
number of hits with EC50 values less than 1.4 µM (5 hits in cluster 1, 4 hits in cluster 2, 
and no hits in cluster 3 or cluster 4). Thus, the chemical scaffold of cluster 1 may have 
the greatest potential for designing chemical analogs and to develop strong Nrf2 
activators. 
The present study validates the top 0.5% hits (238 compounds) with eleven 
concentrations in a wide range of concentrations. Thus, the EC50 value for activating 
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Nrf2 of each compound is available, which makes the comparison of the potency of the 
compounds possible. In addition, the concentration-response assay also generates the 
highest maximum fold-increase in luminescence data, and the ranking of the top hits 
was modified accordingly. For example, KU0105510 was shown to increase the 
luminescence 26-fold at 10 µM. However, the concentration-response assay shows that 
KU0105510 can increase the luminescence 119-fold at 18 µM, which makes it the 
second most effective hit in the full library (Fig. 9.4A). Some extremely potent 
compounds activated Nrf2 at low concentrations, and the activity decreased at higher 
concentrations. For example, KU0103737 increased the luminescent signal by 18-fold 
at 10 µM. However, the concentration-response assay shows that KU0103737 induced 
the luminescent signal most at 3.9 µM (116-fold), and the induction was blunted at 
higher concentrations (Fig. 9.4). Collectively, the concentration-response assay 
identified extremely effective and potent compounds among the top 0.5% hits.    
The concentration-response studies also revealed two distinct patterns in Nrf2-
ARE induction. The first battery of hits (example: KU0103737 and KU0105510) 
increased the luminescent signal markedly (over 110-fold), but the increase was blunted 
at higher concentrations after reaching the maximum fold-increase. The second battery 
of hits (example: KU0009102 and KU0003004) increased the luminescence moderately 
(70-fold), reached a plateau, but also increased the luminescence moderately (60-70 
fold) at higher concentrations (6-30 µM). Compared with the first battery of hits, the 
second battery of hits may be more plausible for drug development to have a steady 
effect over a wide range of drug concentrations. 
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For luciferase reporter-based assays, one major concern is identifying false 
active compounds that increase the luminescent signal not through activation of the 
target, but through stabilization of the luciferase enzyme. Therefore, a counter screen 
was performed to rule out such false positive hits. The 196 hits from the primary screen 
were randomly selected and tested for the capability of stabilizing purified firefly 
luciferase. Among these 196 hits, only 11 hits tested stabilized luciferase enzyme, and 
thus could be false positives (data not shown).  
To investigate whether the validated hits from the primary screen can also induce 
Nrf2 target genes, a secondary screen was designed to test the ability of the hit 
compounds to induce Nqo1, the prototypical Nrf2 target gene, in Hepa1c1c7 cells. The 
result shows that 17 of the 30 compounds increase Nqo1 mRNA in a concentration-
dependent manner. The relatively low validation rate may result from four reasons. First, 
once Nrf2 translocates into the nucleus upon activation, Nrf2 heterodimerizes with other 
transcription factors (example: small Mafs, c-Jun, and c-Fos) and Nrf2-ARE signaling is 
affected by these Nrf2-binding transcription factors. Second, ERα was shown to bind 
Nrf2 in the nucleus and facilitates Nrf2-dependent gene transcription (Ansell et al., 
2005). Thus, the different responses of AREc32 cells and Hepa1c1c7 cells to Nrf2-ARE 
activation may result from distinct estrogen signaling in these two cell lines (human 
breast cancer cells versus mouse hepatoma cells). Thirdly, the luciferase gene in the 
AREc32 cells contains eight AREs in the promoter region (Wang et al., 2006). However, 
the mouse Nqo1 gene is induced through one functional ARE (Malhotra et al., 2010). 
Thus, the secondary assay may be less sensitive to Nrf2 activators than the primary 
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assay. Lastly, the AREc32 and Hepa1c1c7 cells may have distinct expression of uptake 
transporters, resulting in different bioavailability of the test compounds. 
As for all transcription activation-based assays, neither the primary nor the 
secondary screening assay provide information about how active compounds activate 
the Keap1-Nrf2-ARE pathway. However, previous reports suggest that these active 
compounds may activate Keap1-Nrf2-ARE pathway through multiple mechanisms 
(Giudice et al., 2010), as shown in Fig. 9.7.  Some active compounds may disrupt 
binding of Keap1 to Nrf2, leading to the release of Nrf2, and allowing Nrf2 to translocate 
to the nucleus (Dinkova-Kostova et al., 2002). Some active compounds may lead to 
ubiquitination of Keap1 instead of Nrf2, and facilitate Nrf2 accumulation (Zhang et al., 
2005). Some active compounds may cause an inactivation of the Nrf2 export signal, 
increasing Nrf2 accumulation in the nucleus (Li et al., 2006). Some active compounds 
may increase nuclear export of Bach1, which competes with Nrf2 for small Maf binding 
(Suzuki et al., 2003). Lastly, some active compounds may activate protein kinase 
cascades (example: MAPK and PI3K) (Eggler et al., 2008), causing enhanced Nrf2 
phosphorylation.  
In conclusion, the present study documents the development, implementation, 
and validation of a high-throughput screen to identify activators of the Keap1-Nrf2-ARE 
pathway.  Eight compounds which are extremely potent and effective in activating Nrf2 
were uncovered. In addition, the present study also summarized four novel chemical 
scaffolds that may be have great potential to activate Nrf2, and thus could be used in 
the therapy of oxidative/electrophilic stress-induced diseases. 
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Chapter 10 : SCREENING OF NATURAL COMPOUNDS AS ACTIVATORS OF THE 
KEAP1-NRF2-ARE PATHWAY 
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Abstract 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator that 
promotes transcription of cytoprotective genes in response to oxidative/electrophilic 
stress. A large number of natural dietary compounds have been reported to induce 
genes involved in antioxidant defense and phase-II drug metabolism through activating 
Nrf2. To select natural compounds as Nrf2 activators and compare their efficacy and 
potency to activate Nrf2, a library of 54 natural compounds were collected and screened  
using AREc32 cells that contain a luciferase gene under the control of ARE promoters. 
Each natural compound was tested at 13 concentrations: 0.02, 0.04, 0.08, 0.16, 0.32, 
0.59, 1, 2, 3.5, 6.5, 10.7, 18, and 30 µM. Known Nrf2 activators, tert-butylhydroquinone 
(tBHQ) and 2-cyano-3,12-dioxooleana-1,9-diene-28-imidazolide (CDDO-Im), were 
tested as positive controls in parallel with the natural compounds. Among the 54 tested 
natural compounds, andrographolide had the highest efficacy, followed by trans-
chalcone, sulforaphane, curcumin, flavone, kahweol, and carnosol, all which had better 
efficacy than tBHQ. Among the compounds tested, CDDO-Im was the most potent, with 
an EC50 at 0.41 µM. Seven of the natural compounds, namely andrographolide, trans-
chalcone, sulforaphane, curcumin, flavone, kahweol, and cafestol had higher EC50 
values than CDDO-Im, but lower than tBHQ. The present study provides insights in 
which natural compounds activate the Keap1-Nrf2 pathway and thus might be useful for 
detoxifying oxidative/electrophilic stress. 
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Introduction 
A number of natural compounds are known to be antioxidants. Some of these 
natural compounds have been shown to exhibit antioxidant effects through activating 
the Nrf2 pathway. For example, oleanolic acid is known to protect against the toxicity of 
multiple hepatotoxicants (Liu et al., 1995a) by unknown mechanisms. Recently, it was 
reported that oleanolic acid stimulates the nuclear translocation of Nrf2 and induces 
Nrf2-dependent genes, which contributes to protection from acetaminophen 
hepatotoxicity (Reisman et al., 2009a). Carnosol and curcumin, purified natural 
compounds, as well as extracts from coffee, thyme, broccoli, rosemary, turmeric, and 
red onion have been shown to activate the Keap1-Nrf2 pathway in vitro and in vivo 
(Balstad et al., 2011). Other numerous natural compounds, including sulforaphane, allyl 
sulfides, resveratrol, and a battery of dietary flavonoids have been shown to activate the 
Keap1-Nrf2 pathway and have chemopreventive effect in various cell lines and tissues 
(Surh et al., 2008).  
In addition to descriptive studies showing protective effects of natural compounds 
against oxidative/electrophilic stress through activating Nrf2, studies revealing molecular 
mechanisms of how natural compounds activate the Keap1-Nrf2 pathway have provided 
further knowledge to develop Nrf2 activators as potential therapeutic drugs. For 
example, quercetin was shown to increase Nrf2 mRNA and protein synthesis, and 
reduce Keap1 protein through post-translational modification in HepG2 cells (Tanigawa 
et al., 2007).  Carnosol activates the PI3K-Akt pathway to induce phosphorylation and 
translocation of Nrf2 into the nucleus of P12 cells (Martin et al., 2004). Sulforaphane 
causes Nrf2 to escape from Keap1-mediated degradation in NIH3T3 cells (Zhang and 
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Hannink, 2003), as well as ubiquitination and degradation of Keap1 to facilitate Nrf2 
activation in COS-1 cells (Zhang et al., 2005).  
Collectively, various natural chemicals act as antioxidants and are used for 
chemoprevention and therapy of oxidative/electrophilic stress-induced tissue damage. 
However, given the fact that Nrf2 activation also leads to induction of certain phase-I 
and phase-II drug metabolism genes as well as efflux transporters, Nrf2 activators may 
be involved in drug-drug interactions and chemotherapeutic resistance. Despite studies 
that investigated the effect and mechanisms of individual natural compounds on the 
Keap1-Nrf2 pathway, there are no data comparing the efficacy and potency of natural 
compounds to activate Nrf2. In the present study, 54 natural compounds were tested as 
potential Nrf2 activators, and their efficacy and potency to activate Nrf2 was examined 
using AREc32 cells, which contain a luciferase gene under the control of eight copies of 
the rat ARE in the promoter region. Results from this screening provide novel insights in 
which natural compounds might detoxify oxidative/electrophilic stress. 
Results 
Induction of ARE-regulated luciferase activity by known Nrf2 activators 
To validate the AREc32 cell line model for screening Nrf2 activators from a 
natural compound library, tBHQ, a prototypical Nrf2 activator, and CDDO-Im, an 
extremely potent Nrf2 activator, were tested in the assay. Both tBHQ and CDDO-Im 
increased the luminescence signal in a concentration-dependent manner. tBHQ 
increased the luciferase activity at concentrations higher than 2 µM, and the luciferase 
activity was increased 14-fold at 30 µM (Fig. 10.1A). In contrast, CDDO-Im increased  
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the luciferase activity 13-fold at 0.02 µM, had maximum induction at 1 µM (77-fold), but 
the induction of luciferase activity was blunted at higher concentrations (Fig. 10.1B). 
 Induction of ARE-regulated luciferase activity by natural compounds 
Fifty-three natural compounds, as potential Nrf2 activators, were screened using 
the AREc32 cell line. The maximum-fold induction and EC50 concentration of each 
individual compound are summarized in Table 10.1, and the maximum fold-induction 
value as well as EC50 concentrations for tBHQ and CDDO-Im are listed as positive 
controls. As shown in Fig. 10.2, andrographolide produced the highest maximum-fold 
induction over vehicle controls, with an 88-fold increase in luminescence at 30 µM. Six 
natural compounds had a lower induction of luminescence signal than CDDO-Im but 
higher than tBHQ: trans-chalcone (50-fold), sulforaphane (46-fold), curcumin (39-fold), 
flavone (35-fold), kahweol (30-fold), and carnosol (15-fold). Six additional natural 
compounds, namely cafestol, caffeic acid, chlorgenic acid, allyl disulfide, chrysin, and 
myricetin were less effective than tBHQ, but still produced moderate induction of the 
luminescence signal (5-13 fold).  
EC50 values of tBHQ, CDDO-Im, and the natural compounds to activate the Nrf2 
pathway are summarized in Fig. 10.3. The concentration-response curve of each 
compound was fitted to a log-linear extrapolation model and EC50 values were 
calculated as constrained to a 100-fold induction. Among all the compounds tested, 
CDDO-Im was the most potent, with an EC50 of 0.41 µM. There were seven compounds 
that had higher EC50 values than CDDO-Im, but lower EC50 values than tBHQ: 
andrographolide (17 µM), trans-chalcone (18 µM), sulforaphane (33 µM),  
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Table 10.1. Chemical names, EC50 (constrained to 100-fold), and maximum fold-
induction of all the test natural chemicals. 
Compound EC50 (µM) Maximum fold-induction 
CDDO-Im 0.41 78 
Andrographolide 17 89 
Trans-chalcone 18 52 
Sulforaphane 33 47 
Curcumin 36 40 
Flavone 42 36 
Kahweol 41 31 
tBHQ 61.6 20 
Cafestol 51 14 
Carnosol >100 17 
Caffeic acid >100 13 
Caffeic acid phenethyl ester >100 8 
Chlorgenic acid >100 8 
Allyl disulfide >100 6 
Chrysin >100 5 
Myricetin >100 5 
Apigenin >100 5 
(s,s)-(+)-Tetrandrine >100 5 
Quercetin >100 4 
Luteolin >100 4 
Berberine >100 4 
Fisetin >100 4 
Resveratrol >100 3 
Baicalin >100 3 
Kaempferol >100 3 
Galangin >100 3 
(-)-Epicatechin >100 3 
Hesperetin >100 3 
Genistein >100 2 
Indole-3-carbinol >100 2 
Chlorophyllin >100 2 
Daidzein >100 2 
Lupeol >100 2 
Glycitein >100 2 
Daidzin >100 2 
Evodiamine >100 2 
Quercitrin >100 2 
Zebularine >100 2 
Naringenin >100 2 
Silymarin >100 1 
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Table 10.1-Con’d 
Matrine >100 1
Oleanolic acid >100 1
Sennoside B >100 1
Crocin >100 1
Morin >100 1
Oxymatrine >100 1
Chrysophanic acid >100 1
Icariin >100 1
Silibinin >100 1
Glycyrrhetinic acid >100 1
Synephrine >100 1
Rutin >100 1
Epigallocatechin 3-gallate >100 1
Naringin >100 1
(+)-Catechin >100 1
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Figure 10.2. Maximum fold-induction of the ARE luciferase reporter by tBHQ, CDDO-Im, 
and natural compounds. AREc32 cells were seeded at 3,500 cells/well in a 384-well 
plate, 46 µL/well.  24 h after seeding, cells were treated with compound (0.02-30 µM in 
0.5% DMSO) or DMSO vehicle.  24 h after treatment, luciferase activity was assessed 
using the Steady-Glo luciferase assay with a luminescence readout. The luminescence 
of each well was divided by the median luminescence of the DMSO vehicle control wells 
to generate the fold Nrf2 activation. 
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curcumin (36 µM), flavone (42 µM), kahweol (42 µM), and cafestol (51 µM). All other 
natural compounds had EC50 values higher than 100 µM for activating the Nrf2 pathway. 
Concentration-response of top 10 hits 
Figure 10.4 depicts concentration-response curves of the top 10 natural 
compounds as well as tBHQ and CDDO-Im as positive controls. CDDO-Im induced 
luminescence signal 13-fold at the lowest concentration tested (20 nM), with a 
continued increase in luminescence signal as the concentration increased, reaching a 
maximum fold-induction at 1 µM. The luminescence decreased to basal levels at higher 
concentrations of CDDO-Im. Trans-chalcone increased the luminescence signal at 
concentrations higher than 3.5 µM, reached a maximum fold-induction at 18 µM, but the 
induction decreased to basal levels at 30 µM. In contrast, tBHQ and the other nine 
natural compounds did not increase the luminescence at concentrations lower than 3.5 
µM, and reached the maximum fold-induction at the highest concentration tested (30 
µM).  
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Figure 10.3. EC50 of tBHQ, CDDO-Im, and natural compounds to activate Nrf2. AREc32 
cells were cultured and treated as described in figure 2. The EC50s were calculated 
based on the data from concentration-response curve of each individual compound and 
contrained to 100-fold induction.  
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Discussion 
The present study compared the efficacy and potency of two synthetic Nrf2 
activators as well as 54 natural compounds to activate the Keap1-Nrf2 pathway using 
the AREc32 cell line system. Results showed that seven natural compounds, namely 
andrographolide, trans-chalcone, sulforaphane, curcumin, flavone, kahweol, and 
carnosol were more effective than the classic Nrf2 activator tBHQ, but none of the 
natural compounds were more potent than CDDO-Im, the potent synthetic Nrf2 activator.  
tBHQ is a prototypical Nrf2 activator, and has been shown to activate Nrf2 and 
protect against oxidative stress-induced toxicity in vitro and in vivo. For example, tBHQ 
has been shown to activate the Keap1-Nrf2 pathway and prevent ethanol-induced 
apoptosis in cranial neural crest cells in vitro (Yan et al., 2010). tBHQ has also been 
shown to inhibit LPS-induced microglial activation through Nrf2 activation in microglial 
cells (Koh et al., 2009). In addition, tBHQ protects against mitochondrial stress through 
induction of the Nrf2-driven antioxidant response in mice (Shih et al., 2005). CDDO-Im 
has emerged in recent years as a protective compound against oxidative stress. CDDO-
Im activates the Nrf2-Keap1 pathway (Liby et al., 2005), and leads to a cytoprotective 
response through the up-regulation of gene expression. CDDO-Im has been shown to 
protect against acetaminophen-induced hepatotoxicity in mice (Reisman et al., 2009b). 
In addition to the known synthetic Nrf2 activators, two well-established natural Nrf2 
activators, namely sulforaphane and curcumin, were also active in the screening system 
of the present study. Sulforaphane has been used in a pharmacological model to study 
protein-protein interactions between Keap1 and Nrf2 (Zhang and Hannink, 2003), as 
well as to identify Nrf2 downstream target genes (Thimmulappa et al., 2002). The 
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present study shows both synthetic and natural compounds increase the luminescence 
signal in the AREc32 cell line in a concentration-dependent manner, indicating that this 
system is excellent for determining the efficacy and potency of potential Nrf2 activators. 
Among the 54 natural compounds tested in the AREc32 cell line system, 
compounds with a diterpene structure, including andrographolide, kahweol, cafestol, 
and carnosol, were shown to be the most active compounds. Andrographolide was even 
more effective than CDDO-Im, a triterpenoid known to be an extremely strong activator 
of the Keap1-Nrf2 pathway. Andrographolide is a diterpene lactone that exists in leaves 
and stems of Andrographis paniculata, which is a plant used for medicinal purposes in 
India (Mishra et al., 2011). Andrographolide has been shown to have strong anti-
inflammatory effects through inactivation of NFκB (Lu et al., 2011), and anti-cancer 
effects by inhibition of androgen receptor signaling (Liu et al., 2011). Recently, 
andrographolide was shown to induce heme oxygenase-1 (HO-1) by activating Nrf2 in 
human endothelial cells, and the Nrf2-HO1 pathway was suggested to be involved in 
the andrographolide-induced suppression of inflammation (Yu et al., 2010).  Kahweol 
and cafestol are coffee specific diterpenes that produce chemoprevention to a broad 
range of carcinogens, including 7,12-dimethylbenz[a]anthracene, aflatoxin B1, 
benzo[a]pyrene, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, at least partially 
through induction of phase-II drug metabolism genes, as well as genes involved in 
cellular antioxidant defense (Cavin et al., 2002). Recently, it was reported that kahweol 
and cafestol induce cytoprotective genes primarily by Nrf2 (Higgins et al., 2008). 
Similarly, carnosol also activates phase-II drug metabolism genes and antioxidant 
genes through activating Nrf2 in vitro (Takahashi et al., 2009) and in vivo (Balstad et al., 
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2011). In parallel with the previous observations, results from the present study indicate 
that these diterpenes (andrographolide, kahweol, cafestol, and carnosol) are highly 
effective activators of the Nrf2 pathway. 
In addition to andrographolide, kahweol, cafestol, and carnosol, trans-chalcone 
was reported to activate Nrf2 in certain cell lines or animal models, and also activate 
Nrf2 in the present study. Trans-chalcone was the top hit of 43 potential 
chemopreventive chemicals to increase glutathione content in rat liver cells (White et al., 
1998). Recently, a series of chalcone derivatives were synthesized, and 2-
trifluoromethyl-2'-methoxychalone was shown to be a potent Nrf2 activator in human 
lung epithelial cells and in mice (Kumar et al., 2011b). The present study further 
confirms the efficacy of trans-chalcone to activate the Keap1-Nrf2 pathway, and 
provides further mechanistic information on the induction of Nrf2 target genes by those 
natural compounds.  
In the present study, both caffeic acid and its derivative caffeic acid phenethyl 
ester (CAPE) were shown to activate Nrf2, with caffeic acid more effective than CAPE 
(13-fold versus 8-fold maximum increase of luminescence signal). In previous reports, 
CAPE was shown to activate Nrf2 in multiple cell lines. However, whether caffeic acid 
activates the Keap1-Nrf2 pathway was unknown. For example, CAPE was shown to 
induce Nrf2 target genes in porcine renal epithelial proximal tubule cells and rat kidney 
epithelial cells (Balogun et al., 2003), rat liver tissue macrophages (Hess et al., 2003), 
and human colon carcinoma cells (Lee et al., 2010b). The present study indicates that 
caffeic acid has the potential to be a novel Nrf2 activator, and more in vivo studies are 
necessary to test the antioxidative activity of caffeic acid in whole animals. 
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Dietary flavonoids are a family of natural compounds that have been shown to 
have cancer preventive effects through inducing phase-II drug metabolism genes 
(Saracino and Lampe, 2007), and antioxidative effects against ultraviolet radiation 
(Dinkova-Kostova, 2008). In addition, a large number of dietary flavonoids, including 
luteolin (Wruck et al., 2007), epigallocatechin-3-gallate (Tsai et al., 2011), and quercetin 
(Miyamoto et al., 2011) induce Nrf2 target genes in various cell lines and animal models. 
Thus, 27 dietary flavonoids were screened in the present study to test whether these 
dietary flavonoids activate the Nrf2 pathway. Surprisingly, only flavone was highly 
effective (33-fold increase in luminescence) to activate Nrf2, and the remaining 
flavonoids tested exhibited slight or no increase in Nrf2 activation. Similarly, several 
natural compounds, including resveratrol, xanthohumol, isoliquiritigenin, and oleanolic 
acid have been reported to activate Nrf2, but were inactive in the present study. For 
example, resveratrol was shown to protect against oxidative/electrophilic stress via 
inducing Nrf2 target genes in human lung epithelial cells (Kode et al., 2008), rat primary 
hepatocytes (Rubiolo et al., 2008), coronary arterial endothelial cells, and branches of 
the femoral artery in mice (Ungvari et al., 2010). Xanthohumol and isoliquiritigenin 
alkylate cysteine 151 on Keap1 protein, leading to Nrf2 activation in vitro and in vivo 
(Luo et al., 2007). Oleanolic acid has been shown to activate Nrf2 in mouse liver 
(Reisman et al., 2009a) and rat vascular smooth muscle cells (Feng et al., 2011). 
However, resveratrol, xanthohumol, isoliquiritigenin, and oleanolic acid did not activate 
Nrf2 in the present study, indicating that activation of Nrf2 by those natural chemicals 
may be cell line specific. In addition, oleanolic acid was recently shown to inhibit 
estradiol-17β-glucuronide uptake by OATP1B1, an uptake transporter, suggesting that 
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oleanolic acid is an OATP1B1 substrate (Roth et al., 2011), and uptake transport maybe 
required to increase the bioavailability of oleanolic acid. Collectively, oleanolic acid, 
together with other natural compounds may require transport and/or bio-transformation 
to activate the Keap1-Nrf2 pathway. 
In conclusion, the present study compared the efficacy and potency of 54 natural 
compounds to activate the Keap1-Nrf2 pathway. Andrographolide, trans-chalcone, 
sulforaphane, curcumin, flavone, kahweol, and carnosol were more effective than 
classic Nrf2 activator tBHQ, but none of the natural compounds were more potent than 
CDDO-Im, the most potent synthetic Nrf2 activator.  
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The present dissertation has characterized the global target genes of the 
transcription factor Nrf2 in mouse liver, and investigated the protective role of Nrf2 
against chemical-induced oxidative stress and subsequent liver injury in mice. In 
addition, the present dissertation identified effective and potent activators of Nrf2 from a 
library of 47,000 compounds, and compared the efficacy and potency of natural existing 
antioxidants to activate the Nrf2 pathway. 
Oxidative stress and electrophilic stress are major mechanisms of pathogenesis 
of various disease conditions including carcinogenesis, inflammation, and aging. Nrf2 is 
considered as the master regulator to protect cells from oxidative/electrophilic stress via 
induction of its target genes. Liver is the most important organ in regard to xenobiotic 
detoxification as well as many other physiological functions. As a transcription factor, 
the direct effect of Nrf2 activation or deficiency is alteration of gene transcription profiles. 
Although the antioxidative role of Nrf2 was proposed and studied for over ten years, the 
global Nrf2 target genes in liver remain unknown. The present dissertation utilized a 
Nrf2 “gene dose-response” model to genetically modulate the amount of Nrf2 in mouse 
liver, and compared the transcription profiles in this Nrf2 “gene dose-response” model. 
Thus, the Nrf2-target genes in mouse liver were investigated systemically. 
Chapter 4 summarizes the genes that were either induced or suppressed with 
graded Nrf2 activation. Pathway analyses indicate that genes induced by Nrf2 are 
involved in glutathione synthesis, oxidation/reduction using NADPH as the co-factor, 
and xenobiotic metabolism. In addition, mRNA of genes involved in pentose phosphate 
pathways as well as malic enzyme are decreased without Nrf2, and/or increased with 
Nrf2 activation, indicating that Nrf2 promotes NADPH generation. Surprisingly, in 
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addition to the 115 genes that are induced by Nrf2, I also found 80 genes that are 
suppressed with graded Nrf2 activation. Among these genes that are suppressed by 
Nrf2, the majority of them is involved in lipid synthesis and fatty acid desaturation. Thus, 
observations in Chapter 2 suggests that Nrf2 protects against environmental insults by 
promoting the generation of NADPH, which is preferentially consumed by pathways that 
protect against of oxidative stress rather than by fatty acid synthesis and desaturation. 
In addition to being a transcription factor that increases the production of proteins 
that protect against oxidative stress, Nrf2 also plays a role in xenobiotic detoxification. 
Chapter 5 summarizes the mRNA abundance of 124 drug processing genes in the Nrf2 
“gene dose-response” model. With graded Nrf2 activation, 47 genes are induced, 74 
genes are not altered, and 5 genes are suppressed. Specifically, Nrf2 did not have a 
marked effect on the mRNA of uptake transporters, except for Oatp1a1, NTCP 
decreased with Nrf2 activation. The effect of Nrf2 on cytochrome P450 (Cyp) genes was 
minimal, with only Cyp2a5, Cyp2c50, Cyp2c54, and Cyp2g1 being increased, but 
Cyp2u1 being decreased with enhanced Nrf2 activation. However, Nrf2 increased 
mRNA of many non P-450 phase-I enzymes, such as aldo-keto reductases, carbonyl 
reductases, and aldehyde dehydrogenase 1.  Many genes involved in phase-II drug 
metabolism were induced by Nrf2, including most isoforms of the Gst gene family. A 
number of efflux transporters, such as Mrps, Bcrp, as well as Abcg5 and Abcg8 were 
induced by Nrf2. Thus, Chapter 5 suggests that Nrf2 has a minor role in regulating 
uptake transporters and P-450 phase-I enzymes that are involved in xenobiotic 
activation, but facilitates electrophile detoxification through inducing non P-450 phase-I 
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enzymes that reduce electrophiles, Gsts that conjugates electrophiles, and Mrp efflux 
transporters that excrete electrophile-GSH conjugates out of cells.  
After the effect of Nrf2 on the global gene transcription profile of mouse liver had 
been determined, Chapter 6 to Chapter 8 report the function of Nrf2 in vivo, by testing 
whether Nrf2 activation protects against chemical-induced oxidative stress and 
subsequent liver injury in mice. Oxidative stress and lipid accumulation play important 
roles in ethanol-induced liver injury. Chapter 6 shows that genes involved in antioxidant 
defense are induced, whereas genes involved in lipid biosynthesis are suppressed in 
livers of Nrf2 activated mice. Thus, I investigated whether Nrf2 protects against ethanol-
induced liver injury using the Nrf2 “gene dose-response model”. Binge administration of 
ethanol (5g/kg, oral gavage) increased serum ALT and LDH activities in Nrf2-null mice 
and wild-type mice, but not in Nrf2-enhanced mice, indicating that Nrf2-enhanced mice 
are more resistant to ethanol toxicity. Ethanol increased serum triglycerides and free 
fatty acids in livers of Nrf2-null mice, and these increases were blunted in Nrf2-
enhanced mice. After ethanol exposure, reactive oxygen species were increased in 
livers and primary hepatoctyes in Nrf2-null mice but not in Nrf2-enhanced mice.  
Mechanistic studies show that Nrf2 prevents ethanol-induced oxidative stress through 
inducing cytoprotective genes including Nqo1 and Gclc, and prevents accumulation of 
free fatty acids in liver by suppressing the Srebp1 pathway. 
Chapter 7 demonstrates the protective effect of Nrf2 against cadmium-induced 
acute liver injury. The mechanisms of Cd-induced acute hepatotoxicity involve a 
biphasic process, which is initiated by the binding of Cd to the sulfhydryls of glutathione 
and proteins, resulting in the generation of reactive oxygen species (ROS) and protein 
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inactivation. The second phase is initiated by the activation of kupffer cells and followed 
by ROS release by kupffer cells and neutrophils. In the present study, I found that Nrf2-
null mice are more susceptible, whereas Nrf2-enhanced mice are more resistant to 
cadmium-induced acute liver injury. Multiple genes involved in antioxidant defense, 
namely Gclc, Gpx2, and Srxn-1 were only induced in Nrf2-enhanced mice, but not in 
Nrf2-null mice, indicating that Nrf2 protects against cadmium induced oxidative stress 
and subsequent acute liver injury at least partially through the induction of these 
cytoprotective genes. Surprisingly, metallothioneins (Mt-1 and Mt-2), a family of 
cysteine-rich proteins that scavenge cadmium to prevent toxicity, were induced 
markedly in both Nrf2-null and Nrf2-enhanced mice. Thus, the date in Chapter 7 shows 
that there are distinct pathways to protect cadmium-induced toxicity: Nrf2-dependent 
induction of antioxidative genes and Nrf2-independent induction of metallothioneins. 
Chapter 8 demonstrates the protective effect of Nrf2 against diquat-induced lung 
and liver injury. Diquat is a contact herbicide that is minimally metabolized, and 
undergoes oxidation/reduction cycling, resulting in the generation of superoxide. Diquat-
induced tissue injury serves as a model to study ROS generation and oxidative stress. 
Thus, it is not surprising that Nrf2 activation prevents diquat-induced lethality, alveolar 
collapse in lungs, and necrosis in livers of mice. Nrf2 activation also prevents 
glutathione depletion in mouse lung and liver tissues, and increased ROS staining in 
primary hepatocytes.  
Data in the previous Chapters (Chapters 6 to 8) suggest potential therapeutic 
applications of the Keap1-Nrf2 pathway, and thus Nrf2 is a promising drug target for in 
the treatment of oxidative/electrophilic stress-induced diseases. To develop effective 
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and potent Nrf2 activators, a library of synthetic (Chapter 9) and natural existing 
(Chapter 10) compounds were screened to test their efficacy and potency to activate 
Nrf2.  
Chapter 9 documents the development, implementation, and validation of a high-
throughput screen to identify activators of the Keap1-Nrf2-ARE pathway using AREc32 
cells, which contain a luciferase gene under the control of eight copies of rat Gsta2 ARE 
in the promoter region. By screening 47,000 compounds, we found 238 compounds 
(0.5%) that had comparable or better efficacy to activate Nrf2 than tBHQ, the 
prototypical Nrf2 activator. Among these 238 compounds, 19 compounds had better 
efficacy than CDDO-Im, the most effective and potent Nrf2 activator that has been 
discovered. However, none of the compounds screened had better potency than 
CDDO-Im. In addition, chemical structure relationship analysis of these 238 compounds 
showed enrichment of four chemical scaffolds (diaryl amides and diaryl ureas, oxazoles 
and thiazoles, pyranones and thiapyranones, and pyridinones and pyridazinones). The 
top 30 compounds were also screened in Hepa1c1c7 cells for increase in Nqo1 mRNA, 
the prototypical Nrf2 target gene. The results show that 17 of the 30 most active hits 
increased Nqo1 mRNA in a concentration-dependent manner. Results from this 
screening identified Nrf2 activators, and provide novel insights in chemical scaffolds that 
might prevent oxidative/electrophilic stress-induced toxicity and carcinogenesis. 
In addition to synthetic compounds, a number of natural compounds are known 
to be antioxidants, and some of these natural compounds have been shown to exhibit 
antioxidant effects through activating the Nrf2 pathway. Utilizing the same screening 
system (AREc32 cells), Chapter 10 evaluates the capability of 54 natural existing 
199 
 
compounds to activate Nrf2. Among the 54 tested natural compounds, andrographolide 
had the highest efficacy, followed by trans-chalcone, sulforaphane, curcumin, flavone, 
kahweol, and carnosol, which were all more efficient than tBHQ. Among the compounds 
tested, CDDO-Im was still the most potent. Seven of the natural compounds, namely 
andrographolide, trans-chalcone, sulforaphane, curcumin, flavone, kahweol, and 
cafestol had higher EC50 values than CDDO-Im, but lower than tBHQ. 
In addition to the extension of the current knowledge on the Keap1-Nrf2-ARE 
pathway, the present dissertation provides hints and clues for more hypotheses that 
could be future directions of this area. For example, Nrf2 is known to heterodimerize 
with its transcription partners (MafG, c-Jun, and c-Fos) to promote its target gene 
transcription (Baird and Dinkova-Kostova, 2011). However, the transcription partners of 
Nrf2 were investigated under in vitro systems in various cell lines. It is still unknown 
which transcription factors act as Nrf2 partners in vivo, especially in liver. Transcription 
factor binding site over-representation analysis shows that putative binding sites of 
certain transcription factors, including PPARγ, IRF2, and HNF4α are also enriched in 
promoter region of genes induced by Nrf2 (Chapter 5). The transcription factor binding 
site co-enrichment indicates potential Nrf2 partners in vivo. However, more specific 
experiments (for example, ChiP-Seq) are needed to study the Nrf2 binding site in 
mouse liver, and to better predict co-enrichment of other transcription factors as 
potential Nrf2 partners in the nucleus. Furthermore, mice deficient in the predicted 
transcription factor should be used to confirm whether Nrf2 promotes certain target 
gene expression in a predicted partner-dependent manner. 
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As described in Chapter 4, there are 80 genes suppressed with graded Nrf2 
activation. Recently, it was published that Nrf2 binds to the promoter regions of certain 
genes to inhibit their transcription (Thangasamy et al., 2011). Thus, it is possible that 
genes suppressed with Nrf2 activation may be a direct target of Nrf2, and their 
transcription may be inhibited through binding of Nrf2 in the promoter region. ChiP-Seq 
experiments as well as site-directed mutagenesis studies of the promoters are needed 
to further confirm if Nrf2 acts as a transcription “repressor” of these genes. 
As described in Chapters 6, 7 and 8, Nrf2 protects chemical-induced oxidative 
stress and liver injury through induction of a battery of cytoprotective genes (Nqo1, Gclc, 
Gpx2, Srxn, and Txnrd1). However, it is unknown which downstream Nrf2 target genes 
are essential for the protective function of Nrf2. To address this question, Nrf2-target 
gene-knockout mice (for example, Nqo1 knockout) are needed to investigate the 
protective capacity of Nrf2 in the absence of a certain downstream target genes.  
As described in Chapters 9 and 10, a number of synthetic and natural existing 
compounds were shown to be effective in activating Nrf2. However, it is also important 
to know whether these compounds protect against oxidative stress-induced 
pathogenesis in vivo, and whether the protective effect of these compounds is Nrf2-
dependent. To demonstrate the specificity of these compounds, one can do a 
microarray analysis to compare the transcription profiles in livers of compound-treated 
wild-type mice and Nrf2-null mice, and test which genes are still altered by these 
compounds in Nrf2-null mice. To demonstrate the activity of these compounds in vivo, 
one can test whether these compounds protect against ethanol-, cadmium-, and diquat-
induced liver oxidative stress and liver injury in mice. 
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In conclusion, the Nrf2 target genes are involved in NADPH generation, NADPH-
facilitated oxidative stress reduction, and detoxification and excretion of electrophiles. 
Nrf2 activation protects ethanol-, cadmium-, and diquat-induced liver oxidative stress 
and liver injury in mice. Lastly, a few synthetic and natural existing compounds have 
been shown to be potent and effective in activating the Keap1-Nrf2-ARE pathway.  
  
202 
 
 
 
 
 
 
 
 
 
Chapter 12 : REFERENCES 
  
203 
 
 
Abu-Bakar A, Lamsa V, Arpiainen S, Moore MR, Lang MA, and Hakkola J (2007) 
Regulation of CYP2A5 gene by the transcription factor nuclear factor (erythroid-
derived 2)-like 2. Drug Metab Dispos 35:787-794. 
 
Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S, Choi AM, Burow ME, 
and Tou J (2000) Mechanism of heme oxygenase-1 gene activation by cadmium 
in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription 
factor. J Biol Chem 275:27694-27702. 
 
Aleksunes LM and Manautou JE (2007) Emerging role of Nrf2 in protecting against 
hepatic and gastrointestinal disease. Toxicol Pathol 35:459-473. 
 
Alnouti Y and Klaassen CD (2008) Tissue distribution, ontogeny, and regulation of 
aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal 
enzyme inducers in mice. Toxicol Sci 101:51-64. 
 
Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, and Aggarwal BB (2008) 
Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer 
Lett 267:133-164. 
 
Anbar M and Neta P (1967) A compilation of specific bimolecular rate constants for the 
reactions of hydrated electrons, hydrogen atoms and hydroxyl radicals with 
inorganic and organic compounds in aqueous solution. The International Journal 
of Applied Radiation and Isotopes 18:493-531. 
 
Andoh Y, Mizutani A, Ohashi T, Kojo S, Ishii T, Adachi Y, Ikehara S, and Taketani S 
(2006) The antioxidant role of a reagent, 2',7'-dichlorodihydrofluorescin diacetate, 
detecting reactive-oxygen species and blocking the induction of heme 
oxygenase-1 and preventing cytotoxicity. J Biochem 140:483-489. 
 
Ansell PJ, Lo SC, Newton LG, Espinosa-Nicholas C, Zhang DD, Liu JH, Hannink M, and 
Lubahn DB (2005) Repression of cancer protective genes by 17beta-estradiol: 
ligand-dependent interaction between human Nrf2 and estrogen receptor alpha. 
Mol Cell Endocrinol 243:27-34. 
 
Arosio P and Levi S (2010) Cytosolic and mitochondrial ferritins in the regulation of 
cellular iron homeostasis and oxidative damage. Biochim Biophys Acta 
1800:783-792. 
 
Axelsen PH, Komatsu H, and Murray IV (2011) Oxidative stress and cell membranes in 
the pathogenesis of Alzheimer's disease. Physiology (Bethesda) 26:54-69. 
 
Bae SH, Sung SH, Cho EJ, Lee SK, Lee HE, Woo HA, Yu DY, Kil IS, and Rhee SG 
(2011) Concerted action of sulfiredoxin and peroxiredoxin I protects against 
alcohol-induced oxidative injury in mouse liver. Hepatology 53:945-953. 
204 
 
 
Baird L and Dinkova-Kostova AT (2011) The cytoprotective role of the Keap1-Nrf2 
pathway. Arch Toxicol 85:241-272. 
 
Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J, and Motterlini R 
(2003) Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 
and the antioxidant-responsive element. Biochem J 371:887-895. 
 
Balstad TR, Carlsen H, Myhrstad MC, Kolberg M, Reiersen H, Gilen L, Ebihara K, Paur 
I, and Blomhoff R (2011) Coffee, broccoli and spices are strong inducers of 
electrophile response element-dependent transcription in vitro and in vivo - 
studies in electrophile response element transgenic mice. Mol Nutr Food Res 
55:185-197. 
 
Barden A, Zilkens RR, Croft K, Mori T, Burke V, Beilin LJ, and Puddey IB (2007) A 
reduction in alcohol consumption is associated with reduced plasma F2-
isoprostanes and urinary 20-HETE excretion in men. Free Radic Biol Med 
42:1730-1735. 
 
Barski OA, Tipparaju SM, and Bhatnagar A (2008) The aldo-keto reductase superfamily 
and its role in drug metabolism and detoxification. Drug Metab Rev 40:553-624. 
 
Barve A, Khor TO, Nair S, Lin W, Yu S, Jain MR, Chan JY, and Kong AN (2008) 
Pharmacogenomic profile of soy isoflavone concentrate in the prostate of Nrf2 
deficient and wild-type mice. J Pharm Sci 97:4528-4545. 
 
Baur JA (2010) Biochemical effects of SIRT1 activators. Biochim Biophys Acta 
1804:1626-1634. 
 
Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, Luyendyk JP, Roth RA, 
and Arteel GE (2006) Metformin prevents alcohol-induced liver injury in the 
mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology 
130:2099-2112. 
 
Bertram C and Hass R (2008) Cellular responses to reactive oxygen species-induced 
DNA damage and aging. Biol Chem 389:211-220. 
 
Biswas SK and Rahman I (2009) Environmental toxicity, redox signaling and lung 
inflammation: the role of glutathione. Mol Aspects Med 30:60-76. 
 
Blake DJ, Singh A, Kombairaju P, Malhotra D, Mariani TJ, Tuder RM, Gabrielson E, and 
Biswal S (2010) Deletion of Keap1 in the lung attenuates acute cigarette smoke-
induced oxidative stress and inflammation. Am J Respir Cell Mol Biol 42:524-536. 
 
Brigelius-Flohe R and Traber MG (1999) Vitamin E: function and metabolism. FASEB J 
13:1145-1155. 
205 
 
 
Bursch W, Karwan A, Mayer M, Dornetshuber J, Frohwein U, Schulte-Hermann R, Fazi 
B, Di Sano F, Piredda L, Piacentini M, Petrovski G, Fesus L, and Gerner C (2008) 
Cell death and autophagy: cytokines, drugs, and nutritional factors. Toxicology 
254:147-157. 
 
Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, and Schilter B (2002) 
Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic 
activity. Food Chem Toxicol 40:1155-1163. 
 
Cejas P, Casado E, Belda-Iniesta C, De Castro J, Espinosa E, Redondo A, Sereno M, 
Garcia-Cabezas MA, Vara JA, Dominguez-Caceres A, Perona R, and Gonzalez-
Baron M (2004) Implications of oxidative stress and cell membrane lipid 
peroxidation in human cancer (Spain). Cancer Causes Control 15:707-719. 
 
Chae HZ, Kim HJ, Kang SW, and Rhee SG (1999) Characterization of three isoforms of 
mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. 
Diabetes Res Clin Pract 45:101-112. 
 
Chan K, Han XD, and Kan YW (2001) An important function of Nrf2 in combating 
oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci U S A 
98:4611-4616. 
 
Chan K, Lu R, Chang JC, and Kan YW (1996) NRF2, a member of the NFE2 family of 
transcription factors, is not essential for murine erythropoiesis, growth, and 
development. Proc Natl Acad Sci U S A 93:13943-13948. 
 
Chavan H, Oruganti M, and Krishnamurthy P (2011) The ATP-binding cassette 
transporter ABCB6 is induced by arsenic and protects against arsenic cytotoxicity. 
Toxicol Sci 120:519-528. 
 
Chen J and Shaikh ZA (2009) Activation of Nrf2 by cadmium and its role in protection 
against cadmium-induced apoptosis in rat kidney cells. Toxicol Appl Pharmacol 
241:81-89. 
 
Cheng Q, Taguchi K, Aleksunes LM, Manautou JE, Cherrington NJ, Yamamoto M, and 
Slitt AL (2011) Constitutive activation of nuclear factor-E2-related factor 2 
induces biotransformation enzyme and transporter expression in livers of mice 
with hepatocyte-specific deletion of Kelch-like ECH-associated protein 1. J 
Biochem Mol Toxicol 25:320-329. 
 
Chiarugi P, Pani G, Giannoni E, Taddei L, Colavitti R, Raugei G, Symons M, Borrello S, 
Galeotti T, and Ramponi G (2003) Reactive oxygen species as essential 
mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase 
is required for cell adhesion. J Cell Biol 161:933-944. 
 
206 
 
Chiba M, Kubo M, Miura T, Sato T, Rezaeian AH, Kiyosawa H, Ohkohchi N, and Yasue 
H (2008) Localization of sense and antisense transcripts of Prdx2 gene in mouse 
tissues. Cytogenet Genome Res 121:222-231. 
 
Cho HY, Reddy SP, Yamamoto M, and Kleeberger SR (2004) The transcription factor 
NRF2 protects against pulmonary fibrosis. FASEB J 18:1258-1260. 
 
Chu FF, Doroshow JH, and Esworthy RS (1993) Expression, characterization, and 
tissue distribution of a new cellular selenium-dependent glutathione peroxidase, 
GSHPx-GI. J Biol Chem 268:2571-2576. 
 
Chung J, Veeramachaneni S, Liu C, Mernitz H, Russell RM, and Wang XD (2009) 
Vitamin E supplementation does not prevent ethanol-reduced hepatic retinoic 
acid levels in rats. Nutr Res 29:664-670. 
 
Cohen JI, Roychowdhury S, DiBello PM, Jacobsen DW, and Nagy LE (2009) 
Exogenous thioredoxin prevents ethanol-induced oxidative damage and 
apoptosis in mouse liver. Hepatology 49:1709-1717. 
 
Comporti M, Signorini C, Leoncini S, Gardi C, Ciccoli L, Giardini A, Vecchio D, and 
Arezzini B (2010) Ethanol-induced oxidative stress: basic knowledge. Genes Nutr 
5:101-109. 
 
Copple IM, Goldring CE, Kitteringham NR, and Park BK (2010) The keap1-nrf2 cellular 
defense pathway: mechanisms of regulation and role in protection against drug-
induced toxicity. Handb Exp Pharmacol:233-266. 
 
Cullinan SB, Gordan JD, Jin J, Harper JW, and Diehl JA (2004) The Keap1-BTB protein 
is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress 
sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24:8477-8486. 
 
Dargel R (1992) Lipid peroxidation--a common pathogenetic mechanism? Exp Toxicol 
Pathol 44:169-181. 
 
Deroo BJ, Hewitt SC, Peddada SD, and Korach KS (2004) Estradiol regulates the 
thioredoxin antioxidant system in the mouse uterus. Endocrinology 145:5485-
5492. 
 
Dhakshinamoorthy S and Jaiswal AK (2000) Small maf (MafG and MafK) proteins 
negatively regulate antioxidant response element-mediated expression and 
antioxidant induction of the NAD(P)H:Quinone oxidoreductase1 gene. J Biol 
Chem 275:40134-40141. 
 
Ding WX, Li M, Chen X, Ni HM, Lin CW, Gao W, Lu B, Stolz DB, Clemens DL, and Yin 
XM (2010) Autophagy reduces acute ethanol-induced hepatotoxicity and 
steatosis in mice. Gastroenterology 139:1740-1752. 
207 
 
 
Dinis-Oliveira RJ, De Jesus Valle MJ, Bastos ML, Carvalho F, and Sanchez Navarro A 
(2006) Kinetics of paraquat in the isolated rat lung: Influence of sodium depletion. 
Xenobiotica 36:724-737. 
 
Dinkova-Kostova AT (2008) Phytochemicals as protectors against ultraviolet radiation: 
versatility of effects and mechanisms. Planta Med 74:1548-1559. 
 
Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, 
Yamamoto M, and Talalay P (2002) Direct evidence that sulfhydryl groups of 
Keap1 are the sensors regulating induction of phase 2 enzymes that protect 
against carcinogens and oxidants. Proc Natl Acad Sci U S A 99:11908-11913. 
 
Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams 
C, Risingsong R, Honda T, Gribble GW, Sporn MB, and Talalay P (2005) 
Extremely potent triterpenoid inducers of the phase 2 response: correlations of 
protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 
102:4584-4589. 
 
Dinkova-Kostova AT, Talalay P, Sharkey J, Zhang Y, Holtzclaw WD, Wang XJ, David E, 
Schiavoni KH, Finlayson S, Mierke DF, and Honda T (2010) An exceptionally 
potent inducer of cytoprotective enzymes: elucidation of the structural features 
that determine inducer potency and reactivity with Keap1. J Biol Chem 
285:33747-33755. 
 
Doorn JA, Maser E, Blum A, Claffey DJ, and Petersen DR (2004) Human carbonyl 
reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry 43:13106-13114. 
 
Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 
82:47-95. 
 
Ebert B, Kisiela M, Malatkova P, El-Hawari Y, and Maser E (2010) Regulation of human 
carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer 
cells. Biochemistry 49:8499-8511. 
 
Eggler AL, Gay KA, and Mesecar AD (2008) Molecular mechanisms of natural products 
in chemoprevention: induction of cytoprotective enzymes by Nrf2. Mol Nutr Food 
Res 52 Suppl 1:S84-94. 
 
Eismann T, Huber N, Shin T, Kuboki S, Galloway E, Wyder M, Edwards MJ, Greis KD, 
Shertzer HG, Fisher AB, and Lentsch AB (2009) Peroxiredoxin-6 protects against 
mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice. 
Am J Physiol Gastrointest Liver Physiol 296:G266-274. 
 
Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T, and 
Yamamoto M (2001) High sensitivity of Nrf2 knockout mice to acetaminophen 
208 
 
hepatotoxicity associated with decreased expression of ARE-regulated drug 
metabolizing enzymes and antioxidant genes. Toxicol Sci 59:169-177. 
 
Enomoto N, Takei Y, Yamashina S, Ikejima K, Kitamura T, and Sato N (2007) Anti-
inflammatory strategies in alcoholic steatohepatitis. J Gastroenterol Hepatol 22 
Suppl 1:S59-61. 
 
Farfan Labonne BE, Gutierrez M, Gomez-Quiroz LE, Konigsberg Fainstein M, Bucio L, 
Souza V, Flores O, Ortiz V, Hernandez E, Kershenobich D, and Gutierrez-Ruiz 
MC (2009) Acetaldehyde-induced mitochondrial dysfunction sensitizes 
hepatocytes to oxidative damage. Cell Biol Toxicol 25:599-609. 
 
Feng J, Zhang P, Chen X, and He G (2011) PI3K and ERK/Nrf2 pathways are involved 
in oleanolic acid-induced heme oxygenase-1 expression in rat vascular smooth 
muscle cells. J Cell Biochem 112:1524-1531. 
 
Filippin LI, Vercelino R, Marroni NP, and Xavier RM (2008) Redox signalling and the 
inflammatory response in rheumatoid arthritis. Clin Exp Immunol 152:415-422. 
 
Florczyk UM, Jozkowicz A, and Dulak J (2008) Biliverdin reductase: new features of an 
old enzyme and its potential therapeutic significance. Pharmacol Rep 60:38-48. 
 
Fu Y, Cheng WH, Porres JM, Ross DA, and Lei XG (1999) Knockout of cellular 
glutathione peroxidase gene renders mice susceptible to diquat-induced 
oxidative stress. Free Radic Biol Med 27:605-611. 
 
Gabbay KH, Bohren KM, Morello R, Bertin T, Liu J, and Vogel P (2010) Ascorbate 
synthesis pathway: dual role of ascorbate in bone homeostasis. J Biol Chem 
285:19510-19520. 
 
Gao SS, Choi BM, Chen XY, Zhu RZ, Kim Y, So H, Park R, Sung M, and Kim BR (2010) 
Kaempferol suppresses cisplatin-induced apoptosis via inductions of heme 
oxygenase-1 and glutamate-cysteine ligase catalytic subunit in HEI-OC1 cell. 
Pharm Res 27:235-245. 
 
Gardner R, Kazi S, and Ellis EM (2004) Detoxication of the environmental pollutant 
acrolein by a rat liver aldo-keto reductase. Toxicol Lett 148:65-72. 
 
Girotti AW (1998) Lipid hydroperoxide generation, turnover, and effector action in 
biological systems. J Lipid Res 39:1529-1542. 
 
Giudice A, Arra C, and Turco MC (2010) Review of molecular mechanisms involved in 
the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. 
Methods Mol Biol 647:37-74. 
 
209 
 
Gloire G, Legrand-Poels S, and Piette J (2006) NF-kappaB activation by reactive 
oxygen species: fifteen years later. Biochem Pharmacol 72:1493-1505. 
 
Goering PL and Klaassen CD (1983) Altered subcellular distribution of cadmium 
following cadmium pretreatment: possible mechanism of tolerance to cadmium-
induced lethality. Toxicol Appl Pharmacol 70:195-203. 
 
Goven D, Boutten A, Lecon-Malas V, Marchal-Somme J, Soler P, Boczkowski J, and 
Bonay M (2010) Induction of heme oxygenase-1, biliverdin reductase and H-
ferritin in lung macrophage in smokers with primary spontaneous pneumothorax: 
role of HIF-1alpha. PLoS One 5:e10886. 
 
Grisham MB (2004) Reactive oxygen species in immune responses. Free Radic Biol 
Med 36:1479-1480. 
 
Gu J, Zhang QY, Genter MB, Lipinskas TW, Negishi M, Nebert DW, and Ding X (1998) 
Purification and characterization of heterologously expressed mouse CYP2A5 
and CYP2G1: role in metabolic activation of acetaminophen and 2,6-
dichlorobenzonitrile in mouse olfactory mucosal microsomes. J Pharmacol Exp 
Ther 285:1287-1295. 
 
Guan X, Hoffman B, Dwivedi C, and Matthees DP (2003) A simultaneous liquid 
chromatography/mass spectrometric assay of glutathione, cysteine, 
homocysteine and their disulfides in biological samples. J Pharm Biomed Anal 
31:251-261. 
 
Gutterman DD, Miura H, and Liu Y (2005) Redox modulation of vascular tone: focus of 
potassium channel mechanisms of dilation. Arterioscler Thromb Vasc Biol 
25:671-678. 
 
Handler JA and Thurman RG (1990) Redox interactions between catalase and alcohol 
dehydrogenase pathways of ethanol metabolism in the perfused rat liver. J Biol 
Chem 265:1510-1515. 
 
Hassoun EA and Stohs SJ (1996) Cadmium-induced production of superoxide anion 
and nitric oxide, DNA single strand breaks and lactate dehydrogenase leakage in 
J774A.1 cell cultures. Toxicology 112:219-226. 
 
He X, Chen MG, and Ma Q (2008) Activation of Nrf2 in defense against cadmium-
induced oxidative stress. Chem Res Toxicol 21:1375-1383. 
 
Hensley K, Robinson KA, Gabbita SP, Salsman S, and Floyd RA (2000) Reactive 
oxygen species, cell signaling, and cell injury. Free Radic Biol Med 28:1456-1462. 
 
Hernandez-Montes E, Pollard SE, Vauzour D, Jofre-Montseny L, Rota C, Rimbach G, 
Weinberg PD, and Spencer JP (2006) Activation of glutathione peroxidase via 
210 
 
Nrf1 mediates genistein's protection against oxidative endothelial cell injury. 
Biochem Biophys Res Commun 346:851-859. 
 
Hess A, Wijayanti N, Neuschafer-Rube AP, Katz N, Kietzmann T, and Immenschuh S 
(2003) Phorbol ester-dependent activation of peroxiredoxin I gene expression via 
a protein kinase C, Ras, p38 mitogen-activated protein kinase signaling pathway. 
J Biol Chem 278:45419-45434. 
 
Higgins LG, Cavin C, Itoh K, Yamamoto M, and Hayes JD (2008) Induction of cancer 
chemopreventive enzymes by coffee is mediated by transcription factor Nrf2. 
Evidence that the coffee-specific diterpenes cafestol and kahweol confer 
protection against acrolein. Toxicol Appl Pharmacol 226:328-337. 
 
Higuchi Y (2004) Glutathione depletion-induced chromosomal DNA fragmentation 
associated with apoptosis and necrosis. J Cell Mol Med 8:455-464. 
 
Hinshelwood A, McGarvie G, and Ellis E (2002) Characterisation of a novel mouse liver 
aldo-keto reductase AKR7A5. FEBS Lett 523:213-218. 
 
Hong F, Freeman ML, and Liebler DC (2005a) Identification of sensor cysteines in 
human Keap1 modified by the cancer chemopreventive agent sulforaphane. 
Chem Res Toxicol 18:1917-1926. 
 
Hong F, Sekhar KR, Freeman ML, and Liebler DC (2005b) Specific patterns of 
electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J Biol 
Chem 280:31768-31775. 
 
Horton JD, Goldstein JL, and Brown MS (2002) SREBPs: activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 
109:1125-1131. 
 
Hoshino Y, Nakamura T, Sato A, Mishima M, Yodoi J, and Nakamura H (2007) 
Neurotropin demonstrates cytoprotective effects in lung cells through the 
induction of thioredoxin-1. Am J Respir Cell Mol Biol 37:438-446. 
 
Huo Y, Qiu WY, Pan Q, Yao YF, Xing K, and Lou MF (2009) Reactive oxygen species 
(ROS) are essential mediators in epidermal growth factor (EGF)-stimulated 
corneal epithelial cell proliferation, adhesion, migration, and wound healing. Exp 
Eye Res 89:876-886. 
 
Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, 
Miyazono K, and Gotoh Y (1997) Induction of apoptosis by ASK1, a mammalian 
MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275:90-
94. 
 
211 
 
Imai H and Nakagawa Y (2003) Biological significance of phospholipid hydroperoxide 
glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic Biol Med 
34:145-169. 
 
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, and Speed 
TP (2003) Exploration, normalization, and summaries of high density 
oligonucleotide array probe level data. Biostatistics 4:249-264. 
 
Ishii T, Yamada M, Sato H, Matsue M, Taketani S, Nakayama K, Sugita Y, and Bannai 
S (1993) Cloning and characterization of a 23-kDa stress-induced mouse 
peritoneal macrophage protein. J Biol Chem 268:18633-18636. 
 
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, 
Hatayama I, Yamamoto M, and Nabeshima Y (1997) An Nrf2/small Maf 
heterodimer mediates the induction of phase II detoxifying enzyme genes 
through antioxidant response elements. Biochem Biophys Res Commun 
236:313-322. 
 
Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M (1999) 
Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 
through binding to the amino-terminal Neh2 domain. Genes Dev 13:76-86. 
 
Iversen PW, Eastwood BJ, Sittampalam GS, and Cox KL (2006) A comparison of assay 
performance measures in screening assays: signal window, Z' factor, and assay 
variability ratio. J Biomol Screen 11:247-252. 
 
Jansen PJ, Lutjohann D, Abildayeva K, Vanmierlo T, Plosch T, Plat J, von Bergmann K, 
Groen AK, Ramaekers FC, Kuipers F, and Mulder M (2006) Dietary plant sterols 
accumulate in the brain. Biochim Biophys Acta 1761:445-453. 
 
Jeffrey AM (1985) DNA modification by chemical carcinogens. Pharmacol Ther 28:237-
272. 
 
Jeyapaul J and Jaiswal AK (2000) Nrf2 and c-Jun regulation of antioxidant response 
element (ARE)-mediated expression and induction of gamma-glutamylcysteine 
synthetase heavy subunit gene. Biochem Pharmacol 59:1433-1439. 
 
Ji Y, Lee HJ, Goodman C, Uskokovic M, Liby K, Sporn M, and Suh N (2006) The 
synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by 
activating the Smad and ERK signaling pathways in HL60 leukemia cells. Mol 
Cancer Ther 5:1452-1458. 
 
Jimenez-Lopez JM and Cederbaum AI (2005) CYP2E1-dependent oxidative stress and 
toxicity: role in ethanol-induced liver injury. Expert Opin Drug Metab Toxicol 
1:671-685. 
 
212 
 
Jurado J, Prieto-Alamo MJ, Madrid-Risquez J, and Pueyo C (2003) Absolute gene 
expression patterns of thioredoxin and glutaredoxin redox systems in mouse. J 
Biol Chem 278:45546-45554. 
 
Kassner N, Huse K, Martin HJ, Godtel-Armbrust U, Metzger A, Meineke I, Brockmoller J, 
Klein K, Zanger UM, Maser E, and Wojnowski L (2008) Carbonyl reductase 1 is a 
predominant doxorubicin reductase in the human liver. Drug Metab Dispos 
36:2113-2120. 
 
Kensler TW, Wakabayashi N, and Biswal S (2007) Cell survival responses to 
environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol 
Toxicol 47:89-116. 
 
Khan AQ, Nafees S, and Sultana S (2011) Perillyl alcohol protects against ethanol 
induced acute liver injury in Wistar rats by inhibiting oxidative stress, NFkappa-B 
activation and proinflammatory cytokine production. Toxicology 279:108-114. 
 
Khanal T, Choi JH, Hwang YP, Chung YC, and Jeong HG (2009) Saponins isolated 
from the root of Platycodon grandiflorum protect against acute ethanol-induced 
hepatotoxicity in mice. Food Chem Toxicol 47:530-535. 
 
Kiermayer C, Michalke B, Schmidt J, and Brielmeier M (2007) Effect of selenium on 
thioredoxin reductase activity in Txnrd1 or Txnrd2 hemizygous mice. Biol Chem 
388:1091-1097. 
 
Kim SJ, Lee JW, Jung YS, Kwon do Y, Park HK, Ryu CS, Kim SK, Oh GT, and Kim YC 
(2009) Ethanol-induced liver injury and changes in sulfur amino acid 
metabolomics in glutathione peroxidase and catalase double knockout mice. J 
Hepatol 50:1184-1191. 
 
Kim YC, Yamaguchi Y, Kondo N, Masutani H, and Yodoi J (2003) Thioredoxin-
dependent redox regulation of the antioxidant responsive element (ARE) in 
electrophile response. Oncogene 22:1860-1865. 
 
Kirby J, Halligan E, Baptista MJ, Allen S, Heath PR, Holden H, Barber SC, Loynes CA, 
Wood-Allum CA, Lunec J, and Shaw PJ (2005) Mutant SOD1 alters the motor 
neuronal transcriptome: implications for familial ALS. Brain 128:1686-1706. 
 
Kitteringham NR, Abdullah A, Walsh J, Randle L, Jenkins RE, Sison R, Goldring CE, 
Powell H, Sanderson C, Williams S, Higgins L, Yamamoto M, Hayes J, and Park 
BK (2010) Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular 
defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. J 
Proteomics 73:1612-1631. 
 
Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol 
transporters: function and regulation. Pharmacol Rev 62:1-96. 
213 
 
 
Klaassen CD and Liu J (1997) Role of metallothionein in cadmium-induced 
hepatotoxicity and nephrotoxicity. Drug Metab Rev 29:79-102. 
 
Klaassen CD and Liu J (1998) Induction of metallothionein as an adaptive mechanism 
affecting the magnitude and progression of toxicological injury. Environ Health 
Perspect 106 Suppl 1:297-300. 
 
Klaassen CD, Liu J, and Choudhuri S (1999) Metallothionein: an intracellular protein to 
protect against cadmium toxicity. Annu Rev Pharmacol Toxicol 39:267-294. 
 
Klaassen CD, Liu J, and Diwan BA (2009) Metallothionein protection of cadmium 
toxicity. Toxicol Appl Pharmacol 238:215-220. 
 
Klaassen CD and Lu H (2008) Xenobiotic transporters: ascribing function from gene 
knockout and mutation studies. Toxicol Sci 101:186-196. 
 
Klaassen CD and Reisman SA (2010) Nrf2 the rescue: effects of the 
antioxidative/electrophilic response on the liver. Toxicol Appl Pharmacol 244:57-
65. 
 
Knight JA (1997) Reactive oxygen species and the neurodegenerative disorders. Ann 
Clin Lab Sci 27:11-25. 
 
Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, and 
Yamamoto M (2004) Oxidative stress sensor Keap1 functions as an adaptor for 
Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 
24:7130-7139. 
 
Kobayashi M, Itoh K, Suzuki T, Osanai H, Nishikawa K, Katoh Y, Takagi Y, and 
Yamamoto M (2002) Identification of the interactive interface and phylogenic 
conservation of the Nrf2-Keap1 system. Genes Cells 7:807-820. 
 
Kobayashi M and Yamamoto M (2006) Nrf2-Keap1 regulation of cellular defense 
mechanisms against electrophiles and reactive oxygen species. Adv Enzyme 
Regul 46:113-140. 
 
Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, and Rahman I (2008) 
Resveratrol induces glutathione synthesis by activation of Nrf2 and protects 
against cigarette smoke-mediated oxidative stress in human lung epithelial cells. 
Am J Physiol Lung Cell Mol Physiol 294:L478-488. 
 
Koh K, Cha Y, Kim S, and Kim J (2009) tBHQ inhibits LPS-induced microglial activation 
via Nrf2-mediated suppression of p38 phosphorylation. Biochem Biophys Res 
Commun 380:449-453. 
 
214 
 
Krause KH (2004) Tissue distribution and putative physiological function of NOX family 
NADPH oxidases. Jpn J Infect Dis 57:S28-29. 
 
Kropotov A, Usmanova N, Serikov V, Zhivotovsky B, and Tomilin N (2007) 
Mitochondrial targeting of human peroxiredoxin V protein and regulation of 
PRDX5 gene expression by nuclear transcription factors controlling biogenesis of 
mitochondria. FEBS J 274:5804-5814. 
 
Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, and Pasternack 
GR (1994) Fatty acid synthesis: a potential selective target for antineoplastic 
therapy. Proc Natl Acad Sci U S A 91:6379-6383. 
 
Kumar A, Singh CK, Lavoie H, Dipette D, and Singh U (2011a) Resveratrol restores 
Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a 
rodent model of Fetal Alcohol Spectrum Disorders. Mol Pharmacol. 
 
Kumar V, Kumar S, Hassan M, Wu H, Thimmulappa RK, Kumar A, Sharma SK, Parmar 
VS, Biswal S, and Malhotra SV (2011b) Novel chalcone derivatives as potent 
Nrf2 activators in mice and human lung epithelial cells. J Med Chem 54:4147-
4159. 
 
Kwak MK, Wakabayashi N, and Kensler TW (2004) Chemoprevention through the 
Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res 555:133-
148. 
 
Lamle J, Marhenke S, Borlak J, von Wasielewski R, Eriksson CJ, Geffers R, Manns MP, 
Yamamoto M, and Vogel A (2008) Nuclear factor-eythroid 2-related factor 2 
prevents alcohol-induced fulminant liver injury. Gastroenterology 134:1159-1168. 
 
Lamsa V, Levonen AL, Leinonen H, Yla-Herttuala S, Yamamoto M, and Hakkola J 
(2010) Cytochrome P450 2A5 constitutive expression and induction by heavy 
metals is dependent on redox-sensitive transcription factor Nrf2 in liver. Chem 
Res Toxicol 23:977-985. 
 
Lee CY, Chew EH, and Go ML (2010a) Functionalized aurones as inducers of 
NAD(P)H:quinone oxidoreductase 1 that activate AhR/XRE and Nrf2/ARE 
signaling pathways: synthesis, evaluation and SAR. Eur J Med Chem 45:2957-
2971. 
 
Lee HC and Wei YH (2007) Oxidative stress, mitochondrial DNA mutation, and 
apoptosis in aging. Exp Biol Med (Maywood) 232:592-606. 
 
Lee Y, Shin DH, Kim JH, Hong S, Choi D, Kim YJ, Kwak MK, and Jung Y (2010b) 
Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase 
inhibition are involved in NFkappaB inhibitory effect: structural analysis for 
NFkappaB inhibition. Eur J Pharmacol 643:21-28. 
215 
 
 
Lemasters JJ, Theruvath TP, Zhong Z, and Nieminen AL (2009) Mitochondrial calcium 
and the permeability transition in cell death. Biochim Biophys Acta 1787:1395-
1401. 
 
Lenzen S, Drinkgern J, and Tiedge M (1996) Low antioxidant enzyme gene expression 
in pancreatic islets compared with various other mouse tissues. Free Radic Biol 
Med 20:463-466. 
 
Li M, Chiu JF, Kelsen A, Lu SC, and Fukagawa NK (2009) Identification and 
characterization of an Nrf2-mediated ARE upstream of the rat glutamate cysteine 
ligase catalytic subunit gene (GCLC). J Cell Biochem 107:944-954. 
 
Li W, Yu SW, and Kong AN (2006) Nrf2 possesses a redox-sensitive nuclear exporting 
signal in the Neh5 transactivation domain. J Biol Chem 281:27251-27263. 
 
Li X, Zhang D, Hannink M, and Beamer LJ (2004) Crystal structure of the Kelch domain 
of human Keap1. J Biol Chem 279:54750-54758. 
 
Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, 
Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, and Sporn MB 
(2005) The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent 
inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65:4789-
4798. 
 
Lieber CS (2000) Alcoholic liver disease: new insights in pathogenesis lead to new 
treatments. J Hepatol 32:113-128. 
 
Lieber CS (2004) Alcoholic fatty liver: its pathogenesis and mechanism of progression 
to inflammation and fibrosis. Alcohol 34:9-19. 
 
Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, 
and Gao AC (2011) Andrographolide targets androgen receptor pathway in 
castration-resistant prostate cancer. Genes Cancer 2:151-159. 
 
Liu J, Goyer R, and Waalkes MP (2007) Toxic effects of metals, in: Casarett and Doull's 
Toxicology - the Basic Science of Poisons (Klaassen CD ed), pp 931-979, 
McGraw Hill. 
 
Liu J, Kershaw WC, Liu YP, and Klaassen CD (1992) Cadmium-induced hepatic 
endothelial cell injury in inbred strains of mice. Toxicology 75:51-62. 
 
Liu J, Liu Y, Michalska AE, Choo KH, and Klaassen CD (1996) Metallothionein plays 
less of a protective role in cadmium-metallothionein-induced nephrotoxicity than 
in cadmium chloride-induced hepatotoxicity. J Pharmacol Exp Ther 276:1216-
1223. 
216 
 
 
Liu J, Liu Y, Parkinson A, and Klaassen CD (1995a) Effect of oleanolic acid on hepatic 
toxicant-activating and detoxifying systems in mice. J Pharmacol Exp Ther 
275:768-774. 
 
Liu J, Qu W, and Kadiiska MB (2009) Role of oxidative stress in cadmium toxicity and 
carcinogenesis. Toxicol Appl Pharmacol 238:209-214. 
 
Liu Y, Liu J, Iszard MB, Andrews GK, Palmiter RD, and Klaassen CD (1995b) 
Transgenic mice that overexpress metallothionein-I are protected from cadmium 
lethality and hepatotoxicity. Toxicol Appl Pharmacol 135:222-228. 
 
Liu Y, Liu J, and Klaassen CD (2001) Metallothionein-null and wild-type mice show 
similar cadmium absorption and tissue distribution following oral cadmium 
administration. Toxicol Appl Pharmacol 175:253-259. 
 
Loft S and Poulsen HE (1998) Estimation of oxidative DNA damage in man from urinary 
excretion of repair products. Acta Biochim Pol 45:133-144. 
 
Lowther WT and Haynes AC (2011) Reduction of cysteine sulfinic acid in eukaryotic, 
typical 2-Cys peroxiredoxins by sulfiredoxin. Antioxid Redox Signal 15:99-109. 
 
Lu H, Gonzalez FJ, and Klaassen C (2010) Alterations in hepatic mRNA expression of 
phase II enzymes and xenobiotic transporters after targeted disruption of 
hepatocyte nuclear factor 4 alpha. Toxicol Sci 118:380-390. 
 
Lu SC and Mato JM (2005) Role of methionine adenosyltransferase and S-
adenosylmethionine in alcohol-associated liver cancer. Alcohol 35:227-234. 
 
Lu WJ, Lee JJ, Chou DS, Jayakumar T, Fong TH, Hsiao G, and Sheu JR (2011) A 
novel role of andrographolide, an NF-kappa B inhibitor, on inhibition of platelet 
activation: the pivotal mechanisms of endothelial nitric oxide synthase/cyclic 
GMP. J Mol Med (Berl) 89:1261-1273. 
 
Lu Y and Cederbaum AI (2008) CYP2E1 and oxidative liver injury by alcohol. Free 
Radic Biol Med 44:723-738. 
 
Luo Y, Eggler AL, Liu D, Liu G, Mesecar AD, and van Breemen RB (2007) Sites of 
alkylation of human Keap1 by natural chemoprevention agents. J Am Soc Mass 
Spectrom 18:2226-2232. 
 
MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K, and 
Hayes JD (2009) Characterization of the cancer chemopreventive NRF2-
dependent gene battery in human keratinocytes: demonstration that the KEAP1-
NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection 
217 
 
against electrophiles as well as redox-cycling compounds. Carcinogenesis 
30:1571-1580. 
 
Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G, Tanaka Y, Scheffer GL, Chan JY, 
Manautou JE, Chen Y, Dalton TP, Yamamoto M, and Klaassen CD (2007) 
Oxidative and electrophilic stress induces multidrug resistance-associated 
protein transporters via the nuclear factor-E2-related factor-2 transcriptional 
pathway. Hepatology 46:1597-1610. 
 
Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C, Shyr C, 
Wakabayashi N, Kensler TW, Wasserman WW, and Biswal S (2010) Global 
mapping of binding sites for Nrf2 identifies novel targets in cell survival response 
through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38:5718-
5734. 
 
Malhotra JD and Kaufman RJ (2007) Endoplasmic reticulum stress and oxidative stress: 
a vicious cycle or a double-edged sword? Antioxid Redox Signal 9:2277-2293. 
 
Mamede AC, Tavares SD, Abrantes AM, Trindade J, Maia JM, and Botelho MF (2011) 
The role of vitamins in cancer: a review. Nutr Cancer 63:479-494. 
 
Manea A (2010) NADPH oxidase-derived reactive oxygen species: involvement in 
vascular physiology and pathology. Cell Tissue Res 342:325-339. 
 
Margis R, Dunand C, Teixeira FK, and Margis-Pinheiro M (2008) Glutathione 
peroxidase family - an evolutionary overview. FEBS J 275:3959-3970. 
 
Mari M, Morales A, Colell A, Garcia-Ruiz C, and Fernandez-Checa JC (2009) 
Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 
11:2685-2700. 
 
Marklund SL, Westman NG, Lundgren E, and Roos G (1982) Copper- and zinc-
containing superoxide dismutase, manganese-containing superoxide dismutase, 
catalase, and glutathione peroxidase in normal and neoplastic human cell lines 
and normal human tissues. Cancer Res 42:1955-1961. 
 
Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, and 
Cuadrado A (2004) Regulation of heme oxygenase-1 expression through the 
phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in 
response to the antioxidant phytochemical carnosol. J Biol Chem 279:8919-8929. 
 
Martinez JA (2006) Mitochondrial oxidative stress and inflammation: an slalom to 
obesity and insulin resistance. J Physiol Biochem 62:303-306. 
 
218 
 
McLellan LI, Judah DJ, Neal GE, and Hayes JD (1994) Regulation of aflatoxin B1-
metabolizing aldehyde reductase and glutathione S-transferase by 
chemoprotectors. Biochem J 300 ( Pt 1):117-124. 
 
Meister A and Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760. 
 
Merrell MD, Jackson JP, Augustine LM, Fisher CD, Slitt AL, Maher JM, Huang W, 
Moore DD, Zhang Y, Klaassen CD, and Cherrington NJ (2008) The Nrf2 activator 
oltipraz also activates the constitutive androstane receptor. Drug Metab Dispos 
36:1716-1721. 
 
Mishra K, Dash AP, and Dey N (2011) Andrographolide: A Novel Antimalarial Diterpene 
Lactone Compound from Andrographis paniculata and Its Interaction with 
Curcumin and Artesunate. J Trop Med 2011:579518. 
 
Miyamoto N, Izumi H, Miyamoto R, Kondo H, Tawara A, Sasaguri Y, and Kohno K 
(2011) Quercetin induces the expression of peroxiredoxins 3 and 5 via the 
Nrf2/NRF1 transcription pathway. Invest Ophthalmol Vis Sci 52:1055-1063. 
 
Moinova HR and Mulcahy RT (1999) Up-regulation of the human gamma-
glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to 
an electrophile responsive element. Biochem Biophys Res Commun 261:661-
668. 
 
Muraoka M, Kawakita M, and Ishida N (2001) Molecular characterization of human 
UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter, a novel nucleotide 
sugar transporter with dual substrate specificity. FEBS Lett 495:87-93. 
 
Natsch A and Emter R (2008) Skin sensitizers induce antioxidant response element 
dependent genes: application to the in vitro testing of the sensitization potential 
of chemicals. Toxicol Sci 102:110-119. 
 
New LS and Chan EC (2008) Evaluation of BEH C18, BEH HILIC, and HSS T3 (C18) 
column chemistries for the UPLC-MS-MS analysis of glutathione, glutathione 
disulfide, and ophthalmic acid in mouse liver and human plasma. J Chromatogr 
Sci 46:209-214. 
 
Nishinaka T and Yabe-Nishimura C (2005) Transcription factor Nrf2 regulates promoter 
activity of mouse aldose reductase (AKR1B3) gene. J Pharmacol Sci 97:43-51. 
 
Novak RF and Woodcroft KJ (2000) The alcohol-inducible form of cytochrome P450 
(CYP 2E1): role in toxicology and regulation of expression. Arch Pharm Res 
23:267-282. 
 
Ntambi JM, Buhrow SA, Kaestner KH, Christy RJ, Sibley E, Kelly TJ, Jr., and Lane MD 
(1988) Differentiation-induced gene expression in 3T3-L1 preadipocytes. 
219 
 
Characterization of a differentially expressed gene encoding stearoyl-CoA 
desaturase. J Biol Chem 263:17291-17300. 
 
Nunoya K, Yokoi T, Itoh K, Itoh S, Kimura K, and Kamataki T (1995) S-oxidation of (+)-
cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidin-4-one hydrochloride by rat hepatic flavin-
containing monooxygenase 1 expressed in yeast. Xenobiotica 25:1283-1291. 
 
Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, 
Takeda K, Utsunomiya H, Oda K, Warabi E, Ishii T, Osaka K, Hyodo I, and 
Yamamoto M (2008) Ursodeoxycholic acid stimulates Nrf2-mediated 
hepatocellular transport, detoxification, and antioxidative stress systems in mice. 
Am J Physiol Gastrointest Liver Physiol 295:G735-747. 
 
Okado-Matsumoto A, Matsumoto A, Fujii J, and Taniguchi N (2000) Peroxiredoxin IV is 
a secretable protein with heparin-binding properties under reduced conditions. J 
Biochem 127:493-501. 
 
Okawa H, Motohashi H, Kobayashi A, Aburatani H, Kensler TW, and Yamamoto M 
(2006) Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers 
potent resistance against acute drug toxicity. Biochem Biophys Res Commun 
339:79-88. 
 
Osburn WO, Wakabayashi N, Misra V, Nilles T, Biswal S, Trush MA, and Kensler TW 
(2006) Nrf2 regulates an adaptive response protecting against oxidative damage 
following diquat-mediated formation of superoxide anion. Arch Biochem Biophys 
454:7-15. 
 
Perez VI, Lew CM, Cortez LA, Webb CR, Rodriguez M, Liu Y, Qi W, Li Y, Chaudhuri A, 
Van Remmen H, Richardson A, and Ikeno Y (2008) Thioredoxin 2 
haploinsufficiency in mice results in impaired mitochondrial function and 
increased oxidative stress. Free Radic Biol Med 44:882-892. 
 
Pi J, Leung L, Xue P, Wang W, Hou Y, Liu D, Yehuda-Shnaidman E, Lee C, Lau J, 
Kurtz TW, and Chan JY (2010) Deficiency in the nuclear factor E2-related factor-
2 transcription factor results in impaired adipogenesis and protects against diet-
induced obesity. J Biol Chem 285:9292-9300. 
 
Pilka ES, Niesen FH, Lee WH, El-Hawari Y, Dunford JE, Kochan G, Wsol V, Martin HJ, 
Maser E, and Oppermann U (2009) Structural basis for substrate specificity in 
human monomeric carbonyl reductases. PLoS One 4:e7113. 
 
Ponnusamy M and Pari L (2011) Protective role of diallyl tetrasulfide on cadmium-
induced testicular damage in adult rats: a biochemical and histological study. 
Toxicol Ind Health 27:407-416. 
 
220 
 
Porter NA, Caldwell SE, and Mills KA (1995) Mechanisms of free radical oxidation of 
unsaturated lipids. Lipids 30:277-290. 
 
Prabu SM, Shagirtha K, and Renugadevi J (2010) Amelioration of cadmium-induced 
oxidative stress, impairment in lipids and plasma lipoproteins by the combined 
treatment with quercetin and alpha-tocopherol in rats. J Food Sci 75:T132-140. 
 
Primiano T, Kensler TW, Kuppusamy P, Zweier JL, and Sutter TR (1996) Induction of 
hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive 
dithiolethiones. Carcinogenesis 17:2291-2296. 
 
Puertollano MA, Puertollano E, de Cienfuegos GA, and de Pablo MA (2011) Dietary 
antioxidants: immunity and host defense. Curr Top Med Chem 11:1752-1766. 
 
Raghow R, Yellaturu C, Deng X, Park EA, and Elam MB (2008) SREBPs: the 
crossroads of physiological and pathological lipid homeostasis. Trends 
Endocrinol Metab 19:65-73. 
 
Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, 
Yamamoto M, Petrache I, Tuder RM, and Biswal S (2004) Genetic ablation of 
Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J 
Clin Invest 114:1248-1259. 
 
Reisman SA, Aleksunes LM, and Klaassen CD (2009a) Oleanolic acid activates Nrf2 
and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-
independent processes. Biochem Pharmacol 77:1273-1282. 
 
Reisman SA, Buckley DB, Tanaka Y, and Klaassen CD (2009b) CDDO-Im protects from 
acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. 
Toxicol Appl Pharmacol 236:109-114. 
 
Reisman SA, Csanaky IL, Aleksunes LM, and Klaassen CD (2009c) Altered disposition 
of acetaminophen in Nrf2-null and Keap1-knockdown mice. Toxicol Sci 109:31-
40. 
 
Reisman SA, Csanaky IL, Yeager RL, and Klaassen CD (2009d) Nrf2 activation 
enhances biliary excretion of sulfobromophthalein by inducing glutathione-S-
transferase activity. Toxicol Sci 109:24-30. 
 
Reisman SA, Yeager RL, Yamamoto M, and Klaassen CD (2009e) Increased Nrf2 
activation in livers from Keap1-knockdown mice increases expression of 
cytoprotective genes that detoxify electrophiles more than those that detoxify 
reactive oxygen species. Toxicol Sci 108:35-47. 
 
Rikans LE and Yamano T (2000) Mechanisms of cadmium-mediated acute 
hepatotoxicity. J Biochem Mol Toxicol 14:110-117. 
221 
 
 
Roede JR, Stewart BJ, and Petersen DR (2008) Decreased expression of peroxiredoxin 
6 in a mouse model of ethanol consumption. Free Radic Biol Med 45:1551-1558. 
 
Room R, Babor T, and Rehm J (2005) Alcohol and public health. Lancet 365:519-530. 
 
Roth M, Araya JJ, Timmermann BN, and Hagenbuch B (2011) Isolation of Modulators of 
the Liver-Specific Organic Anion-Transporting Polypeptides (OATPs) 1B1 and 
1B3 from Rollinia emarginata Schlecht (Annonaceae). J Pharmacol Exp Ther 
339:624-632. 
 
Rubiolo JA, Mithieux G, and Vega FV (2008) Resveratrol protects primary rat 
hepatocytes against oxidative stress damage: activation of the Nrf2 transcription 
factor and augmented activities of antioxidant enzymes. Eur J Pharmacol 
591:66-72. 
 
Rushmore TH, Morton MR, and Pickett CB (1991) The antioxidant responsive element. 
Activation by oxidative stress and identification of the DNA consensus sequence 
required for functional activity. J Biol Chem 266:11632-11639. 
 
Sakurai A, Nishimoto M, Himeno S, Imura N, Tsujimoto M, Kunimoto M, and Hara S 
(2005) Transcriptional regulation of thioredoxin reductase 1 expression by 
cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J Cell 
Physiol 203:529-537. 
 
Saracino MR and Lampe JW (2007) Phytochemical regulation of UDP-
glucuronosyltransferases: implications for cancer prevention. Nutr Cancer 
59:121-141. 
 
Shah ZA, Li RC, Thimmulappa RK, Kensler TW, Yamamoto M, Biswal S, and Dore S 
(2007) Role of reactive oxygen species in modulation of Nrf2 following ischemic 
reperfusion injury. Neuroscience 147:53-59. 
 
Shih AY, Imbeault S, Barakauskas V, Erb H, Jiang L, Li P, and Murphy TH (2005) 
Induction of the Nrf2-driven antioxidant response confers neuroprotection during 
mitochondrial stress in vivo. J Biol Chem 280:22925-22936. 
 
Shimomura I, Shimano H, Korn BS, Bashmakov Y, and Horton JD (1998) Nuclear sterol 
regulatory element-binding proteins activate genes responsible for the entire 
program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J Biol 
Chem 273:35299-35306. 
 
Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, Liby KT, Sporn 
MB, Yamamoto M, and Kensler TW (2009) Role of Nrf2 in prevention of high-fat 
diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J 
Pharmacol 620:138-144. 
222 
 
 
Short DM, Lyon R, Watson DG, Barski OA, McGarvie G, and Ellis EM (2006) 
Metabolism of trans, trans-muconaldehyde, a cytotoxic metabolite of benzene, in 
mouse liver by alcohol dehydrogenase Adh1 and aldehyde reductase AKR1A4. 
Toxicol Appl Pharmacol 210:163-170. 
 
Singh S, Sreenath K, Pavithra L, Roy S, and Chattopadhyay S (2010) SMAR1 regulates 
free radical stress through modulation of AKR1a4 enzyme activity. Int J Biochem 
Cell Biol 42:1105-1114. 
 
Smathers RL, Galligan JJ, Stewart BJ, and Petersen DR (2011) Overview of lipid 
peroxidation products and hepatic protein modification in alcoholic liver disease. 
Chem Biol Interact 192:107-112. 
 
Smith CV (1987) Effect of BCNU pretreatment on diquat-induced oxidant stress and 
hepatotoxicity. Biochem Biophys Res Commun 144:415-421. 
 
Soerensen J, Jakupoglu C, Beck H, Forster H, Schmidt J, Schmahl W, Schweizer U, 
Conrad M, and Brielmeier M (2008) The role of thioredoxin reductases in brain 
development. PLoS One 3:e1813. 
 
Spalding DJ, Mitchell JR, Jaeschke H, and Smith CV (1989) Diquat hepatotoxicity in the 
Fischer-344 rat: the role of covalent binding to tissue proteins and lipids. Toxicol 
Appl Pharmacol 101:319-327. 
 
Stewart D, Killeen E, Naquin R, Alam S, and Alam J (2003) Degradation of transcription 
factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J 
Biol Chem 278:2396-2402. 
 
Stocker R and Keaney JF, Jr. (2004) Role of oxidative modifications in atherosclerosis. 
Physiol Rev 84:1381-1478. 
 
Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, and Ames BN (1987) Bilirubin is an 
antioxidant of possible physiological importance. Science 235:1043-1046. 
 
Storz P (2005) Reactive oxygen species in tumor progression. Front Biosci 10:1881-
1896. 
 
Sugamura K and Keaney JF, Jr. (2011) Reactive oxygen species in cardiovascular 
disease. Free Radic Biol Med 51:978-992. 
 
Surh YJ, Kundu JK, and Na HK (2008) Nrf2 as a master redox switch in turning on the 
cellular signaling involved in the induction of cytoprotective genes by some 
chemopreventive phytochemicals. Planta Med 74:1526-1539. 
 
223 
 
Suzuki H, Tashiro S, Sun J, Doi H, Satomi S, and Igarashi K (2003) Cadmium induces 
nuclear export of Bach1, a transcriptional repressor of heme oxygenase-1 gene. 
J Biol Chem 278:49246-49253. 
 
Taguchi K, Maher JM, Suzuki T, Kawatani Y, Motohashi H, and Yamamoto M (2010) 
Genetic analysis of cytoprotective functions supported by graded expression of 
Keap1. Mol Cell Biol 30:3016-3026. 
 
Takahashi T, Tabuchi T, Tamaki Y, Kosaka K, Takikawa Y, and Satoh T (2009) 
Carnosic acid and carnosol inhibit adipocyte differentiation in mouse 3T3-L1 cells 
through induction of phase2 enzymes and activation of glutathione metabolism. 
Biochem Biophys Res Commun 382:549-554. 
 
Takebe G, Yarimizu J, Saito Y, Hayashi T, Nakamura H, Yodoi J, Nagasawa S, and 
Takahashi K (2002) A comparative study on the hydroperoxide and thiol 
specificity of the glutathione peroxidase family and selenoprotein P. J Biol Chem 
277:41254-41258. 
 
Takeda K, Noguchi T, Naguro I, and Ichijo H (2008) Apoptosis signal-regulating kinase 
1 in stress and immune response. Annu Rev Pharmacol Toxicol 48:199-225. 
 
Tanaka A, Hamada N, Fujita Y, Itoh T, Nozawa Y, Iinuma M, and Ito M (2010) A novel 
kavalactone derivative protects against H2O2-induced PC12 cell death via 
Nrf2/ARE activation. Bioorg Med Chem 18:3133-3139. 
 
Tanaka Y, Aleksunes LM, Cui YJ, and Klaassen CD (2009) ANIT-induced intrahepatic 
cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and 
independent signaling. Toxicol Sci 108:247-257. 
 
Tanaka Y, Aleksunes LM, Yeager RL, Gyamfi MA, Esterly N, Guo GL, and Klaassen CD 
(2008) NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in 
mice fed a high-fat diet. J Pharmacol Exp Ther 325:655-664. 
 
Tanigawa S, Fujii M, and Hou DX (2007) Action of Nrf2 and Keap1 in ARE-mediated 
NQO1 expression by quercetin. Free Radic Biol Med 42:1690-1703. 
 
Thangasamy A, Rogge J, Krishnegowda NK, Freeman JW, and Ammanamanchi S 
(2011) Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine 
kinase receptor-mediated cancer cell invasion. J Biol Chem 286:32115-32122. 
 
Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, and Biswal S (2002) 
Identification of Nrf2-regulated genes induced by the chemopreventive agent 
sulforaphane by oligonucleotide microarray. Cancer Res 62:5196-5203. 
 
Tsai PY, Ka SM, Chang JM, Chen HC, Shui HA, Li CY, Hua KF, Chang WL, Huang JJ, 
Yang SS, and Chen A (2011) Epigallocatechin-3-gallate prevents lupus nephritis 
224 
 
development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting 
NLRP3 inflammasome activation. Free Radic Biol Med 51:744-754. 
 
Umemura T, Kuroiwa Y, Kitamura Y, Ishii Y, Kanki K, Kodama Y, Itoh K, Yamamoto M, 
Nishikawa A, and Hirose M (2006) A crucial role of Nrf2 in in vivo defense 
against oxidative damage by an environmental pollutant, pentachlorophenol. 
Toxicol Sci 90:111-119. 
 
Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo R, and 
Csiszar A (2010) Resveratrol confers endothelial protection via activation of the 
antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 299:H18-24. 
 
Vander Jagt DL, Kolb NS, Vander Jagt TJ, Chino J, Martinez FJ, Hunsaker LA, and 
Royer RE (1995) Substrate specificity of human aldose reductase: identification 
of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta 
1249:117-126. 
 
Vesey DA (2010) Transport pathways for cadmium in the intestine and kidney proximal 
tubule: focus on the interaction with essential metals. Toxicol Lett 198:13-19. 
 
Vogt BL and Richie JP, Jr. (2007) Glutathione depletion and recovery after acute 
ethanol administration in the aging mouse. Biochem Pharmacol 73:1613-1621. 
 
Waalkes MP (2003) Cadmium carcinogenesis. Mutat Res 533:107-120. 
 
Waddell WJ and Marlowe C (1980) Tissue and cellular disposition of paraquat in mice. 
Toxicol Appl Pharmacol 56:127-140. 
 
Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S, Imakado 
S, Kotsuji T, Otsuka F, Roop DR, Harada T, Engel JD, and Yamamoto M (2003) 
Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. 
Nat Genet 35:238-245. 
 
Wang XJ, Hayes JD, and Wolf CR (2006) Generation of a stable antioxidant response 
element-driven reporter gene cell line and its use to show redox-dependent 
activation of nrf2 by cancer chemotherapeutic agents. Cancer Res 66:10983-
10994. 
 
Waris G, Felmlee DJ, Negro F, and Siddiqui A (2007) Hepatitis C virus induces 
proteolytic cleavage of sterol regulatory element binding proteins and stimulates 
their phosphorylation via oxidative stress. J Virol 81:8122-8130. 
 
White EL, Ross LJ, Schmid SM, Kelloff GJ, Steele VE, and Hill DL (1998) Screening of 
potential cancer preventing chemicals for induction of glutathione in rat liver cells. 
Oncol Rep 5:507-512. 
 
225 
 
Wiegand H, Wagner AE, Boesch-Saadatmandi C, Kruse HP, Kulling S, and Rimbach G 
(2009) Effect of dietary genistein on Phase II and antioxidant enzymes in rat liver. 
Cancer Genomics Proteomics 6:85-92. 
 
Winterbourn CC and Kettle AJ (2004) Reactions of superoxide with myeloperoxidase 
and its products. Jpn J Infect Dis 57:S31-33. 
 
Woods CG, Fu J, Xue P, Hou Y, Pluta LJ, Yang L, Zhang Q, Thomas RS, Andersen ME, 
and Pi J (2009) Dose-dependent transitions in Nrf2-mediated adaptive response 
and related stress responses to hypochlorous acid in mouse macrophages. 
Toxicol Appl Pharmacol 238:27-36. 
 
Wruck CJ, Claussen M, Fuhrmann G, Romer L, Schulz A, Pufe T, Waetzig V, Peipp M, 
Herdegen T, and Gotz ME (2007) Luteolin protects rat PC12 and C6 cells against 
MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J 
Neural Transm Suppl:57-67. 
 
Wu KC, Cui JY, and Klaassen CD (2011a) Beneficial role of Nrf2 in regulating NADPH 
generation and consumption. Toxicol Sci 123:590-600. 
 
Wu KC, Cui JY, and Klaassen CD (2011b) Beneficial Role of Nrf2 in Regulating NADPH 
Generation and Consumption. Toxicol Sci. 
 
Xu W, Hellerbrand C, Kohler UA, Bugnon P, Kan YW, Werner S, and Beyer TA (2008) 
The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis. 
Lab Invest 88:1068-1078. 
 
Yamano T, DeCicco LA, and Rikans LE (2000) Attenuation of cadmium-induced liver 
injury in senescent male fischer 344 rats: role of Kupffer cells and inflammatory 
cytokines. Toxicol Appl Pharmacol 162:68-75. 
 
Yan D, Dong J, Sulik KK, and Chen SY (2010) Induction of the Nrf2-driven antioxidant 
response by tert-butylhydroquinone prevents ethanol-induced apoptosis in 
cranial neural crest cells. Biochem Pharmacol 80:144-149. 
 
Yanardag R, Ozsoy-Sacan O, Ozdil S, and Bolkent S (2007) Combined effects of 
vitamin C, vitamin E, and sodium selenate supplementation on absolute ethanol-
induced injury in various organs of rats. Int J Toxicol 26:513-523. 
 
Yang C, Zhang X, Fan H, and Liu Y (2009) Curcumin upregulates transcription factor 
Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res 
1282:133-141. 
 
Yang YC, Lii CK, Lin AH, Yeh YW, Yao HT, Li CC, Liu KL, and Chen HW (2011) 
Induction of glutathione synthesis and heme oxygenase 1 by the flavonoids 
226 
 
butein and phloretin is mediated through the ERK/Nrf2 pathway and protects 
against oxidative stress. Free Radic Biol Med 51:2073-2081. 
 
Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, 
Baumgartner KJ, Roebuck BD, Liby KT, Yore MM, Honda T, Gribble GW, Sporn 
MB, and Kensler TW (2006) Potent protection against aflatoxin-induced 
tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-
[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res 66:2488-
2494. 
 
Yeager RL, Reisman SA, Aleksunes LM, and Klaassen CD (2009) Introducing the 
"TCDD-inducible AhR-Nrf2 gene battery". Toxicol Sci 111:238-246. 
 
Yeligar SM, Machida K, and Kalra VK (2010) Ethanol-induced HO-1 and NQO1 are 
differentially regulated by HIF-1alpha and Nrf2 to attenuate inflammatory cytokine 
expression. J Biol Chem 285:35359-35373. 
 
Yokota SI, Higashi E, Fukami T, Yokoi T, and Nakajima M (2010) Human CYP2A6 is 
regulated by nuclear factor-erythroid 2 related factor 2. Biochem Pharmacol. 
 
Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, 
Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Kimura 
S, Ishibashi S, and Yamada N (2001) Identification of liver X receptor-retinoid X 
receptor as an activator of the sterol regulatory element-binding protein 1c gene 
promoter. Mol Cell Biol 21:2991-3000. 
 
Yu AL, Lu CY, Wang TS, Tsai CW, Liu KL, Cheng YP, Chang HC, Lii CK, and Chen HW 
(2010) Induction of heme oxygenase 1 and inhibition of tumor necrosis factor 
alpha-induced intercellular adhesion molecule expression by andrographolide in 
EA.hy926 cells. J Agric Food Chem 58:7641-7648. 
 
Zakhari S (2006) Overview: how is alcohol metabolized by the body? Alcohol Res 
Health 29:245-254. 
 
Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and 
Brouwer KL (2006) The important role of Bcrp (Abcg2) in the biliary excretion of 
sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, 
and harmol in mice. Mol Pharmacol 70:2127-2133. 
 
Zhang DD and Hannink M (2003) Distinct cysteine residues in Keap1 are required for 
Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by 
chemopreventive agents and oxidative stress. Mol Cell Biol 23:8137-8151. 
 
Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, and Hannink M (2005) 
Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets 
227 
 
Keap1 for degradation by a proteasome-independent pathway. J Biol Chem 
280:30091-30099. 
 
Zhang H, Shih A, Rinna A, and Forman HJ (2009) Resveratrol and 4-hydroxynonenal 
act in concert to increase glutamate cysteine ligase expression and glutathione in 
human bronchial epithelial cells. Arch Biochem Biophys 481:110-115. 
 
Zhang JH, Chung TD, and Oldenburg KR (1999) A Simple Statistical Parameter for Use 
in Evaluation and Validation of High Throughput Screening Assays. J Biomol 
Screen 4:67-73. 
 
Zhang YK, Yeager RL, Tanaka Y, and Klaassen CD (2010) Enhanced expression of 
Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-
deficient diet. Toxicol Appl Pharmacol 245:326-334. 
 
Zhu M and Fahl WE (2001) Functional characterization of transcription regulators that 
interact with the electrophile response element. Biochem Biophys Res Commun 
289:212-219. 
 
 
 
 
 
 
